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1.1 DCD donors - The forgotten donors  
 
Historical aspects 
 In the infancy of clinical transplantation, organs were recovered from donors declared 
dead by cardio-pulmonary criteria, known as non-heart-beating donation (NHBD).  In 1968, 
given the availability of the Harvard‟s brain-dead criteria,1 and given the better results of 
organ transplantation and the potential for multi-organ procurement from donation after brain 
death (DBD),
2
 heart-beating donation (HBD) has almost replaced NHBD. NHBD is now 
termed „donation after cardiac death‟ or, more recently, „donation after circulatory death‟ 
(DCD), or donation after circulatory determination of death” (DCDD).3 
The renewed interest in DCD started since the 1990s following the growing gap 
between the demand for transplantation and the supply of optimal DBD donors (i.e. standard 
criteria donors, SCD), and following the limited success of the transplant community to 
expand the donor pool through the liberalization of the donor acceptance criteria, the use of 
suboptimal or marginal donors (extended criteria donors - ECD), the application of split 
technique (transaction of an entire deceased-donor (DD) organ into two transplantable 
portions), and the promotion of living donors (kidney, liver, pancreas, small bowel, and lung). 
Even with these persistent and innovative efforts, the disparity between organ supply and 
demand never comes to an end. The inability to address the transplantation need and donation 
shortage represents the root causes for many patients dying or having a poor quality of life 
and for unacceptable practices, such as organ trafﬁcking and transplant tourism.4 Continuing 
organ deficiency increases the number of patients on the waiting list with longer waiting time, 
higher pre-transplant mortality and worse post-transplant outcomes. More patients are now 
believed to die while waiting for a DD transplant than actually receive one.
5
 The use of this 
alternative donor source is hence hopefully thought to solve this large discrepancy.  
 
DCD classification  
In the United States (US), DCD is considered uncontrolled (uDCD) when the 
cessation of cardio-pulmonary activity occurs suddenly and unexpectedly without any prior 
plans to procure organs, and controlled (cDCD) when the cardio-pulmonary arrest is expected 
shortly after a planned withdrawal of life-sustaining treatment (WLST) and is coordinated 
with a subsequent organ procurement.
6
 In Europe, DCD is differentiated into 4 categories by 





Categories 1 and 2 are perceived as uncontrolled, category 3 as controlled, and category 4 as 
either uncontrolled or controlled depending on the individual circumstances. This 
classification is helpful in discussing some of the legal and ethical issues surrounding DCD. It 
also highlights differences in the potential for organ viability between categories.
8
 New types 








Table 1.1.1. DCD Maastricht classification 
Category Circumstance of death Location of death Organ viability 
1 Dead upon arrival 
 
Outside the hospital  Viability testing 
2 Unsuccessful resuscitation A&E (Accident and Emergency Unit ) 
ICU (Intensive Care Unit) 
Viability testing 
3 Awaiting cardiac arrest 
 
ICU Transplantation 
4 Cardiac arrest  
while brain dead 
ICU Transplantation 
 
In DCD, the heart must cease beating before organ recovery can begin. DCD organs 
are therefore subjected to variable degrees of warm ischemia (WI) prior to organ retrieval.  
Warm ischemia time (WIT) is usually unpredictable and longest in categories 1 and 2, but 
shorter and possibly predictable in categories 3 and 4. As a result, organs from cDCD suffer 
less damage and have better chance of recovery compared with those from uDCD. By 
contrast, in DBD, the heart remains beating. DBD organs are perfused by the donor‟s heart 
throughout the recovery process, and do not thus experience WI. Anoxia, acidosis, loss of 
intracellular homeostasis, and activation of inflammatory pathways may occur during WIT, 
and hence characterizing the fundamental difference between DCD and DBD. In this regard, 
WIT is the most important factor for damage to DCD organs. 
 
Elements of protocols for recovering organs after cardiac death  
Generally, cDCD donors are individuals who have an unrecoverable catastrophic 
neurologic injury resulting in ventilator dependency but not fulfilling brain-dead criteria, or 
who suffer from a terminal illness, like high spinal cord injury, end-stage neuro-muscular 
disease, and end-stage cardio-pulmonary disease. The clinical decision to discontinue medical 
treatment is based on the futility of further treatments, and on the request of the donor or the 
next of kin. The DCD candidate is then evaluated for the medical suitability and the request 
5 
 
for organ donation is discussed with the family. Attempt should be made to determine 
whether a patient will expire in a time frame consistent with donation. Subsequently, life-
sustaining measures are withdrawn in the ICU or the operating room (OR) with or without the 
presence of the family. Once there are circulatory arrest and lack of respiration, a period of 
observation (also namely, no-touch period, hands-off period, or stand-off time) is mandated 
before organ retrieval can begin. After the observation period and death declaration, the 
recovery team may begin flushing preservation solutions and start the surgical procedure if 
withdrawal takes place in the OR. If withdrawal undergoes in the ICU, transport to the OR 
may start during or after the observation period in accordance with the family's wishes and the 
procedure is initiated only after the waiting period and death pronouncement.
13
 In cDCD, the 
retrieval team is in place, and the donor is usually in stable condition prior to cardiac arrest, 
therefore limiting WI. 
Figure 1.1.1.  Timeline of events associated with cDCD.14-16 Withdrawal of life-supporting therapy 
(WLST) is a critical event in the process of cDCD, which affects the time to donor death and thus 
needs to be meticulously delineated.  
 
uDCD donors have an unexpected and irreversible cardiac arrest outside or inside the 
hospital, leading to an extensive WI of the organs. The recovery and use of these organs 
requires a permanent availability and a fast answer from the transplant team, as well as a strict 
WI protocol and careful donor management.
17
 After a failed CPR, the potential donor is taken 
to the hospital in a mobile ICU under mechanical ventilation, external cardiac massage, and 
fluid perfusion to maintain adequate hemodynamic conditions. Upon arrival, the physician in 
WLST   Donation 
WLST   
Cardiac  
arrest  
Discussion        
  1–2  
    hr 
Perfusion Death  
declaration 
 2 - 10  
  min 
CIT <   8 hr liver 
       < 18 hr pancreas 
       < 24 hr kidney 
WIT < 30-45 min liver 
        < 45-60 min pancreas, kidney 






charge of the A&E room diagnoses the death and signs the death certificate. There is no 
additional „no-touch‟ period. The DD is then checked for the conventional prerequisites for 
donation and transferred to the OR where an in-situ cold perfusion (using double-balloon triple-
lumen (DBTL) catheters) or a cardio-pulmonary bypass (CPB) with external oxygenation and 
hypo- or normo-thermia, known as ECMO (extracorporeal membrane oxygenation), is 
performed to preserve the organs inside the body until retrieval while all legal requirements 
(judicial permission and family consent) are obtained. Afterward, organ extraction can start. 
 
 
Figure 1.1.2. Timeline of events associated with uDCD.10,17,18 CRP: cardio-pulmonary resuscitation. 
Cardiac arrest is only considered irreversible if lesions provoking the cardiac arrest are incompatible 
with life, and if effective heartbeats cannot be recovered after a stipulated period of at least 30 min.  
 
Although the aforementioned principles for the recovery of DCD organs are widely 
recognized, considerable variations exist between transplant centers in the US, Europe and 
other countries regarding the ethical and procedural aspects of DCD (Table 1.1.2).
19-21
 The 
lack of consistency in DCD practice may cause disparate organ recovery results that may 
impact organ function, contribute to public confusion, misunderstanding, and hesitation in 
acceptance of this mode of donation, and place health care providers at risk of civil or 
criminal liability.
22,23
 Organ donation efforts can go terribly wrong if appropriate procedures 
are not followed.
24
 Increased consistency of procedures, along with complete transparency, 
serves directly to increase public trust in DCD as an ethical means of organ retrieval, and 






of CPR Perfusion  Procurement  
Death declaration 
          + 
Reperformance of CPR 
 
  
           
  ≥30 
  min 
2 - 10  
 min 
WIT < 120 min liver 
             < 150 min kidney 
  180-240 
      min 
CIT  < 4-6 hr  liver 
        < 18  hr  kidney 
Cardiac  
arrest  Transplantation 
Time 
15 min liver 
30 min kidney 
  min 
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Table 1.1.2. Some controversies and debates over the policies of DCD (predominantly cDCD) 
Topics Problems Current consensus References 






Premortem medications  -Heparin: standard of care 
-Other drugs? 
14,29 
Premortem femoral cannulation Under presumed consent or  
family’s informed consent  
15 
WLST Location and mode of WLST In the OR, extubation and  
cessation of all inotropes 
15,16 
Death prediction  Various predictive tools for 
imminent death after WLST 
Donation procedure should be 





Various confirmatory tests 
 




time   
Various definitions and 
recommended thresholds of WI 
WIT: time interval from WLST 




Various  time frames  after 
which organs could no longer 
be recovered (1 – 5 hours) 
Time frame consistent with 
organ donation is 1-2 hours  
13,40-42 
No-touch period  Various lengths of waiting time  
(2-20 min) 
At least 2 min and not more 




Various perfusion techniques  In-situ perfusion: technique of 
choice in uDCD 
10,45 
Super-rapid laparotomy with 
direct aortic cannulation:   





Machine perfusion (MP)  
Static cold storage (SCS) 
MP for all DCD categories? 
(kidney, liver, lung) 
50-55 
Surgical technique 
of organ retrieval 





High or low risk recipients 
Local/national sharing 




Logistic requirements for recovering organs after cardiac death 
 Implementation of a DCD program implies a very important logistical effort, both 
inside and outside the hospital, with an increased resource utilization in view of a lower yield 
of organs per retrieval episode and, to some extent, uncertain long-term outcomes.
26
 With 
regard to WI, DCD is an emergency and a race against the clock because of the need to 
preserve organs as quickly as possible after cardiac arrest. To achieve an acceptable WIT, it is 
8 
 
necessary to have good planning, management, and organization, as well as a well-trained 
rapid-respond team.
62
 uDCD requires more complex organization than cDCD. With regard to 
medical efficiency, DCD is a challenge for the transplant team because advanced medical 
technologies must be used to assure organ viability and acceptable post-transplant results and 
thus are associated with high medical costs. Estimates of 30-50% increase in hospital charges 
for patients receiving DCD kidneys and livers have been reported.
63,64
  
Apart from legal and ethical barriers, logistics appears to be the most difficult part of 
the policy on DCD, mainly because it depends on the collaboration of many individuals. 
Locating these people and motivating them are the keys.
65
 Efforts focused toward improving 
resource utilization such as better scoring systems and identifying donor risk variables would 




Ethical and legal issues  
The renewed interest in DCD has resulted in renewed examination of the concept and 
meaning of death, the nature of consent, the propriety of interventions for the beneﬁt of the 
recipient and not the donor, potential conﬂicts of interest, and the definition of futility.67,68 
Sensible ethical recommendations for the establishment of DCD programs have been 
published elsewhere. The Institute of Medicine in the US states that “recovery of organs from 
DCD is an important, medically effective, and ethically acceptable approach” in meeting the  
need for donated organs.
69
  
Legal problems depend on the legislation of each country (opting out - presumed 
consent or opting in – informed and explicit consent), and in some instances, speciﬁc changes 
on the legislation must be done. Legal and ethical problems are specific for each type of 
DCD, controlled or uncontrolled, and can be solved by reaching agreements with the 
government, society, and medical community.
68,70,71
  
The ethical, legal, organizational, and technical issues make evident the inherent 
difﬁculties in starting and consolidating a program of this nature and explain why DCD 
activity is just confined in some experienced transplant centers and some countries. Five 
European countries with highest DCD activity are UK, Netherlands, Spain, Belgium and 
France. While the organization of DCD procurement and transplant is at national level in UK, 
Netherlands, and Belgium, it is confined to center level in Spain and France.
19
 Particularly, 
three countries in the world that have published national recommendations on the use of 





Potential and efficiency of DCD programs: are DCD donors a true additional donor 
source? 
Though the transplant outcome from DCD may  not  be  as  good  as  that  from DBD,  
its  potential  donor  pool  is much larger for both the adult and pediatric populations. uDCD 
even has a greater potential than cDCD despite the fact that it now just makes a smaller 
contribution to the total DD pool.
74
 Nonetheless, WIT is a limiting factor for this potential. 
The current stand-down rate is about 20-40%, essentially due to a prolonged time to death 
following WLST that results in severe ischemic injury to the organ or makes organ recovery 
logistically impracticable.
16,75
 DCD donors usually contribute 10-30% of the national DD 
pool (exceptionally 2% in France, 5% in Spain, 30-50% in the United Kingdom (UK) and 
Netherlands, and exclusively the main donor source (>80%) in some Asian countries, like 
Japan).
76-78
 Due to the great potential of DCD to resolve the problem of organ shortage, no 
hospital with an established program in organ donation should lose a potential category-4 
donor. Hospitals with extensive experience in organ donation and transplantation should have 
a policy on uDCD, seeking for these donors in the A&E room or ICU, and hospitals with the 
most experience in DBD and in-hospital uDCD should begin an out-of-hospital DCD policy 
with donors coming from the streets, since this is the biggest source for DCD.
65
 In the US, all 
organ-procurement organizations (OPO) and transplant centers are required to develop 
protocols to facilitate DCD organ recovery, according to the Organ Procurement and 
Transplantation Network and the United Network for Organ Sharing (OPTN/UNOS).
69
  
Some experts in the field question whether DCD really adds to DD pool available. 
While uDCD is really a clear additional donor source for transplantation in France and Spain, 
cDCD might negatively impact DBD activity in Belgium, Netherlands and United Kingdom.
19
 
The shift from potential DBD to DCD without enlargement of the donor pool, some kind of 
donor-type substitution or redistribution, has been observed in some studies.
75,79-81
 
The efficiency of a DCD program is evaluated not only by the number of donors per 
million population (pmp), but also by the number of organs recovered and transplanted per 
donor (ORPD and OTPD), and the discard rate. The ORPD and OTPD are always 
substantially lower for DCD than for DBD while the discard rate is consistently higher. uDCD 
is related to a higher discard rate of organs. Inspection of UNOS data reveals that an average 
of 3.6 and 3.1 organs were recovered and transplanted from DBD donors compared to 2.5 and 
1.9 organs from DCD, respectively. On average per 100 donors, DCD donates 20 less kidneys 





 Therefore, if a negative impact of cDCD on DBD is a reality, it certainly influences 
the transplantation practices, especially for organs such as hearts because of lower yield of 
organs per retrieval episode.
19
 Furthermore, the lower degree of utilization of DCD organs 
makes the initial optimistic impression that DCD could compensate for the dwindling supply 
of DBD donors may not be the case.
83
 
Organs especially suitable for transplantation from DCD are kidney, liver, pancreas, 
and lung. DCD kidney transplantation (KT) has progressively evolved into the routine clinical 
practice and currently makes up 10-50% of all DD-KT at the national level.
77
 However, DCD 
remains underused and its contribution to the DD kidney pool is expected to increase further 
in the coming years. The full use of DCD kidneys could expand the DD kidney pool 2-4.5 




The use of DCD livers is more limited in experienced transplant centers due to a high 
rate of biliary complications that leads to a reduced graft survival and an increased need for 
re-transplantation, as well as a lack of a reliable viability testing prior to liver transplantation 
(LT). The rate of DCD- over DD-LT in the world varies between 5% and 20%. Using a  
mathematical model to analyze the potential impact of a DCD policy on LT programs, Chaib 
reported if 1%, 5% and 10% of deceased individuals became DCD donors, there would be 
8%, 27%, and 37% relative reductions in the size of waiting  list, respectively.
85
 
Pancreas transplantation (PT) from DCD has not yet gained widespread acceptance 
due to concerns about the primary graft dysfunction, graft thrombosis and no validated means 
of testing viability before implantation. The total number of DCD-PT is still very limited and 
has grown at a slow pace. It is still unknown exactly how much the DCD donor pool could 
contribute to expand PT. Present data endorse the use of DCD pancreas in select 
circumstances to expand the donor pool.
86
 
Lung transplantation from DCD is just a slowly emerging field, but represents a 
signiﬁcant and increasing source of DD lungs. The lack of awareness of DCD lung suitability 




General results of thoracic and abdominal organ transplantation from DCD 
 Almost DCD programs in the world started with KT and expanded later with extra-
renal organ transplantation. The success of extra-renal allografts from DCD has encouraged 
the investigation into the possibility of even DCD heart transplant.
88
 Long-term follow-up 
11 
 
data confirm the value of DCD in alleviating the organ shortage crisis and promote the idea 
that DCD donors are on par with DBD transplants in keeping patients off the waiting lists 
with functioning grafts.
89
 In the following section, we will examine the general results 
regarding each organ. 
 
Kidneys  
 All studies agree that DCD- compared to DBD-KT results in a higher rate and longer 
duration of early graft dysfunction, including primary non-function (PNF) and delayed graft 
function (DGF). Consequently, the hazard of graft loss is greater for DCD than for DBD 
kidneys in the early post-transplant period. Viable DCD kidneys that have overcome the early 
post-operative period function as well and as long as DBD counterparts with the same risk of 
graft failure, a comparable rate of graft survival and a similar rate of glomerular filtration rate 
(GFR) decline over time. Survival of transplant recipients from DCD and DBD donors is 
equivalent. Long-term follow-up data are now available up to 15 years post-transplant.
89-91
 
The benefit of accepting a DCD kidney was clearly demonstrated in a recent study, in 
which dialysis patients who are on the waiting list will enjoy longer life-expectancy after 
DCD-KT compared to continuation of dialysis treatment with the option of later receiving a 
conventional DBD kidney.
92
 Nonetheless, DCD-KT may induce unnecessary risks of surgery, 
immune-suppression, and allo-immunization for transplant candidates with PNF;
90
 extended 





LT from DCD has poorer outcomes than from DBD. Higher risk of early graft 
dysfunction (PNF and IPF - initial poor function), more frequent vascular and ischemia-type 
biliary lesions, higher rates of re-listing, and re-transplantation, and lower graft and patient 
survivals are all deﬁnite disadvantages in DCD liver grafts. However, the dangers of DCD 
liver grafts need to be viewed from the perspective of the consequences of not receiving a 
liver transplant in time.
89
 Although DCD liver grafts are not as good as DBD counterparts, it 
is still better than dying because of turning down a DCD offer and continuing to wait for a 
DBD liver on these days as the patient‟s choice is frequently not between marginal livers 
(including DCD) and standard livers but between marginal livers and no livers.
94
 The benefit 
of earlier access to LT provided by a DCD graft could outweigh the risks of prolonged 






Equal graft and patient survivals between cDCD and DBD groups up to five-year 
follow-up have been reported in large series of simultaneous pancreas and kidney transplants 
from DCD despite higher risks of pancreas thrombosis, kidney DGF and longer hospital stay. 
DCD pancreases function as well as DBD organs with respect to glycemic control as 
measured by fasting serum glucose, HbA1c levels, and assisted glycemic control.
86,96
 Isolated 
DCD pancreas transplants are less reported and results seem inferior to DBD counterparts, 
thus DCD pancreases are better utilized if implanted simultaneously with a kidney 
66
. 





 Graft and patient survivals of cDCD lung grafts appear to compare well with those of 
DBD grafts up to 5-year follow-up, in combination with no difference in the incidence of 
primary graft dysfunction and bronchiolitis obliterans syndrome (BOS), as well as lung graft 
function, despite few long-term follow-up data available.
99,100
 The high rate of recovery, 






 Transplantation of DCD heart grafts remains essentially in the pre-clinical phase so 
far. Myocardial vulnerability to ischemic injury would make donor management in the DCD 
setting challenging.
102
 Although the potential donor pool expansion could be interesting, no 




    Table 1.1.3. Clinical evidences in organ transplantation from DCD 
Organs  Graft and patient survivals Challenges 
Kidney DCD kidney      < = DBD kidney 
 
PNF, DGF 
Pancreas  DCD pancreas  < = DBD pancreas PNF, DGF 
Graft thrombosis 
Reperfusion pancreatitis 
Liver  DCD liver          <    DBD liver IPF, PNF 
Ischemic cholangiopathy  
Lung DCD lung         > = DBD lung IPF, PNF 
Bronchiolitis obliterans syndrome 
   PNF: primary non-function, DGF: delayed graft function, IPF: initial poor graft function.    
13 
 
Allocation policy  
DCD organs are more likely to be transplanted locally, firstly because of the transplant 
center‟s preference to inspect and procure the organs personally, secondly due to allocation 
policies (center - driven allocation), and thirdly in order to minimize the ischemic time. 
Nonetheless, parallel (back-up) offers should also be made to expedite organ placement.
14
 
Only Eurotransplant countries (except Germany and Croatia) distribute organs from DCD 
nationally, by applying general allocation criteria.  
 Low immunologic risk or unsensitized recipients are prone to be chosen to receive 
DCD transplants to reduce the ischemic time lost due to a potentially positive 
crossmatch.
66,104
 Transplantation with organs that provides prolongation of life (liver or lung) 
merits consideration. In these patients, DCD organs should only be offered if a DBD graft 
cannot be quickly obtained and patients can be dead due to rapid deterioration of the medical 
conditions, or rapid progression of the underlying disease, such as cirrhotic patients with high 
MELD (model of end-stage liver disease) score, hepato-cellular carcinoma outside the Milan 
criteria…Otherwise, transplanting a marginal organ into a critically ill patient is associated 
with worse results for both the recipient and the graft. Perhaps the optimal environment for a 
DCD graft is a low-risk recipient.
61
 However, high-risk recipients should be meticulously 
considered as their risk of death on the waiting list outweighs that of receiving a DCD graft.
105
 
Donor - recipient matching remains a controversial problem.   
 
Ischemia - reperfusion injury and its consequences 
 Organs procured from DCD donors sustain the insult of ischemia reperfusion injury 
(IRI) at 4 distinct phases: (i) a variable and inevitable period of WI at body temperature 
between cardiac arrest and initiation of cold perfusion, (ii) a rather long period of cold 
ischemia (CI) when organs are stored on ice at 0 - 4°C, (iii) a relatively shorter period of WI 
during the vascular anastomosis - this is when organs are taken out of ice and slowly warm 
up, and finally, (iv) a reperfusion period when organs are suddenly re-instituted with the 
recipient‟s oxygenated normothermic blood. Each phase plays a role in organ damage, and 
each can influence the likelihood of transplantation success and interplay in the ultimate 
outcome. Prolongation of any of the ischemia phases (warm, cold, and re-warm) is expected 







 Ischemia renders tissues and cells devoid of blood, oxygen and nutrients, and 
eliminates the means for disposal of metabolic waste products. At the cellular level, main  
biochemical changes are anaerobic glycolysis, accumulation of metabolic end-products (such 
as lactates, protons, hypoxanthine…), depletion of cellular energy stores (high-energy 
phosphates and energy substrates), reduced intracellular pH (due to build-up of acidic 
products), increased intracellular calcium (due to redistribution of calcium from endoplasmic 
reticulum stores and influx of extracellular calcium), activation of lysosomal enzymes 
(proteases like calpains and caspases, phospholipases, and nuclease), production of free 
radicals (superoxide O2-, hydrogen peroxide H2O2, hydroxyl radicals OH-…), inhibition of 
cytoprotective mechanisms (heme oxygenase-1 (HO-1) and heat shock protein-70), and cell 




 pump insufﬁciency).107 These 
alterations induce an accelerated structural and functional cellular deterioration, leading to 
cell death by cell membrane rupture (or necrosis). Because the injury rate is greater at higher 
temperature, a relatively short period of WI is more detrimental to cells than a much longer 
period of CI. Each minute of WI has been considered equivalent to an hour of CI. This WI 
considerably reduces the cold storage period and can make organs unusable.
108
 
Kidneys can tolerate WI at 37°C for 30 min and recover from acute tubular necrosis in 
a predictable manner. 30 to 60 min of WI results in severe injury with unpredictable recovery 
and 25% mortality. Lengthening WI up to 90 min causes permanent loss of function and 80% 
mortality in experimental studies.
109,110
 Renal tubular cells (especially proximal convoluted 
tubules and proximal ascending limb of the loop of Henle) are the primary target of injury by 
WI.
111,112
 For other organs, the WI tolerance is far more limited. 
The lung is unique when compared with other solid organs as lung parenchymal cells 
do not rely solely on perfusion for cellular respiration and can maintain tissue ATP levels as 
long as oxygen is supplied.
113
 Lungs remain viable for at least 60 to 90 min (and potentially 
up to 4 hours) post-circulatory arrest. Ventilation adds to the lung viability during the WI 
period by providing alveolar expansion and oxygenation.
114
 However, a lack of perfusion with 
oxygenated blood to the airway may contribute to ischemic damage of the airway post-
transplant.  
There is no strict maximum WIT. In practice, allowable maximum WIT varies in a 
qualitative manner, depending on donor age and donor co-morbidities, such as diabetes 
mellitus, hypertension, and peripheral vascular disease (Table 1.1.4).
16,115
  Moreover, the lack 
of a universal agreement in the description and calculation of WIT has made 
15 
 
recommendations on the desirable duration of WIT complex and the comparison between 
various studies difficult (Figure 1.1.3).  
Recently, extraction time, defined as the time between aortic cross-clamp and 
perfusion/cooling and removal of kidneys from the body and placement on ice on the back 
table, has been proposed as an additional insult of WI.
116
 During this time, after the usual 
interval for aortic and sometimes portal perfusion, the ice packed in the abdomen is removed, 
and the kidneys are left to begin re-warming while other organs are removed. 
 
 
Figure 1.1.3. Heterologous definitions of warm ischemia in cDCD.8,15,16,34,36-38 BP : blood pressure. 
Given the importance of events (hypotension, hypoxia) in the agonal phase (from WLST to cardiac 
arrest), the agonal warm period needs to be accurately and clearly described to enable informed 
decisions on the safety of transplantation of organs from DCD donors. This time period could 
arbitrarily start once the systolic blood pressure, MAP or oxygenation falls below a given value.  
 
Cold ischemia  
Cold itself is detrimental to tissues. It can cause changes similar to those observed in 
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ischemia is the rate at which injury develops. At 0 – 4°C, accumulation of injury will continue 
at a rate of approximately 10% from normal.
118
 Organs exposed to cold ischemic (CI) damage 
may or may not recover function depending on the length of cold storage.
119
 Otherwise, 
hypothermia is known to provide considerable protection against ischemic damage by 




Organs can tolerate prolonged CI or some WI without signiﬁcant deterioration of 
function, but when both factors act in the same tissue, their additive or synergistic effect 
easily produces profound injury with marked cell death. Limiting the cold storage period is 
thus of paramount importance when transplanting warm ischemically-sustained organs.
115,121
 
The combined effect of cold and warm ischemia may be explained by the differing 
sensitivities of vascular endothelial cells and parenchymal cells to warm and cold ischemia 
leading to different patterns of cell killing. In kidneys, CI damages glomerular podocytes, 
peri-tubular endothelial cells and proximal tubules, whilst WI triggers injury primarily to 
proximal tubular cells.
122
 WI alone causes minimal damage to the renal vasculature, but when 
combined with cold storage causes severe renal vascular injury with a loss of endothelial cell 
function.
123
 Cell death induced by CI is primarily necrotic in nature,
124
 although apoptotic 
mechanism is also observed. In livers, WI renders prominent injury to hepatocytes and 
Kupffer cells. CI followed by reperfusion causes marked changes in sinusoidal endothelial 




In practice, the length of CIT is correlated with the occurrence of both DGF and PNF. 
Shortening the CIT less than 16 hr allowed a significant reduction in the percentage of DGF 
and better graft survival for DCD kidneys.
129,130
 When CIT was limited to less than 12 hr, the 
rate of DGF in DCD kidneys approached that of SCD kidneys (25.2% versus 19.5%, p = ns), 
and was reduced by 15% compared to CIT greater than 12 hr.
131
  In DCD-LT, the incidence of 
PNF was 2.5 times less in patients with CIT ≤ 8 hr versus those with CIT > 8 hr (5% versus 
13%).
60
 The incidence of graft failure within 60 days of transplantation was 10.8% if CIT < 8 
hr and substantially increased to 30.4% and 58.3% if CIT >8 hr and >12 hr, respectively.
58
 
The recommended CIT is less than 4-6 hr for uDCD, and less than 8 hr for cDCD liver grafts. 
For DBD liver grafts without additional risk factors, the maximal CIT may be up to 16 hr, but 





Table 1.1.4. Potential clinical viability of human organs for transplantation after static cold storage 
(SCS) at 4°C14,16,108,133,134 
 DBD  Controlled DCD 
 CIT (hr) Total WI (min) True WI (min) CIT (hr) 
Heart 6 - - - 
Lung 8 - 60* 6 
Small intestine 12 - - - 
Liver 18-20 30-45 20-30** 8 
Pancreas  18-20 45-60 30 18 
Kidney  36-48 45-60 30-45 24 
*Time to re-inﬂation of the lungs rather than cold perfusion. Despite the comments on the protective 
effect of ventilation cited earlier, it is the long-term function of the small and moderate sized airways 
and their vasculature that determine graft and patient survival in lung transplantation.39 
**May be limited to 20 min in sub-optimal donors 
 
Re-warm ischemia 
At the time of implantation, organs are removed out of cold preservation solutions and 
re-warm from 4°C toward body temperature. The injury process that has begun during WI and 
hypothermia is furthered during the re-warming period. The length of this period depends 
mainly on the surgical technique, besides recipient BMI, donor and recipient‟s vascular 
anatomy, and biliary and urinary tract status…  
Human kidneys warm up at a rate of approximately 0.5°C/min according to a 
logarithmic curve, and at the end of vascular anastomosis, the average kidney temperature is 
about 16-20°C (range: 7-30°C). Larger kidneys warm up more slowly than do smaller ones. 
Keeping the kidney temperature during the time of vascular anastomosis below 16 or 17°C is 
strongly suggested. Increased second WI over 30-45 min is associated with an increased risk 
of DGF.
135,136
 Therefore, the prognostic factor for DGF is not only the time itself, but also the 
actual kidney temperature prior to reperfusion.
137,138
 In DBD-LT, prolonged CIT only (>12 
hr) or re-warming time only (>45 min) was not associated with early graft dysfunction and 
graft loss, but simultaneously prolonged CIT and re-warming time significantly caused 






 Reperfusion injury is characterized by the repair and regeneration processes occurring 
in parallel with the cellular apoptosis, autophagy, and necrosis. The fate of an organ thus 
18 
 
depends on whether cell death or regeneration prevails. Reperfusion produces re-warming, re-
oxygenation, a return to aerobic metabolism (including oxidative phosphorylation), and 
production of ATP (adenosine triphosphate). However, the paradox of reperfusion is that 
ischemic injuries are continued and further exacerbated. The postulated mechanisms consist 
of a rapid burst of reactive oxygen species (ROS) shortly following reperfusion which 
exceeds the protective ability of their scavengers, the action of pro-inflammatory mediators, 
the infiltration of leukocytes (neutrophils, monocytes/macrophages, natural killer cells, and T 
cells) into the graft tissues, and the “no-reﬂow” phenomenon (due to intra-vascular 
obstruction by necrotic cells, thrombosis, accumulation of neutrophils and platelets within 
blood vessels, and interstitial edema extrinsically compressing blood vessels, which all 
attenuate flow and prolong focal ischemia). ROS are toxic molecules that alter cellular 
proteins, lipids and ribonucleic acids, leading to cell dysfunction or death. They probably 
trigger endothelial injury, since only after reperfusion, endothelial cells, which seem fairly 
well preserved after the ischemic phase, become edematous and leaky to proteins and small 
particles. Neutrophils may cause direct cytotoxicity via the production of ROS and release of 
cytokines. They control peri-vascular tissue edema, damage endothelial cells directly, and 
promote platelet aggregation. The characteristic feature of severe reperfusion injury is 




Ischemia-reperfusion and immune injury 
  Apart from the risk of initial graft dysfunction, IRI may increase the graft allogenicity 
and mediate the links between tissue damage, innate and adaptive immune responses through 
Toll-like receptors (TLR) and antigen presenting cells (Matzinger‟s injury theory).141 
According to this theory, the less the initial insult, the smaller the agitation of adaptive 
immunity and the lower the chances for early and late responses to the allograft. “Danger 
signals”, “alarmins” or damage-associated molecule patterns (DAMP) are released during 
ischemia and reperfusion, and include ROS, graft-derived DNA and RNA, oxidized proteins 
and lipids, HMGB1, uric acid, and calcium pyrophosphate crystals... TLR, expressed on the 
surface of various cells (macrophages/monocytes, dendritic cells, and natural killer cells), 
recognize DAMP and trigger a significant cytokine release. These cytokines recruit and 
activate neutrophils and macrophages as part of the innate immune system, which in turn, 






 In short, IRI represents a continuum of events that are triggered when the organ is 
deprived of oxygen and then re-oxygenated, culminating in parenchymal and endothelial cell 
injury. The resultant functional derangement has varying degrees, the severest is primary non-
function (PNF) which is irreversible, and less severe forms are DGF (for kidney and 
pancreas), or IPF (for liver and lung), which is reversible. In the long-term, non-anastomotic 
biliary strictures and increased incidence of acute and chronic rejection have been attributed 
to the consequences of IRI in case of liver transplantation, and bronchiolitis obliterans 




Strategies to improve results of organ transplantation from DCD 
 Various strategies intervening in both donors and recipients at different phases of the 
transplantation process have been proposed at the aim of alleviating the marginality of this 
type of donation. 
 
Donor management 
Donor selection criteria are not generally different between DCD and DBD. The 
criteria for medical suitability depend on the DCD donor types (controlled or uncontrolled) 
and transplant teams. Potential donors are usually assessed individually for 
acceptance.
10,18,45,144
 More restrictive selection criteria will improve the results of DCD organ 
transplantation, but will unavoidably be associated  with  the discard of viable organs.
48
  
 Techniques for in-vivo organ preservation have been developed and encompass the in-
situ cold perfusion (using DBTL catheters), the mechanical chest compression and 
mechanical ventilation (using automated cardio-pulmonary resuscitation devices) with or 
without manual abdominal compression, and the CPB with ECMO. They effectively maintain 
organ viability inside the body for a short period of time (5 – 6 hr), which is enough for the 
logistic preparations for procurement, family consent and legal formalities, therefore making 
kidney and liver transplantation from uDCD feasible.
10,45,145,146
 For cDCD, rapid laparotomy 
and direct aortic cannulation (or supra-rapid recovery technique) is superior over in-situ cold 
perfusion, and rests the preferred method.
46,47
 CPB with ECMO (pre-mortem cannulation and 
post-mortem ECMO) has also been used to support category-3 DCD with excellent results 
and offers logistical advantages over a supra-rapid recovery technique.
147
 
 Anti-coagulatory (heparin) and thrombolytic agents (streptokinase) have been 
administered to a potential donor before WLST to prevent blood clotting after cardiac arrest 
20 
 
and subsequent poor organ wash-out.
148
 Administration of other agents (like cyto-protective 
substances…) would also be useful approaches. However, serious ethical considerations 
preclude most forms of donor pre-treatment.    
 Donor management plays a critical role in the determination of organ quality and thus 
in the expansion of donor pool.  
 
 Organ preservation and assessment (viability testing) 
Preservation solutions and preservation modes aim at reducing the effects of IRI. 
Although being the current gold standard for static cold storage (SCS) of kidney, liver, 
pancreas, and intestine, University of Wisconsin (UW) solution has some drawbacks (high 
cost, high potassium, high viscosity, red-blood-cell aggregation, crystallization at 2–8°C, and 
glutathion oxidation).
133,149-151
 Newer preservation solutions with beneficial additives and 
enriched compositions, like Institut George Lopez (IGL-1), Solution de Conservation des 
Organes et Tissus (SCOT), and Polysol, have proved advantages over UW solution.
152
 SCS, 
despite being an efficient technique for organ preservation in the past and even now, has three 
fundamental limitations: (i) tissue damage caused by the cold itself, (ii) difficulty in assessing 
function and predicting viability during cold storage, and (iii) inevitable IRI.
134
 These barriers 
have impeded its application in preserving marginal organs which have an increased 
vulnerability to IRI and compromised repair mechanisms. SCS is believed to have reached its 
limitations in maintaining the viability of less than optimal organ. Future progress in the 
resuscitation and preservation of DD organs, especially less than ideal organs, may lie not in 
further reﬁning the cold storage or the basic composition of preservation solutions, but instead 
in supplementing cold storage, or even replacing it in large part, by a more dynamic 




Hypothermic machine perfusion (HMP) has been experimentally and clinically 
demonstrated to improve organ quality, transplant outcome and utilization  rates in KT from 
all DD types (SCD, ECD, DCD),
50-52,156
 and in LT.
53,157,158
 The proposed beneficial 
mechanisms may include a continuous elimination of toxic break-down products, a 
continuous supply of nutrients with or without oxygen, a decrease in vasospasm, a protection 
of endothelial cells via sustained expression of flow-dependent genes (particularly Kruppel - 
like factor 2), a possibility of viability testing, and potential therapeutic interventions 





 Normothermic machine perfusion (NMP) offer a greater chance to recondition 
ischemically-injured organs thank to the maintenance of cellular metabolism in a 
physiological environment, thereby overcoming the 3 major weaknesses inherent in the 
traditional SCS. It is particularly relevant in organs with extensive WI injuries coming from 
DCD. This technique would allow an organ to be transplanted on the basis of its quality rather 
than the current system of donor characteristics and ischemic intervals to judge its 
suitability.
160,161





 The use of MP for preservation of other extra-renal organs, like pancreas and heart, 
is still in the pre-clinical step, and needs to take account of the organ-speciﬁc aspects.159  
 Pressure-flow characteristics, reno-vascular resistance, and perfusate enzyme levels 
during HMP have once been used to select and discard the kidneys because MP is believed to 
predict organ viability and allow one to transplant the kidneys with confidence.
112
 It has been 
advocated that DCD programs should only be established if MP is available.
164
  Subsequent 
studies, however, demonstrated although these parameters were independently associated with 
the risk of PNF or DGF, their predictive value was relatively low. The decision to either 





Choosing a right recipient for a particular DCD organ is essential. Transplantation of a 
marginal graft in a low risk recipient is commonly accepted. The center-driven allocation 
policy that is now applied in DCD to shorten the CIT facilitates the donor – recipient 
matching.  
In KT, several strategies help to improve the early graft function. Optimization of the 
renal transplant perfusion in the peri- and post-operative phases by maintaining adequate 
MAP (>70 mmHg) or systolic blood pressure (>110 mmHg), and central venous pressure (>6 
cmH2O) is crucial to minimize the incidence of DGF and PNF.
168,169
 Immunosuppressive 
protocols using a delayed calcineurin-inhibitor (CNI) therapy after induction with interleukin-
2 receptor antagonists, polyclonal anti-thymocyte globulin, or alemtuzumab are efficient in 
avoiding acute rejection and early CNI-associated nephrotoxicity.
170,171







1.2 Implementation of DCD programs in Liège and Belgium  
 
The first cadaveric KT in Belgium was performed from a DBD donor on June 3
rd
, 
1963 at the Catholic University of Louvain. It was also the first ever in the world. Since that 
time, almost all cadaveric organs were procured from DBD donors, including the first lung 
transplant in 1968, the first LT in 1969, the first heart transplant in 1973, and the first 
pancreas transplant in 1982. The Belgian Law on organ donation and transplantation was 
published on February 1987, relying on the presumed consent principle (or opting-out 
system). On the basis of this Law, the National Council of Physicians has specified rules and 
definitions for DBD and DCD organ retrieval on September 1987 and on June 1994, 
respectively. Following the first International Workshop on NHBD in Maastricht in 1995, 
several DCD protocols have been approved by the Hospital Ethics Committees during the 
period of 1995 to 2000, based on the 12 Maastricht recommendations and statements. 
However, it took 3-4 more years to convince the Belgian medical community for the need of a 
national DCD program with the establishment of a central lab for organ machine perfusion. 
Currently, all 7 Belgian transplant centers have active DCD programs, exploring essentially 
the Maastricht category-3 DCD donors for kidney, liver and lung transplantation; and 
Belgium is a member of the Eurotransplant organization, along with Austria, Croatia, 
Germany, Luxemburg, The Netherlands, and Slovenia.
172,173
  
  At the University Hospital of Liège, clinical transplantation has begun very early since 
1965. The first KT from a related living donor was on July 1
st
, 1965, followed by the first 
heart transplant on February 9
th
, 1983; the first simultaneous kidney and pancreas transplant 
on October 18
th




  Up to the year 2011, more than 
1000 kidneys, 500 livers and 400 hearts have been successfully implanted here. Like other 
transplant centers in Belgium and in the world, transplantation has become the victim of its 
success when the number of patients on the wait list always exceeds the number of organs 
available for transplantation. In an attempt to increase the donor pool, DCD was utilized in 
Liège since 2003 firstly for liver and thereafter for KT since 2005.
175,176
  
 The program was approved by the Hospital Ethics Committee in 2004, and after 
several meetings convoking the ICU and OR representatives, anesthesiologist, and the 
transplant team from the University Hospital of Liège and its collaborating donation hospitals 
(particularly the CHR Citadelle and CHC Saint-Joseph), a common DCD protocol has been 
issued in November 2009, specifying the information mandatory in the medical records, the 
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end of life care procedure, the determination of death, and the issue of pre-mortem organ 
preservation measures (Table 1.2.1).
177
 The first Conference of Hospital Collaboration on 
Organ Donation was held in January, 2012 by the University Hospital of Liège, discussing a 




Table 1.2.1 Detailed controlled DCD protocol at the Liège University Hospital (Belgium) 
Protocol elements Consensus 
Potential cDCD donors Maastricht category 3 in the  ICU 
Donor age <65 years for kidneys, no age limit for livers  
Decision  of WLST At least 3  physicians (intensive care physicians, specialists, 
and the treating physician) 
Family consent for donation 
 
Intensive care physicians and transplant coordinators 
Pre-mortem medications -Heparin just prior to WLST  
-Analgo-sedative medications are switched to volatile 
anesthetics (sevoﬂurane or desﬂurane) 
Location of WLST -In the operating room 
-During the daytime 
-Under responsibility of 3 senior anesthesiologists of  the 
Abdominal Surgery and Transplantation Department (or  
anesthesiologist intensivists at the 2 main collaborating  
hospitals) 
Mode of WLST -Ventilator switch-off or extubation  
-Cessation of all inotropes 
Determination of cardiac arrest  Femoral arterial line: lack of arterial pulsation and arterial 




Maximum agonal time  
(from WLST to cardiac arrest) 
≤ 60 min  
 
Total warm ischemia time  
(from WLST to aortic cold perfusion) 
≤ 30 - 45 min for livers 
≤ 45 - 60 min for kidneys 
Death declaration    
 
Senior anesthesiologists of the Abdominal  Surgery  and  
Transplantation Department or  anesthesiologist  intensivists 
at the 2 main collaborating hospitals, who are independent 
of retrieval/transplant  teams 
Organ preservation technique 
 
-Super-rapid laparotomy and direct aorta cannulation 
-Static cold storage  
Cornea and tissue donation 
 






In a series of clinical studies, this thesis aims to answer the following questions:  
 
1. Does the DCD source really contribute to the deceased donor pool in Liège and 
Belgium? 
 
2. Is the use of DCD in Liège and Belgium worth the effort in terms of kidney and 
liver transplant outcomes in comparison with those from DBD in the literature?  
 







Contribution of DCD Source to Organ Procurement 





2.1 DCD activity in Liège 
 
Published as 
H Le Dinh, N Meurisse, MH Delbouille, J Monard, MF Hans, C Bonvoisin, L Weekers, J 
Joris, A Kaba, S Lauwick, P Damas, F Damas, B Lambermont, L Kohnen, A de Roover, P 
Honoré, JP Squifﬂet, M Meurisse, and O Detry 
 
Contribution of Donors after Cardiac Death to the Deceased Donor Pool: 2002 to 2009 
University of Liege Experience 
Transplantation Proceedings 2010, 42: 4369–4372 
 
ABSTRACT 
Objectives: The organ procurement and transplantation activity from donation after cardiac 
death (DCD) at our institution over an eight-year period was evaluated to determine whether 
this program had any impact on donation after brain death (DBD) activity. 
Methods: We prospectively collected our procurement and transplantation statistics in a 
database for a retrospective review. 
Results: We observed an increasing trend in the potential and actual DCD numbers. The 
mean conversion rate turning potential into effective donors was 58.1%. DCD accounted for 
16.6% of the deceased donor (DD) pool over 8 years. The mean age for effective DCD donors 
was 53.9 years (range, 3–79). Among the effective donors, 63.3% (n=31) came from the 
transplant center and 36.7% (n=18) were referred from collaborative hospitals. All donors 
were Maastricht III category. The number of DCD kidney and liver transplants tended to 
increase. DCD kidney transplants represented 10.8% of the DD kidney pool and DCD liver 
transplants made up 13.9% of the DD liver pool over 8 years. The DBD program activity 
increased in the same time period. In 2009, 17 DCD and 33 DBD procurements were 
performed in a region with a little more than 1 million inhabitants. 
Conclusion: The establishment of a DCD program in our institution enlarged the donor pool 
and did not compromise the development of the DBD program. In our experience, DCD is a 






Confronted with the organ shortage for transplantation, many countries around the 
world have been re-addressing the donation after cardiac death (DCD) as an alternative 
donation source for expanding the donor pool. Estimates suggested that potential DCD 
number may be as high as twice the donation after brain death (DBD) number
179
 and that 
DCD kidneys might contribute to 20-40% of the deceased donor (DD) kidney pool.
180,181
 
Liver, pancreas, lung and even heart from DCD could also be used with success despite a 
greater risk of primary graft dysfunction, re-transplantation and other organ-specific 
complications.
88,182-186
 The University Hospital of Liège in Belgium has a long tradition in 
transplant surgery.
174,187
 The Liège region has one transplant center and 16 collaborative 
donor hospitals. A Maastricht category III DCD program was initiated in 2002
173,175
 following 
the success of DCD programs in pioneering countries like the Netherlands and Spain,
188
 and 
after the 12 Statements and Recommendations of the first International Conference on DCD 
in Maastricht in 1995
189
 which were later approved by the Council of Europe in 1998.
190
 In 
this report, we retrospectively reviewed our experience in organ procurement and 
transplantation from DCD source from 2002 to 2009, in order to assess if this DCD activity 
significantly impacted the transplantation activity of the center, and to exclude any decrease 
of DBD donation as a consequence of the DCD program. 
 
Methods  
The authors prospectively collected all data related to donation and transplantation 
activities at the Department of Abdominal Surgery and Transplantation of the CHU Liège. 
These informations were retrieved from the department database and completed with the 
annual reports of the Eurotransplant organization (accessible via the member site of 
www.eurotransplant.be) and the Belgian Section of Transplant Coordinators.
191-194
 Retrieved 
data related to donation activity included potential and effective donor numbers, percentage of 
donation refusals, reason for denial of donation, and organ yield. Donor profile included 
donor Maastricht type, origin, age, cause of death, time from ventilator switch-off to cardiac 
arrest, and primary warm ischemia time. The local transplantation activity was compared to 
the Belgian experience within the same period. Conversion rate was defined as the percentage 




Data are presented as mean ± standard deviation (SD) or percentage. All statistical 
analyses were performed using SPSS 16.0. Statistical significance was determined with 






The DCD number varied from year to year, with a progressive increase in DCD 
procedures (Figure 2.1.1). All donors were Maastricht III category (Table 2.1.1). The 
proportion of DCD within the deceased donor pool increased from 3.7% in the first year of 
the DCD program, up to 34% in 2009. In addition, in the same time period, the absolute 
number of DBD increased. On average, DCD contributed to 16.6% of the DD pool over 8 
years. From 2006 to 2009, 43 donor procedures were performed among 74 potential donors 
(conversion rate: 58.1%). Among potential donors, reasons of no donation were medical 













































Figure 2.1.1. Annual number of DBD and DCD procurements in Liège region (Belgium)  
leading to at least one transplant from 1995 to 2009.   
 
The mean organ yield per DCD donor was 2.3 organs, which was lower than that of 
DBD.  Mean organ yield per donor according to age category was 2.5 organs in the age group 
<60 years and 1.9 organs in the age group ≥60 years (Table 2.1.2). The mean age for the 
effective DCD donor was 53.9 years (ranges: 3-79 years). Donors ≥60 year-old made up 
33 
 
40.4% of the DCD pool. The rate of retrieved livers and kidneys in this age group was 85% 
and 52.5% respectively. Causes of death were differentiated between DCD and DBD. From 
2006 to 2009, comparing DCD and DBD groups, 26.5% vs. 37.9% died of a cerebro-vascular 
accident, 18.4% vs. 47.7% died of a cranial trauma, 40.8% vs. 6.8% died of brain anoxia, and 
14.3% vs. 7.6% died of other reasons (suicide, intoxication, tumor…). Among the effective 
donors, 63.3% (31 donors) came from the transplant center and 36.7% (18 donors) were 
referred from affiliated non-university hospitals. The mean time from life-support withdrawal 
to cardiac arrest was 11.7 ± 6.4 min (ranges: 1-30 min) and the mean time from life-support 
withdrawal to aortic cold perfusion was 20 ± 9.5 min (ranges 5-60 min). Waiting period or 
no-touch period varied between 3 and 5 minutes.  
 
Table 2.1.1. DCD proﬁle in Liège from 2002 to 2009 (n=49) 
Donor characteristics Data  
Age (mean ± SD) (y) 53.9 ± 15.1 
Age range (y) 3–79 
Age category (%), y 
       <40  
       40-59  





Gender (male/female) (%) 69.4/30.6 
Cause of death (%) 
      Cerebral vascular accident  
      Cranial trauma 
      Anoxia 






Donor type 100% Maastricht III 
Donor origin (%) 
      Transplant center 




Time from switch-off to cardiac arrest (mean ± SD), min 11.7 ± 6.4 
Range of time from switch off to cardiac arrest (min) 1 - 30 
Time from switch off to aortic cold perfusion (mean ± SD), min 20 ± 9.5 
Range of time from switch-off to aortic cold perfusion (min) 5 - 60 
Number of retrieved organs 
      Kidney 
      Liver 
      Pancreas 
      Heart 











From 49 effective DCD donors, 110 organs were harvested and transplanted into 106 
recipients, which included 70 kidneys, 36 livers and 4 lungs. All these organs were allocated 
by the Eurotransplant organization. Twenty-four kidneys and 31 livers were locally 
transplanted, and the other organs were sent to other transplant centers. In addition, one liver 
and one pancreas were retrieved for hepatocyte and islet preparation, respectively. Twenty-
nine hearts were also procured and sent to a tissue bank for homograft valve preparation and 
cryopreservation.  
 
Table 2.1.2. Donor activity and kidney and liver transplantation in Liège 
 2002 2003 2004 2005 2006 2007 2008 2009 
Effective DCD/potential DCD  
(%) 


























NTOD in DCD 
 
2 2.7 0 2 2.4 2.6 1.7 2.1 
DCD/DD kidney transplant  
(%) 
  0/23 
0   
0/49 































Single kidney transplants (including kidney en bloc)/combined kidney transplants. NTOD: number of 
transplanted organs per donor. 
 
The number of DCD kidney and liver transplants also had a tendency to increase each 
year (Figure 2.1.2 and 2.1.3). From 2007 to 2009, the rate of kidney transplants and liver 
transplants using DCD varied between 16.7% and 24.5% of the DD kidney pool and between 
20.7% and 41.9% of the DD liver pool. On average, DCD kidney grafts represented 10.8% of 
the DD kidney pool and DCD liver grafts made up 13.9% of the DD liver pool over 8 years.  
 
Discussion 
The long transplantation waiting lists have triggered interest in expanding the organ 
pool by using DCD again in mid-1990s despite medical and ethical concerns. The potential 
contribution of this type of donors to the entire donor pool is unclear and may approach 
25%.
195
 The potential increase in the supply of kidney transplants by exploration of DCD 
kidneys is estimated about 2-4.5 times.
196
 Promising calculations in the Netherlands and the 
US proposed that the potential supply of DCD kidneys is large enough to satisfy the demand 
35 
 
for renal transplantation and therefore the shortage of kidneys would be a thing of the 
past.
84,196
 However, in practice, single-center reports usually described a proportion of DCD 
kidney transplants of about 20-40% of the DD kidney pool.
180,181,197-200
 Exceptionally, a few 





In the field of liver transplantation, the use of DCD liver could increase the supply of 
liver transplants by 53%.
202
 Using a mathematical model to analyze the potential impact of 
using a DCD policy on liver transplant program, Chaib found that if 1%, 5% and 10% of the 
deceased became DCD, it could result in a relative reduction of 8%, 27% and 37% in the size 
of the waiting list respectively.
85
 Centers with active DCD liver transplantation program 
reported a rate of 4-10% of liver transplants came from DCD source.
203
 At our institution, 
between 19.2% and 41.9% of DD liver transplants were carried out using organs from DCD in 
recent years (Table 1).
175






















































DCD kidney DBD kidney 
 
Figure 2.1.2. Annual number of kidney transplants from DBD and DCD in Liège region (Belgium) from 
1995 to 2009. 
 
However, the introduction of a DCD protocol might have a negative effect on DBD 
program. Some transplant centers observed a remarkable increase in the number of DCD with 
a concomitant decrease in the DBD number, resulting in no significant change in the donor 
pool.
79,80
 As a consequence, DCD may lead to a redistribution of donor types within the donor 
pool. Explanation for this phenomenon may reside in changes of neurosurgical practices in 
patients with cerebral injury, in family choice between a controlled DCD and a DBD 
procedure, or in the eagerness of the medical staff to initiate donation procedures due to high 
36 
 
pressure on intensive-care-unit beds.
167
 This was not the case in our experience, as the 















































DCD liver DBD liver
 
Figure 2.1.3. The annual number of liver transplants from DBD and DCD in Liège region (Belgium) 
from 1995 to 2009. 
 
Additionally the efficiency of DCD programs is also lower than DBD programs in 
terms of number of transplanted organ per donor. In the Liège experience, from 2006 to 2009, 
this number between DCD and DBD was 1.7 - 2.6 organs versus 3 - 3.8 organs. 
 
Conclusion 
This report describing the establishment of a DCD program at the University of Liège, 
showed that DCD may enlarge the total DD pool without compromising the development of 




2.2 DCD activity in Belgium 
 
Published as  
I Jochmans, T Darius, D Kuypers, D Monbaliu, E Gofﬁn, M Mourad, H Le Dinh, L Weekers, 
P Peeters, C Randon, JL Bosmans, G Roeyen, D Abramowicz, AD Hoang, L de Pauw, A 
Rahmel, JP Squifﬂet, and J Pirenne 
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Transplant International 2012, 25: 857–866 
 
ABSTRACT 
Objectives: Worldwide shortage of standard brain dead donors (DBD) has revived the use of 
kidneys donated after circulatory death (DCD). 
Methods: We reviewed the Belgian DCD kidney transplant (KT) experience since its 
reintroduction in 2000. Risk factors for delayed graft function (DGF) were identiﬁed using 
multivariate analysis. Five-year patient and graft survival was assessed using Kaplan–Meier 
curves. The evolution of the kidney donor type and the impact of DCDs on the total KT 
activity in Belgium were compared with the Netherlands. 
Results: Between 2000 and 2009, 287 DCD KT were performed. Primary non-function 
occurred in 1% and DGF in 31%. Five-year patient and death-censored graft survivals were 
93% and 95%, respectively. In multivariate analysis, cold storage (versus machine perfusion), 
cold ischemic time, and HTK (histidine-tryptophan-ketoglutarate) solution were independent 
risk factors for the development of DGF. Despite an increased number of DCD donations and 
transplantations, the total number of deceased donor KT did not increase signiﬁcantly. This 
could suggest a shift from DBDs to DCDs. 
Conclusion: In order to increase KT activity, Belgium should further expand controlled DCD 
programs while simultaneously improve the identiﬁcation of all potential DBDs and avoid 







Organ shortage has urged transplant physicians to expand the acceptance criteria of 
deceased donors (DD). The use of expanded criteria donor (ECD) kidneys and kidneys 
donated after circulatory death (DCD) has increased signiﬁcantly. About one-third of DD 
kidney transplant (KT) activity in the United States is performed with kidneys from ECDs and 
DCDs.
204
 Although DCD was common practice in the early era of transplantation, the 
introduction of brain death criteria and the superior results achieved with organs donated after 
brain death (DBD) pushed DCD to the background.
205
 DCDs were reported to have 
considerably higher incidences of delayed graft function (DGF) and primary non-function 
(PNF) as compared with DBD kidneys (28–88% and 1–18% vs. 13–35% and 1–10%, 
respectively)
206,207
 and inferior graft  outcome. However, with the successful course of clinical 
transplantation activities, the DBD pool rapidly became insufﬁcient to sustain the increasing 
demand for kidney grafts.  Consequently, DCD kidney programs were established as the full 
potential of the DCD pool was estimated larger than that of the DBD pool and could double or 
even quadruple the number of DD KT.
208
 In addition, some landmark publications at the turn 
of the century showed that excellent long-term graft survival, equivalent to DBD kidneys, 
could be achieved with DCD kidneys.
188,209
 These early reports were subsequently conﬁrmed 
in larger series.
206,210,211
 The excellent results of DCD KT combined with the growing organ 
shortage has led to a steady increase of DCD KT activity in countries with the required legal 




Despite a legal framework allowing maximal efforts to stimulate organ donation and 
transplantation (opting-out, legality of DBD, DCD, and living donation
213
) and one of the 
highest deceased donor rates per capita world-wide, Belgium is still confronted with a renal 
graft shortage. Less than 50% of wait-listed patients are transplanted yearly.
212
 Therefore, in 
an attempt to increase the number  of  KT,  DCD  KT programs  were  reintroduced  in  
Belgium  at  the  turn  of  the century. In this report, we review the 10-year Belgian DCD KT 
experience with particular emphasis on (i) results, (ii) risk factors for DGF, (iii) the evolution 
of the different types of kidney donation, and (iv) the evolution of the overall KT activity. 
 





Donor and recipient data from all DCD KT performed in Belgium between January 1
st
, 
2000 and December 31
st
, 2009 were retrieved from the registry of the international organ-
exchange organization Eurotransplant
212
 and the seven Belgian kidney transplant centers, 
represented by the Kidney-Pancreas Committee. Recipients younger than 18 years of age at 
the time of transplantation were excluded, as were combined transplantations. 
Delayed graft function was deﬁned as the need for dialysis in the ﬁrst week after 
transplantation, preceding return of graft function. PNF was deﬁned as a graft that never 
regained function. Warm ischemic time (WIT) was deﬁned as the  time  from  withdrawal  of  
life support to start of cold perfusion, acirculatory time as the time from cardio-circulatory 
arrest until start of cold perfusion, cold ischemic time (CIT) as the time from start of cold 
perfusion to start of the vascular anastomoses, and anastomotic time as the time from start of 
the vascular anastomoses until reperfusion of the graft. HLA mismatching between donor and 
recipient was categorized according to differences at the HLA-A, HLA-B, and HLA-DR loci; 
with 0–1 of six possible mismatches categorized as „level 1‟, 2–4 mismatches as „level 2‟, and 
5–6 as „level 3‟. Graft survival was deﬁned as the time from transplantation to return to 
dialysis, graft nephrectomy or to patient death with a functioning graft, whichever came ﬁrst. 
Early acute rejection was deﬁned as the treatment of biopsy-proven rejection within the ﬁrst 3 
months after transplantation. 
The evolution of kidney donation and transplantation rates in Belgium and the 
Netherlands, both Eurotransplant countries, was studied by comparing activity in three   
chronological eras (1995–1999, 2000–2005, and 2006–2010). Kidney donation and kidney-
only transplantation rates were obtained from the Eurotransplant registry. Rates were adjusted 





Continuous variables are expressed as median (inter-quartile range), categorical 
variables as number (and percentage). Comparisons of continuous variables between groups 
were performed using Mann–Whitney U-test or Kruskall–Wallis test. Comparisons of 
categorical variables were performed using Chi-squared or Fisher‟s exact test. Univariate and 
multivariate logistic regression models were constructed to ﬁnd independent risk factors of 
DGF. The multivariate model was constructed by backward stepwise regression using 
covariates with a univariate p-value <0.15. As only three cases of PNF occurred, no further 
analyses on PNF were performed. Kaplan–Meier curves were used to assess patient and graft 
41 
 
survival. The effect of DCD type (controlled versus uncontrolled DCD) on five-year patient 
and graft survival was assessed using log-rank tests. Because of a limited number of deaths 
and graft losses (n = 25 and n = 18, respectively), no Cox regressions were performed. P-






A total of 287 DCD KT were performed in Belgium during the 10-year study period 
(i.e., 7.4% of all DD KT). In the same period, 175 DCD procedures were performed (i.e., 
7.8% of all DD procedures). Donor and recipient characteristics are shown in Table 2.2.1. 
During the study period, pediatric donors were not considered for DCD and generally the 
upper age limit for DCD was considered to be 60 years. DCD kidneys were allocated 
following standard Eurotransplant allocation rules and were transplanted for all common 
transplant indications (Table 2.2.2). Ninety-one percent of DCD kidneys were procured in 
Belgium, whereas 9% were imported.  Ninety-three percent of kidneys were recovered from 
controlled Maastricht Category III donors leading to relatively short warm ischemic and 
acirculatory times, 7% were recovered from uncontrolled Maastricht Category II donors 
(Table 2.2.1).
7
 Prior to 1998, duration of the „no-touch‟ period varied from 2 to 10 min, 
depending on center practice. However, since the US recommendation of the Institute of 
Medicine, a 5-min period became standard in most centers.
214
 
Histidine-tryptophan-ketoglutarate (HTK) solution was used as ﬂush solution in 83% 
of donors, and University of Wisconsin solution (UW) in 16%. Kidneys were preserved either 
by cold storage (47%) or by machine perfusion (53%), depending on the preference of the 
recipient center. Of machine-perfused kidneys, 82% were placed on the machine directly after 
procurement in the donor center (immediate perfusion). In 18%, machine perfusion was 
started after an initial period of cold storage (delayed perfusion). All kidneys preserved on the 
machine were perfused with Belzer‟s machine perfusion solution, available as KPS-1 (Organ 
Recovery Systems, Itasca, IL, USA).
215
 Between 2000 and 2003, the RM3 machine (Waters 
Medical Systems, Rochester, MN, USA) was used. Thereafter, kidneys were perfused on 
LifePort Kidney Transporter machines (Organ Recovery Systems). Eighty-nine percent of 
machine-preserved kidneys were perfused on LifePort machines.  
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Recipient immune-suppression varied according to center-speciﬁc practice (Table 
2.2.1): 72.6% of recipients received induction therapy, the introduction of calcineurin 
inhibitors was delayed in only 12.3% of cases. Maintenance immune-suppression consisted of 
calcineurin inhibitors (100%), mycophenolate mofetil (93%), and corticosteroids (100%). 
 Recipients were followed for a median of 34 months (18–46), during which time PNF 
developed in 1% and DGF in 31% of cases. Machine-perfused kidneys experienced a 
numerically 9% lower DGF rate compared with cold stored kidneys (27% and 36%, 
respectively, p = 0.07). The DGF incidence of kidneys with delayed versus immediate 
machine perfusion was similar (33% and 26%, respectively, p = 0.48). DGF rate in 
uncontrolled DCD was higher compared with controlled DCD (65.0% vs. 28.5% respectively; 
p = 0.001); however, PNF rates were similar (0% vs. 1%, respectively; p = 0.63). DCD KT 
resulted in excellent 5-year patient and death-censored graft survival (93% and 95%, 
respectively) (Table 2.2.1, Fig. 2.2.1). Patient and death-censored graft survival of 
uncontrolled DCD was similar to controlled DCD (85% vs. 93%; p = 0.22 and 94% vs. 95%; 
p = 0.98, respectively).  
 
Risk factors for the development of DGF  
Results from univariate and multivariate regression analyses are shown in Table 2.2.3. 
After correction for donor and recipient variables, cold storage (versus machine perfusion), 
CIT, and ﬂush with HTK were independent risk factors for DGF. The type of DCD donor 
(uncontrolled or controlled) was not an independent risk factor in multivariate analysis, nor 
was WIT or acirculatory time. 
 
Evolution of kidney donation and transplantation rates in Belgium since 1995  
Between 1995 and 2010, the majority of effective Belgian kidney donors were DD 
[20.6 per million population (pmp) (19.0–22.4)], mainly DBD [19.4 pmp (18.3–20.9)] with a 
small portion of DCD [0.4 pmp (0.2–2.8)]. Living donation [2.2 pmp (1.5–3.8)] increased the 
total number of effective kidney donors in Belgium to 23.0 pmp (21.1–26.0) (Fig. 2.2.2a). KT 
rates showed a similar distribution: a majority of DD [37.9pmp (31.9–38.8)], mainly DBD 
[33.5pmp (30.3–37.1)] and a few DCD [0.7 pmp (0.3–4.8)]. Living donation [2.5 pmp (1.5–
4.0)] increased the total number of KT to 39.2 pmp (34.7–42.8) (Fig. 2.2.2b).  
Although Belgium reintroduced DCD KT in 2000, the number of DCD KT was low 
until 2003, after which a  steady  increase  occurred  with  DCD  comprising up to 16% of DD 
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Table 2.2.1. Characteristics of DCD donors and DCD KT recipients in Belgium between 2000 and 2009 
Donor characteristics (n=179) Recipient characteristics (n=287) 
Age (years)*  44  
(31–55) 
Age (years)* 54  
(45–61) 
Gender, n (%) 
       Male 




Gender, n (%) 
       Male 




Terminal SCr (mg/dl)* 0.70  
(0.56–0.91) 
Dialysis duration (months)* 29  
(17–48) 
History of arterial hypertension, 
n (%)† 
27 (17) Previous transplants, n (%) 
       First transplant 




Donor type, n (%)‡ 
       Uncontrolled (category I + II) 




Panel reactive antibodies, n (%) 
       n = 0–5% 
       n = 6–84% 





Warm ischemic time (min)* 20  
(15–29) 
HLA mismatches, n (%) 
       Level 1 
       Level 2 





Acirculatory time (min)* 10  
(8–14) 
Donor type, n (%) 
      Uncontrolled (category I + II) 




Flush solution, n (%) 
       HTK 
       UW  





Immunosuppression, n (%)† 
Induction therapy 
       Anti-thymocyte globulin 
       IL-2 receptor antagonist 
Calcineurin inhibitor 











Surgical process  287 Primary non-function, n (%) 3 (1) 
Preservation method, n (%) 
       MP 




Delayed graft function, n (%) 89 (31) 
Cold ischemic time (h)* 16 (12–19) Immediate function, n (%) 195 (68) 
Anastomotic time (min)* 31 (11–71) Acute rejection, n (%)† 50 (17.5) 
Graft loss 5 years after 
transplantation 
       All causes 










*Median (inter-quartile range). 
†Data are missing from some recipients who were excluded from percentage calculations. 
‡Donor type was stratiﬁed according to the Maastricht Categories.7 
 
Table 2.2.2. Indication for transplantation in 287 recipients of kidneys  
donated after circulatory death in Belgium between 2000 and 2009 
Indication for transplantation n (%) 
Glomerular diseases 77 (27) 
Polycystic kidneys 58 (20) 
Uncertain etiology 35 (12) 
Tubular and interstitial diseases 30 (11) 
Retransplant/Graft failure 26 (9) 
Diabetes 22 (8) 
Hypertensive nephroangiosclerosis 15 (5) 
Congenital, rare familial, metabolic disorders 11 (4) 
Renovascular and other renal vascular diseases 9 (3) 
Neoplasms 3 (1) 
Others (familial nephropathy) 1 (<1) 
 
 
Figure 2.2.1. Patient and graft Kaplan–Meier survival curves until 5 years post-transplant  
of all kidneys donated after circulatory death in Belgium between 2000 and 2009 
 
kidneys in 2010. Between 2000 and 2005, only 1.5% (0.75–4.25) of all transplanted deceased 
donor kidneys originated from DCD donors. Between 2006 and 2010, this number increased 
to 16% (12–16.5; p = 0.04). Table 2.2.4 shows the evolution of kidney donation and 
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transplantation rates. Despite an increase in DCD donation, total deceased kidney donor rates 
did not increase. Living donors only slightly increased the total kidney donation rates. 
Increased kidney transplants from DCDs and living donors did not result in a signiﬁcant 
increase of total kidney transplant activity.  
 
Figure 2.2.2. Total number of effective kidney donors and transplantations per milion population in 
Belgium (panel a–b) and the Netherlands (panel c–d) between 1995 and 2010. Data adapted from 
Eurotransplant31,212  
 
Evolution of kidney donation and transplantation rates in the Netherlands since 1995 
In the Netherlands, effective kidney donation rates reached 25.0 pmp (19.9–34.9) 
between 1995 and 2010. Kidney donors were equally distributed between living donors [12.2 
pmp (7.3–20.8)] and DD [12.5 pmp (12.0–13.6)], with DBD [8.1pmp (7.4–10.2)] as well as 
DCD [4.1 pmp (2.2–5.5)] (Fig. 2.2.2c). Kidneys were mainly transplanted from DD [23.2 
pmp (22.1–24.9)], both from DBD [14.7 pmp (13.7–19.1)] and DCD [7.6 pmp (3.7–10.0)]. 
Living donor transplants [12.4 pmp (7.3 - 20.8)] increased the total number to 35.4 pmp 
(31.3–44.6) (Fig. 2.2.2d). Table 2.2.4 shows the evolution of kidney donation and 
transplantation rates. Living donation resulted in increased kidney donation rates. Deceased 
46 
 
donation activity remained stable, but DBD activity decreased signiﬁcantly, whereas an 
exponential increase in DCD was observed (Table 2.2.4, Fig. 2.2.3). KT rates also increased, 
mainly because of increased living donations (in 2010, 57% of transplantations were with 
living donor kidneys). DD KT rates remained stable, with increasing use of DCD kidneys and 
decreasing transplants from DBD (Table 2.2.4, Fig. 2.2.3). 
 
Table 2.2.3. Uni- and multivariate logistic regression for the development of delayed graft function* 
Variable  Univariate (n = 287)† Multivariate (n = 203)‡ 
 OR (95% CI) p-value OR (95% CI) p-value 
Donor and surgical characteristics 
Age (years) 1.00 (0.97–1.02) 0.73   
Gender – female versus male 0.78 (0.46–1.34) 0.37   
Terminal SCr (mg/dl) 1.93 (0.90–4.12) 0.09   
History of arterial hypertension 0.91 (0.44–1.90) 0.80   
Uncontrolled versus controlled 
DCD 
4.59 (1.77–11.96) 0.002 3.13 (0.99–9.91) 0.05 
UW versus HTK solution  0.14 (0.04–0.47) 0.001 0.19 (0.57–0.67) 0.01 
Machine perfusion versus cold 
storage 
0.66 (0.40–1.09) 0.11 0.35 (0.16–0.74) 0.01 
Delayed versus immediate 
machine perfusion 
1.44 (0.59–3.52) 0.43   
Warm ischemia time (min) 1.01 (1.0–1.03) 0.10   
Acirculatory time (min) 1.05 (1.01–1.10) 0.03   
Cold ischemic time (h) 1.06 (1.01–1.12) 0.03 1.11 (1.32–1.19) 0.01 
Anastomotic time (min) 1.00 (0.97–1.02) 0.73   
Recipient characteristics 
Age (years) 1.02 (1.00–1.04) 0.07   
Gender - female versus male 0.65 (0.39–1.10) 0.11 0.52 (0.26–1.04) 0.06 
Pre-transplant dialysis duration 
(mo) 
1.01 (1.00–1.02) 0.09 1.02 (1.00–1.03) 0.06 
Retransplant versus ﬁrst 
transplant 
1.18 (0.50–2.76) 0.71   
Panel reactive antibodies (%) 1.01 (0.99–1.02) 0.58   
HLA mismatches 
        Level 2 versus Level 1 




   
*Multivariate model was constructed using backward stepwise regression of covariates with a 
univariate p < 0.15. 
†Data are missing for some recipients; these were excluded case wise from multivariate analysis. 




Table 2.2.4. Evolution of kidney donors and transplants in Belgium and the Netherlands between 
1995 and 2010 
 1995–1999 2000-2005 2006–2010 p value 
Belgium 
Kidney donors (pmp) 
     Total 
     Living donors 
     Deceased donors  
           DBD 

























Kidney transplants (pmp) 
     Total 
     Living donors 
     Deceased donors  
           DBD 


























Kidney donors (pmp) 
     Total 
     Living donors 
     Deceased donors  
           DBD 

























Kidney transplants (pmp) 
     Total 
     Living donors 
     Deceased donors  
           DBD 

























pmp, per million population. Values are presented as median (inter-quartile range). 
 
Discussion 
This Belgian survey shows that DCD KT programs resulted in good immediate 
function and excellent medium-term outcome. Indeed, a 31% DGF incidence in DCD kidneys 
is lower than commonly reported and is in fact comparable to DGF rates observed in DBD 
kidneys (13–35%).206,207 This low DGF rate likely results from short CIT and the use of 
machine perfusion. Our multivariate analysis, although limited by its retrospective nature, 
showed that CIT and cold storage are independent risk factors of DGF. This is consistent with 
a recent Eurotransplant randomized controlled trial showing that machine perfusion 
signiﬁcantly reduces the risk of DGF in DCD kidneys.51,52 Of note, 16% of the kidneys in the 
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current analysis were part of the Eurotransplant trial. Following the report of a UK 
randomized controlled trial that did not show the beneﬁt of machine perfusion,216 it has been 
suggested that kidneys should be machine-perfused immediately following procurement until  
transplantation.
217
 In this analysis, no difference was observed in DGF between immediate 
versus delayed perfusion. However, an effect could have remained undetected because only a 
minority of kidneys underwent delayed machine perfusion.  
We  observed  only  three  PNF  cases  (1%), contrary  to generally  higher  PNF  rates  
reported  in  DCD kidneys.
206,207
 Although no formal analysis on the risk factors of PNF could 
be performed, the low PNF rate is likely explained by the majority of controlled Maastricht 
Category III donors, the relatively short warm ischemic and acirculatory times, anastomotic 
time and CIT, and possibly the use of machine perfusion.
218
 In addition, donors were young 
with excellent kidney function and only rarely suffered from hypertension. 
Unfortunately, the introduction of DCD KT did not lead to a major increase in the 
Belgian KT activity. There are several possible contributing factors.  
Firstly, despite the high number of DBD in Belgium there is room for improvement.  
Only 67% of potential DBDs are identiﬁed and of these 10% are never reported.219 One  
strategy  to  improve  donor  identiﬁcation  and referral  is  the  Spanish  model  of  the „donor  
facilitator‟: professionals responsible for donor identiﬁcation and evaluation, supporting  
intensive care personnel charged with donor maintenance, and interviewing donor families.
220
 
In Belgium, donor facilitators have recently been appointed through a national initiative, the 
GIFT-project. In addition, training of health-care professionals involved in donation and 
transplantation and national campaigns to increase public awareness should be pursued.
221
  
Secondly, the full potential of controlled DCDs is not used. As many as 26% of all  
ICU deaths are potential controlled DCD donors, but less than 4% of DCD are identiﬁed,  
indicating a real possibility to increase the donor pool (survey Ministry of Health, L. De 
Pauw, personal communication). A possible explanation could be the extreme caution and 
skepticism by which DCD were originally approached in Belgium. The initial mixed results  
of  international DCD programs reporting  high DGF and PNF rates
188,222-226
 held the Belgian 
DCD programs back for another 2–3 years.173 At the time, it was advocated that „the 
development of a non-heart beating program is no longer acceptable if machine perfusion and 
viability testing are not available‟.164 The publication by Weber et al., showing equal long-
term results for DBD and DCD kidneys, even without machine perfusion,
209
 increased 
conﬁdence in DCD and lead to a marked increase in DCD KT after 2003. Meanwhile, it has 
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also been shown that viability testing - based on renal vascular resistances and biomarkers in 






Figure 2.2.3. Evolution  of  effective  deceased  kidney  donors  (panel a) and transplants  
(panel b)  per  million  population  in  Belgium  and the Netherlands between 1995 and 2010. 
Data adapted from Eurotransplant212  
 
Although it might be too early to distinguish the effect of DCD programs on the 
overall transplant activity, there is an increasing concern that DBD are being recovered as 
DCD, i.e. potential donors with major, irreversible neurological injury are prematurely 
referred as DCD, before brain death occurs. Especially in the UK
228 
and the Netherlands (Figs 
2.2.2 and 2.2.3, Table 2.2.4) the increase in DCD has been accompanied by an alarming 
decrease in DBD. The shortage of ICU resources and perhaps the erroneous perception that 
DCD and DBD have equivalent results may encourage physicians to refer potential donors 
earlier as DCD, even if they may progress to brain death at a later stage. In addition, the 
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possibility to offer withdrawal of life support earlier could avoid unnecessary prolonged 
suffering for patients and families in case of unrecoverable neurological damage.
75
 
Furthermore, improved  and more aggressive neurosurgical decompressive treatments delay 
or even prevent  development of brain death after neurological disasters.
75
 Although an 
alleged substitution of DBD for DCD is very difﬁcult to prove, the possibility of it occurring 
is extremely worrisome because, as a result, total DD transplant activity is not increasing. 
Furthermore, DCD liver transplantation results in higher rates of biliary complications and 
decreased graft survival, DCD critically diminish the donor population for heart 
transplantation, and there are fewer organs retrieved from DCD with a lower utilization rate.  
The observation that DBD activity has continued to increase – albeit slightly – in most 
European countries, except those with established DCD programs like the Netherlands and 
UK, supports a substitution phenomenon. A survey of the Belgian Ministry of Health has 
shown that the potential of DBD has decreased from 8% to 6% of ICU deaths between 2007 
and 2010 (L. De Pauw, personal communication). 
To effectively increase the DD pool without compromising  the  excellent  results  of  
transplantation, DCD  should  ideally  only  concern  donors  that would  otherwise  not  
progress  to  brain  death.  In  this regard,  uncontrolled  DCD  (Maastricht  Category I and II) 
represent a scarcely  explored  source of kidney  grafts that  does  not  compete  with  DBD. 
Uncontrolled DCD is predominant utilized only in Spain and France, where controlled DCD 
is not allowed.
19
 Although graft survival of uncontrolled DCD kidneys seems to be similar to 
controlled DCD in experienced centers, data on long-term results in large patient cohorts are 
scarce.
9,19,218,229
 Our limited experience with uncontrolled donation has resulted in a higher 
DGF rate, but equally good 5-year outcome compared with controlled DCD. Unfortunately, 
procurement and organ utilization rates in these uncontrolled DCD are lower than in 
controlled DCD with considerably increased use of resources and potentially demotivating 
donor hospitals and procurement teams.
19
 
Another potential source of DCD organs are organs donated after euthanasia. Since 
2002, euthanasia is legal in Belgium under strict conditions.
230
 At the explicit wish of the 
patient requesting euthanasia and after Ethical Committee approval, organ donation can be 
considered. A limited number of cases have been performed with excellent results.
12,231
 The 
potential of donation after euthanasia is substantial; 335 cases of euthanasia with a 






Because of the high rate of deceased donation in Belgium, it has long been thought 
that the need for living donation was less urgent than in countries with low deceased donation. 
However, this review shows that overall DD activity has not increased signiﬁcantly over the 
last 15 years, whereas waiting times for a deceased kidney have increased (median of 787 
days in 2000 and 864 days in 2010). Extensive worldwide experience with living kidney 
donation, the safety of unilateral nephrectomy in selected  healthy living donors,
233-235
 the 
development of minimally invasive surgery, and the superior results of living versus DD 
KT,
236
 support the further development of living donation in Belgium. Matching the living 
donor activity to that in the Netherlands or in the United States would double the total 
transplant activity in Belgium. 
 
Conclusion 
DCD KT in Belgium results in good immediate function and excellent medium-term 
outcome. However, until now DCD programs have not resulted in an increase of total DD KT 
activity, possibly related to a substitution of DBD to DCD donors. To increase its KT activity, 
Belgium should (i) improve the identiﬁcation and reporting of all DBD donors with support of 
appointed donor facilitators; (ii) pursue the development of  controlled  DCD  while  avoiding  
premature referral  of  potential  donors  who  may  progress  to  brain death; (iii) explore 












3.1 DCD kidney transplantation in Liège and Belgium 
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Results of Kidney Transplantation from Controlled Donors after Cardio-Circulatory Death: 
a Single Center Experience  
Transplantation International 2012, 25: 201–209 
 
ABSTRACT 
Objectives: The study aimed at determining results of kidney transplantation (KT) from 
controlled donation after cardio-circulatory death (DCD). Primary end-points were graft and 
patient survival, and post-transplant complications. The influence of delayed graft function 
(DGF) on graft survival and DGF risk factors were analysed as secondary end-points. 
Patients-Methods: This is a retrospective mono-center review of a consecutive series of 59 
DCD-KT performed between 2005 and 2010. 
Results: Overall graft survival was 96.6%, 94.6% and 90.7% at 3 months, 1 and 3 years, 
respectively. Main cause of graft loss was patient‟s death with a functioning graft. No primary 
non-function grafts. Renal graft function was suboptimal at hospital discharge, but nearly 
normalized at 3 months. DGF was observed in 45.6% of all DCD-KT. DGF significantly 
increased post-operative length of hospitalisation but had no deleterious impact on graft 
function or survival. Donor body mass index ≥30 was the only donor factor that was found to 
significantly increase the risk of DGF (p<0.05).  
Conclusions: Despite a higher rate of DGF, controlled DCD-KT offers a valuable 
contribution to the pool of deceased donor kidney grafts, with comparable mid-term results to 







 Confronted with the universal critical organ shortage, many transplant centers have 
started the use of donation after cardio-circulatory death (DCD) as an alternative donor 
source. Results of kidney transplantation (KT) from DCD over the past 30 years showed 
comparable results with those from donation after brain death (DBD).
90,131,199,212,237-239
 These 
results of DCD-KT have led Belgian transplant centers to revisit this option and urged the 
Belgian National Council of Physicians on organ procurement from DCD.
173
 The first DCD-
KT was performed in Belgium in 2000, and up to now all seven Belgian transplant centers 
have active DCD-KT programs.
193,194
 In 2009 there were 60 DCD procurements (21.7% of the 
deceased donor (DD) pool) and 74 DCD-KT (17.3% of the DD kidney pool) in comparison to 
9 DCD procurements (3.8%) and 14 DCD-KT (3.9%) in 2005. A preliminary report over 44 
DCD-KT in Belgium during the 2003–2005 period showed a delayed graft function (DGF) 
rate of 20.5% and a primary non-function (PNF) rate of 9.1%. DCD kidneys preserved by 
machine perfusion had a significant lower rate of DGF than cold-stored kidneys (25% versus 
42%) and the risk of graft loss of 3%.
173
 
   The University Hospital of Liège initiated a program of controlled DCD-KT in 
2005.
240
 This study aimed at evaluating results of DCD-KT at our institute with regard to 
short- and mid-term graft function, graft and patient survival, rejection and surgical 
complications. The influence of DGF on graft function and survival as well as the potential 
DGF risk factors were also analyzed as secondary end-points. 
 
Patients and Methods. 
This study is a retrospective review of the experience of the Department of Abdominal 
Surgery and Transplantation at the University Hospital of Liège with controlled DCD-KT 
from 2005 to 2010. Kidneys procured from DCD donors were distributed within the 
Eurotransplant organization according to the same allocation rules as DBD kidneys (except 
Germany and Croatia where organ procurement and transplantation activity from DCD are 
prohibited by Law). The rate of local, national and international sharing was 47.5%, 44.1% 
and 8.5%, respectively, in this series. The acceptance criteria for DCD kidneys were as 
follows: donor age less than 65 years; no history of renal disease, uncontrolled hypertension, 
complicated diabetes mellitus, systemic sepsis or malignancy; warm ischemia time (WIT) less 
than 45 minutes (from cardio-circulatory arrest to aortic cold perfusion) or less than 60 
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minutes (from withdrawal of life-support to aortic cold perfusion)
14
 and terminal serum 
creatinine < 20 mg/L. Donor characteristics are presented in Table 3.1.1. 
Withdrawal of life-support occurred in the operating room. Heparin was injected 
intravenously prior to withdrawal of both ventilator and cardiac support in most DCD donors. 
Vital signs (blood pressure, heart rate, respiratory rate and trans-cutaneous oxygen saturation) 
were monitored after discontinuation of treatment until cardio-circulatory arrest took place. 
Cardio-circulatory arrest was defined by femoral mean arterial pressure less than 30 mmHg 
without arterial pulse. A 5-minute no-touch period was respected after cardio-circulatory 
arrest, then cardio-circulatory death was declared. Rapid laparotomy with direct aortic 
cannulation technique was utilized to in-situ perfuse organs. HTK was the most common used 
preservation solution (84.7%) and kidneys were cold-stored in most cases (83.1%). Ten 
kidney allografts were preserved by the hypothermic machine perfusion (HMP) technique in 
the context of an Eurotransplant randomized controlled trial about the efficacy of HMP over 
static cold storage (SCS).
51
 Mean total WIT was 20.1 ± 7.2 min (range: 8-39). This time 
period comprised the withdrawal phase (from treatment discontinuation to cardio-circulatory 
arrest, mean: 9.4 ± 5.5 min, range: 2-30) and the acirculatory phase (from cardio-circulatory 
arrest to initiation of aortic cold perfusion, mean: 10.6 ± 4.8 min, range: 5-27). Mean cold 
ischemia time (CIT),  defined as the time interval from aortic cold perfusion until removal of 
the kidney graft out of the cold preservation solution for implantation, was 731.3 ± 267.5 min 
(range: 207-1255). Mean vascular anastomosis suture time was 35.1 ± 9.7 min (range: 18-60).  
Recipient variables are summarized in Table 3.1.2. Mean recipient age was 54.9 ± 
13.5 years (range: 21 – 76). Recipient older than 65 years received kidneys from older donors 
in the context of Eurotransplant Senior Program.
241
 Mean PRA (panel reactive antibodies) at 
transplant was 5.2% ± 15.2% (range: 0-75). Mean number of HLA (human leukocyte 
antigens) mismatches was 2.8 ± 1.0 (range: 0-4). The frequency of 0, 1, 2, 3 and 4 HLA 
mismatches was 1.7%, 8.5%, 28.8%, 32.2% and 28.8%, respectively. Ureteral double J 
catheter was utilized in half of the patients (49.2%), largely depending on the surgeon‟s 
preference and experience. All recipients received induction therapy with anti-CD25 
monoclonal antibody (basiliximab) and a standard triple therapy with tacrolimus or 
cyclosporin, mycophenolate mofetil or mycophenolic acid and steroids. Anti-infective 
prophylaxis comprised sulfamethoxazole/trimethoprim for pneumocystis and urinary tract 
infection for at least 6-12 months, valganciclovir for cytomegalovirus (CMV) depending on 
donor and recipient CMV serologic status (if D+/R-: valganciclovir for 3 months, other cases:  
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Table 3.1.1 and Table 3.1.2. Donor and Recipient  characteristics 
Donor characteristics Mean ± SD or 
n (%) 
Recipient characteristics Mean ± SD or 
n (%) 
Age (years)  45 ± 12.9 
(3-68) 
Age (years)  54.9 ± 13.5 
(21–76) 
Gender 
       Male  





       Male  




BMI (kg/m2) 25.4 ± 3.2 
(20–31.4) 
BMI (kg/m2) 26.8 ± 5.3 
(15.9–38.2) 
Hypertension 
      Yes 
      No  






        Primary GN  
        Hypertension 
        Diabetes          
        Lupus 
        Tubulo-interstitial 
                            nephropathy 
        HIV nephropathy 
        Hemolytic uremic 
                           syndrome   
        Hepato-renal polycystosis 
        Uropathy 
        Unknown causes 
 













      Yes 
      No  





Donor cause of death 
      Head trauma 
      CVA  
      Anoxia 






Length of ICU stay (days) 7.1 ± 6.5 
(0–24)* 
Time on waiting list (days) 535.7 ± 498.5 
(3–2160) 




933.2 ± 617.1 
(0–2425)** 
24 h diuresis (ml) 2841.6 ± 1312.2 
(1270–5940) 
Residual diuresis (ml) 650.4 ± 748.9 
(0–2520) 
Last hour diuresis prior 
to procurement (ml) 
144.2 ± 125.3 
(10–600) 
Previous transplants 
        First transplant 




Peak PRA (%) 11.5 ± 18.7 
(0-70) 
PRA at transplant (%) 5.2 ± 15.2 
(0–75) 
Number of HLA mismatches 
         
2.8 ± 1.0 
(0-4) 
*Euthanasia donors did not stay in the ICU.  
**One pre-emptive kidney transplant in the context of combined liver-kidney transplantation. 
BMI, body mass index; ICU, intensive care unit; ESRD,  end-stage  renal  disease;  PRA,  panel reactive 
antibody; HLA, human leukocyte antigens; HIV, human immune-deﬁciency virus. 
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acyclovir for herpes virus for 3 months). Diagnosis of renal allograft rejection was suggested 
by an unexplained rise in serum creatinine level of > 0.3 mg/dL or a 25% increase from 
baseline level and confirmed by ultrasound-guided per-cutaneous biopsy.  Renal biopsy was 
also routinely done for all grafts at 3 months post-transplant for the purpose of deciding to 
withdraw steroids or not. Given the importance of subclinical rejection as a risk factor for 
interstitial fibrosis and tubular atrophy as well as worse glomerular filtration rate (GFR) and 
graft survival, they were all treated with bolus of steroids. Donor specific HLA antibody was 
checked periodically at the hospital discharge, 3 months and every year post-transplant, 
simultaneously at the time of graft biopsy and after a sensitizing event. Doppler ultrasound 
was systemically done at hospital discharge, 3 months and every year post-transplant or at any 
change of renal allograft function without clear explanation.  
The renal transplant was primary transplant in most cases (93.2%) with one combined 
liver-kidney transplantation. There were four re-transplant recipients (6.8%), of which, one 
was immunized with peak PRA of 61% while the remaining three had no panel reactive 
antibodies. No patients developed donor specific antibodies which were routinely screened by 
single antigen Luminex technique. The average number of HLA mismatches was 2.2 ± 1.5 
(range: 1-4). Cross-match tests were performed at the procurement center with the recipient‟s 
historic sera and repeated again at the transplant center with a recent serum and these tests 
must be negative prior to graft implantation. For primary transplant recipients who were at 
low immunological risk, kidney transplantation was allowed before the result of cross-match 
test to shorten the CIT.  
 Primary endpoints of the study were PNF, DGF, graft function at the hospital 
discharge, 3 months, 1 and 3 years post-transplant, graft and patient survival at 3 months, 1 
and 3 years post-transplant. PNF was defined as inadequate renal function after 
transplantation that necessitates continuation of dialysis, excluding operative technical 
problems. DGF was defined as the requirement for hemo-dialysis during the first week post-
transplant, with subsequent recovery of renal function, except dialysis treatments to correct 
hyper-kalemia or volume overload.
242
 Graft function was estimated via serum creatinine and 
GFR according to the abbreviated Modification of Diet in Renal Disease (MDRD) 
equation.
243,244
 Secondary endpoints of the study were the potential risk factors for DGF, the 
effect of DGF on graft and patient survival, duration of post-transplant hemo-dialysis, length 
of patient's hospital stay, acute rejection rate within the first 3 months post-transplant and the 
61 
 
occurrence of vascular or urological complications. Acute rejection was diagnosed on the base 
of the initiation of anti-rejection treatment or renal biopsy result. 
Statistical analysis was as follows: continuous variables were presented as mean ± 
standard deviation (SD) and categorical variables as percentage. Differences between groups 
were evaluated by non-parametric Mann Whitney U/Wilcoxon Ranked Sum tests for 
continuous variables and Fisher‟s exact test or Chi square test for categorical variables. 
Survival rates were estimated by the Kaplan–Meier method and compared by the log rank test 
with graft failure and patient death as events. Multivariate logistic regression analysis was 
used to identify potential risk factors for DGF. All tests were two-tailed and p-values < 0.05 
were considered as significant. All analyses were performed using the SPSS statistical 
software, version 11.0 for PC Windows. 
 
Results 
 During the 6-year period, there were 59 and 215 renal transplants from controlled 
DCD and DBD donors, respectively. In other words, DCD kidneys made up 21.5% of the DD 
kidney pool and helped to increase the activity of kidney transplantation up to 27.4% without 
impairing the DBD kidney source. The organ procurement and transplantation activity of the 




























































Figure 3.1.1. Organ  donation and kidney transplantation activity in Liège over time.  
The number of DCD-KT increased without impairing the number of DBD-KT. 
 
Functional and survival data 
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 Analysis of Kaplan-Meier survival curves showed overall and death-censored graft 
survival rates were 96.6% and 96.6% at 3 months, 94.6% and 96.6% at 1 year, 90.7% and 
92.6% at 3 years, and 84.6% and 92.6% at 4 years, respectively (Figure 3.1.2). Five renal 
grafts were lost during the post-transplant follow-up, one due to renal vein thrombosis, one 
secondary to the relapse of HIV infection in the allograft and three others because of patient 
deaths. Mean follow-up of patients was 26.5 months (range: 0.5-62 months). Patient survival 
rates at 3 months, 1, 3 and 4 years were 98.3%, 96.3%, 96.3% and 90.3%, respectively 
(Figure 3.1.3). Three patients (5.1%) died during follow-up, one due to acute myocardial 
infarction 24h post-operatively and other two due to broncho-pneumonitis caused by CMV 
and Aspergillus infection at 5 and 41 months.  
 
 
Figure 3.1.2. Overall and death-censored graft survival after DCD-KT (n = 59). Overall and 
actuarial graft survival rates were 96.6% and 96.6% at 3 months, 94.6% and 96.6% at 1 year, 
90.7% and 92.6% at 3 years, and 84.6% and 92.6% at 4 years, respectively. 
 
No PNF grafts were observed in this series. Two recipients were excluded from the 
analysis of DGF rates because one died 24h post-transplant and it was not known whether the 
graft was functioning at the time of patient death, the other lost the kidney graft due to renal 
vein thrombosis. Twenty-six of 57 patients (45.6%) experienced DGF. The occurrence of 
DGF did not adversely influence graft survival, as overall graft survival rates were 100%, 
95%, 95% and 83.1% for patients with DGF compared with 100%, 100%, 91.7  and 91.7% 
for patients without DGF at 3 months, 1, 3 and 4 years, respectively (p=0.52, Figure 3.1.4). In 
addition, DGF did not increase the risk of acute rejection or surgical complications: among 26 
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recipients with DGF, 8 (30.7%) developed acute rejection compared with 8 (25.8%) recipients 
without DGF (p=0.67). The rate of all surgical complications was 34.6% and 25.8% in 
recipients with and without DGF, respectively (p=0.46). 
 
 
Figure 3.1.3. Overall  patient survival after DCD-KT. Patient survival rates at  3  months,  1,  3,  
and 4 years were  98.3%,  96.3%,  96.3%,  and 90.3%, respectively. 
 
 The use of HMP (n=10) was associated with a non statistically significant lower rate 
of DGF in comparison to that of SCS (30% versus 48.5%, respectively, p=0.31). Likewise, 
donor age (≥60 years), donor terminal serum creatinine (≥15 mg/L), recipient age (≥60 years), 
recipient BMI (BMI ≥30), kidney allocation policy (national or international sharing), WIT 
(≥45 min), suture time (≥45 min) as well as CIT (≥18 h) had no apparent effect on the risk for 
DGF (p=NS, both in univariate and multivariate logistic regression analysis, Table 3.1.3). 
Donor body mass index (BMI), in contrast, had an impact on DGF in multivariate model (not 
in univariate analysis). Kidneys from donors with BMI ≥30 compared to ones with BMI< 30 
was 17 times more likely to have DGF (p=0.03).  
 One patient was transplanted due to HIV nephropathy and lost quite rapidly her renal 
allograft (29 months post-transplant) secondary to the relapse of HIV infection in the 
allograft. This was a rare indication of transplantation and this patient was excluded in the 
assessment of renal allograft function. Mean serum creatinine level at hospital discharge was 
22.1 ± 11.7 mg/L (range: 6.8-56.6). The percentage of patients with serum creatinine level at 
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hospital discharge < 20, 20 – 40 and > 40 mg/L was 61.1%, 25.9% and 13%, respectively. 
Renal graft function continued to improve up to 3 months post-transplant and nearly stabilized 
over the following 4 years (Figure 3.1.5). The mean GFR at hospital discharge, 3 months, 1 
and 3 years was 37.1 ± 16.6, 50.7 ± 11.7, 50.9 ± 11.3 and 49.2 ± 11.2 ml/min respectively. 
Among 4 recipients who underwent re-transplantation, two developed DGF. However the four 
kidney grafts functioned well during the study period.  
 
Table 3.1.3. Multivariate logistic regression analysis between the risk of DGF and  
different factors linked to the donor, recipient or transplantation procedure 
Factors Odds ratio 95% CI p value 
Donor age  ≥50 years 0.902 0.235 – 3.465 0.881 
Donor BMI ≥30 17.415 1.258 – 241.179 0.033 
Donor serum creatinine ≥15 mg/L 0.000 0.000 1.000 
Recipient age ≥60 years 3.249 0.776 - 13.610 0.107 
Recipient BMI ≥30 3.505 0.872 – 14.088 0.077 
Kidney allocation policy  
(national or international sharing) 
0.801 0.221 – 2.907 0.736 
WIT ≥30 min 1.982 0.239 – 16.457 0.527 
Suture time ≥45 min 2.276 0.380 – 23.650 0.368 
CIT ≥12 h 2.886 0.572 – 14.556 0.199 
CIT ≥18 h 3.252 0.210 – 50.358 0.399 
Preservation method (HMP) 0.462 0.058 – 3.647 0.463 
 
Postoperative evolution and complications 
 The average number of hemo-dialysis post-transplant in case of DGF was 4.96 ± 6.01 
sessions (range: 1-32). Mean duration of hemo-dialysis was 10.6 ± 17.1 days (median: 7, 
range: 1-90). Mean hospital stay was 17.8 ± 5.7 days (range: 2-32). There was a significant 
difference in length of hospitalization between DGF and IGF (immediate graft function) 
groups (19.3 ± 5.3 versus 13.4 ± 3.9 days, p< 0.001).  
Sixteen of 59 patients (27.1%) experienced graft rejection during the first 3 months 
post-transplant, making up 17 rejection episodes. Rejection might be either clinically 
suspected without graft biopsy (10.1%) or biopsy-proven at the time of rejection suspicion 




Figure 3.1.4. Graft and patient survival between DGF and no DGF groups. The presence of 
DGF did not adversely inﬂuence graft and patient survival (p=NS).  
 
Figure 3.1.5. Sequential serum creatinine levels over time.  
 Early post-operative complications are presented in Table 3.1.4. After hospital 
discharge, renal artery stenosis was detected in two patients (3.4%) and stenting was 
necessary in one of them. Peripheral artery disease developed in two patients and all of them 
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were stented at the level of iliac arteries. Infectious complications included pulmonary 
tuberculosis (one patient) and urinary tract infection (11 patients). Urologic exploration was 
performed in one patient due to repeated urinary infection but no urinary anomaly was found. 
Peri-renal lymphocele occurred in one patient and was treated by puncture aspiration 
technique. One patient became pregnant 20 months post-transplant and gave birth of a healthy 
boy at 33
rd
 amenorrheal week due to pre-eclampsia. No urinary leakage or ureteral obstruction 
was observed during the study period.   
 
Table 3.1.4. Early post-operative complications 
Complications n Treatment 
Renal vein thrombosis 1 transplantectomy  
Peri-graft hematoma  5 conservative treatment (4 patients), surgical re-
intervention (1 patient) 
Hematuria 5 bladder irrigation 
Hydronephrosis 2 resolving spontaneously without urologic intervention 
Abdominal wall bleeding  1 surgical re-intervention 
Rupture of drainage catheter 1 surgical re-intervention 
Urethral stenosis and benign 
prostatic hypertrophy 
3 urethrotomy (1 patient) and transurethral resection of 
prostate (2 patients) 
Acute myocardial infarction 2 coronary artery stenting (1 patient death) 
Cardiac rhythmic disorders   2 cardio-pulmonary resuscitation (1 patient) and cardiac 
pace-maker placement (1 patient) 
Anemia 11 blood transfusion 
 
Discussion 
 This study showed excellent results of controlled DCD-KT which were comparable to 
those from DBD in the literature although the use of DCD kidneys led to an elevated rate of 
DGF due to the unavoidable WIT between the withdrawal of life-support and the initiation of 
cold preservation. DGF increased significantly the length of hospitalization, nonetheless had 
no deleterious impact on post-transplant DCD kidney outcomes as demonstrated in several 
other studies.
245,246
 A recent meta-analysis in studies with controlled DCD donors showed no 
difference in PNF rate between 2 groups of DBD and DCD kidneys. The only significant 
difference was the DGF rate.
206
 In our series, we did not experience any PNF and found a 
DGF rate of 45.6%. However, this high rate of DGF was not associated with an increased 
graft loss. When evaluating risk factors for DGF, only donor BMI ≥30 was significantly 
associated with an increased rate of DGF in multivariate logistic regression model. The 
significance of this finding is not clear.  
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 DCD kidneys recovered their function slowly and in majority of cases failed to 
optimize their function at the time of hospital discharge. However their function continued to 
improve and nearly normalized at 3 months post-transplant. Afterwards renal allograft 
function stabilized over the following 4 years. By examining outcomes of DCD kidney 
transplants which functioned for at least 1 year and had a follow-up of 2–5 years, Chapman 
found that the rate of graft loss at 5 years was similar between DCD and DBD grafts 
(approximately 3%) and both groups showed similar declines in GFR after 1 year (-1.3 
mL/min for the DCD group versus -1.4 mL/min for the DBD group). This means that DCD 
kidneys might have a reduced functioning glomerular mass because of the initial ischemic 
damage, but once transplanted there was no evidence of accelerate deterioration.
247
 
Graft survival rates in this study were favorably comparable to other reported 
series.
198,199,237,248
 The major cause of graft loss was patient death with a functioning graft. 
Although DCD kidneys experienced worse early transplant outcomes than those coming from 
DBD donors, they did provide real survival benefit to patients.
249
 Patients who were willing to 
accept a standard-criteria DCD kidney had a 56% reduction in mortality risk compared with 
those remaining on dialysis or awaiting a standard-criteria DBD kidney. This reduction in 
mortality translates into 2.4-month additional expected lifetime during the first 4 years after 




 The rate of clinical and subclinical rejection in our study was similar to that reported 




 or a recent meta-
analysis.
206
 DCD kidneys, despite experiencing greater DGF rates, do not display a greater 
incidence of acute allograft rejection episodes (10%-19%) compared with DBD kidneys (9%-
18%). Similarly, in a recent publication, Saeb-Parsy did not find any difference in the rate of 
major urological complications (urinary leak and ureteral stenosis) between DCD and DBD 
kidney grafts (3.5% versus 1.7%, p=0.28).
252
 Inversely, Droupy found that the risk of ureteral 
stenosis and fistula was significantly higher for DCD than DBD kidneys (15% versus 7%, 
p=0.04).
253
 In 76 controlled DCD-KT performed at Leiden University Medical Centre, 
Khairoun reported one urinary leakage because of ureteral necrosis and two ureteral 
obstructions (one after removal of the double J stent and the other due to blood clot).
254
   The 
rate of renal artery stenosis in this study was 3.4%. Although the incidence of transplant renal 
artery stenosis is expected to be higher in DCD kidneys because of the exposure to an 
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excessive ischemic injury, many published series, as ours, also did not find any significant 
difference between DCD and DBD kidneys.
255,256
  
 Estimates suggested that the potential increase in the number of DCD kidneys might 
be 2–4.5 times that of DBD kidneys.196 However, in practice, single-center reports usually 
described a 20%–40% proportion of DCD kidney transplants among the DD kidney pool.197-
200
 Exceptionally, a few transplant centers have obtained 50–70%, such as in Maastricht77 or 
Madrid.
45,201
 Recently several transplant centers in the Netherlands,
80
 the United Kingdom 
(UK)
79
 and the United States (US)
75
 have observed a remarkable increase in the number of 
DCD donors with a concomitant decrease in DBD donors, resulting in no significant change 
in the DD pool, some kind of redistribution of donor types within the pool. We have not yet 
observed such a trend in our experience. 
No significant difference in the rate of DGF between ice-stored and machine-perfused 
DCD kidneys was noted in this study, although the DGF rate was lower among machine-
perfused grafts. A recent multi-centric randomized controlled trial, in which 164 DCD kidney 
pairs were split and one allocated to each preservation modality, convincingly demonstrated 
that HMP produced less frequent and less severe DGF as compared with SCS group (54% 
versus 70%).
51
 In a study design similar to Moers's study, Watson in the United Kingdom 
found no benefit of HMP over SCS for DCD kidneys. Nevertheless the author emphasized on 
the ischemia time as an important factor for the differences between the two trials.
257
 A meta-
analysis undertaken by Wright
50
 and studies in the US using the national database
131,258
 all 
confirmed the advantage of HMP over SCS in DCD kidneys.  
 
Conclusion 
The use of controlled DCD kidneys might be an effective way to increase the number 
of kidneys available for transplantation because of good transplant outcomes and acceptable 
post-operative complications. Despite a higher rate of DGF with longer hospitalization, DGF 
had no harmful effect on the graft future in this series. By using this donor source, transplant 
centers could help optimize the quality of life and minimize the mortality of end-stage kidney 
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Clinical Results of Kidney Transplantation from Donors after Cardiac Death 
Transplantation Proceedings 2010, 42: 2407–2414 
 
ABSTRACT 
Objectives: Confronting the critical organ shortage, many transplant centers are now 
increasingly using donation after cardiac death (DCD) since 1990s as an alternative donor 
source to the insufficient donation after brain death (DBD). This review aimed at examining 
the clinical experience in DCD-KT in the world during the 1990s and 2000s, in order to help 
KT programs to develop DCD-KT and to better allocate DCD kidney grafts. 
Methods: We conducted a systemic review of all mono- and multi-centric DCD-KT studies 
in the world over the past 20 years, and evaluated the short- and long-term results of DCD-KT 
in terms of initial graft function (delayed graft function-DGF and primary non-function-PNF), 
graft and patient survival, rejection, post-operative surgical and urological complications.  
Results: Follow-up studies comparing DCD- and DBD-KT have shown comparable long-
term graft function and survival up to 10 - 15 years post-transplant, despite higher rates of 
DGF and PNF in the early post-transplant period. Better transplant outcomes are obtained in 
controlled rather than uncontrolled DCD. 
Conclusion: DCD programs should be continued and expanded. DCD donors constitute a 
potential donor source that may partially solve the imbalance between the number of end-
stage kidney disease patients on the waiting list and the number of available kidney grafts. 







In the early days of transplantation, all cadaveric transplant organs were retrieved from 
donors after cardiac death (DCD). After the establishment of the concept of brain death in 
1968 
1
, DCD have been largely abandoned in the mid 1970s and replaced by donors after 
brain death (DBD). The interest for DCD was renewed in the early 1990s as a potential 
solution for the critical universal shortage of kidney grafts. 
The practice of DCD differs greatly around the world as a consequence of different 
cultures, religions, and legislations. To date DCD donation has been concentrated in Europe, 
the United Kingdom, the United States and Japan (Table 3.2.1). Most countries use mainly 
Maastricht type 3 DCD, except France and Spain, where type 2 DCD are more widely used. 
While type 1 DCD are not used in many countries because of concerns about logistic 
difficulties, ethics and procured organ quality, it turns out to be the main DCD type in Spain. 
In Japan, donation after cardiac death has relied almost exclusively on type 4 DCD. Some 
countries are now starting to use type 2 DCD.  
The contribution of DCD source to deceased donor pool also varies considerably 
between countries (Table 3.2.1). In 2007, the proportion of DCD kidney transplantation (KT) 
was 10.7% of the total cadaveric kidney pool in the United States
259
 and 22.1% in the United 
Kingdom.
260
 In Netherlands almost 50% of deceased donor kidneys are provided by DCD.
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Estimates suggest that DCD programs may contribute 20-40% of cadaveric kidneys for 
transplantation
180,181
 and there might be two times more potential DCD than DBD.
179
 
Therefore the use of DCD might have considerable impact on the kidney graft pool, markedly 
shortens waiting times and improves the survival and quality of life of the patients on the 
waiting lists.  
It is therefore likely that DCD kidneys will be a large part of the transplantable kidney 
graft pool in a next future. The aim of this review is to examine the clinical experience in KT 
using the different types of DCD during the 1990s and 2000s, in order to help KT programs to 
develop DCD-KT and to better allocate DCD kidney grafts. 
 
Differences between DCD and DBD pertinent to transplant outcomes 
DCD differs from DBD in many aspects. The essential differences involve 















% DCD-KT / 
DD-KT 




Belgium 261 2,3,4 ETKAS 65 14.7 13.1 3.7 
Netherlands 261,262 2,3,4 ETKAS 166 36.1  41.1 7 
Spain 76,261   1,2,4 Locally  104 5.1 5.7 2 
France 261,263  1,2,4 Locally 42 1.6 2.4 0.6 
United Kingdom 261,264 2,3,4 Locally   313 22.1 23.3 3.1 
United States 265,266 2,3,4 Locally 1130 10.7 9.8 2.6 
Japan 267 2,4 JOTN  163 87.1 87.6 0.7 
ETKAS: EuroTransplant Kidney Allocation System, JOTN: Japanese Organ Transplant Network, DD: 
deceased donors, pmp: per million population. 
 
Circumstances of death 
Death results from irreversible cessation of cardio-pulmonary or cerebral functions, 
leading to cardiac death or brain death, respectively. Cardiac arrest can occur spontaneously 
and suddenly outside the hospital (type 1) or in the accident and emergency department (type 
2), or can be planed after removal of life-sustaining treatment in a patient who has a non-
recoverable illness/injury with dependence on life-supporting therapy (type 3). Cardiac arrest 
in the presence of brain death is type 4.
7
  
Donation in type 3 and 4 DCD gives the best post-transplant results
237,268
 because 
death is anticipated and medically controlled. There is adequate time to approach the donor 
relatives, to organize medical staffs, and to fulfill legal formalities before death. Organ 
procurement is therefore undertaken with a relatively short warm ischemia time (WIT). 
Moreover DCD hemodynamic stability and respiratory function may be maintained until 
withdrawal of treatment, so the quality of grafts may be assured. Inversely, transplantation 
from type 1 and 2 DCD has worst results
237,268
 because death occurs unexpectedly. There is 
time pressure to arrange logistic supports. Organ harvesting hence takes place in an 
uncontrolled manner with a longer WIT.  
 
Warm ischemia 
DCD kidneys are submitted to an inevitable period of procurement warm ischemia. 
The period of WIT is variable. It is the longest in type 1 and 2 DCD (90-120 minutes), and 
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shorter in type 3 and 4 DCD (15-20 min, rarely exceeding 30 min). Figures 3.2.1 and 3.2.2 
present the primary WIT intervals in each donor type with desirable time frames for 
successful KT. Good results are expected if primary WIT is less than 45-60 min.
14
 Kidney 





Figure 3.2.1. Procedure of kidney donation in type 1 and 2 uncontrolled DCD. AB: asystole time (time 
without cardiac massage) less than 15-30 min.17,269,270 BC: assistance time with advanced cardio-
pulmonary resuscitation (minimum 30 min).17,62 CD: waiting time (no-touch period) between 2-10 
min.14,15  DE: catheter insertion period (less than 20 min).46 AD: time between cardiac arrest and 
arrival to the hospital (less than 90 min).271 AE: time between cardiac arrest and start of in situ 
perfusion or hypothermic ECMO (less than 150 min).17,269,270 EF: in-situ perfusion period (less than 
150 min)263,272 or hypothermic ECMO period (maximum 240 min).17 EG: cold ischemia time (less than 
18 hr).263  
 
Warm ischemia contributes to both primary non-function (PNF) and delayed graft 
function (DGF), and is perceived as the main barrier for the adoption of DCD programs in 
many transplant centers worldwide. For uncontrolled donors, various methods of kidney 
protection and harvesting have been advocated to decrease primary WIT: in situ intra-vascular 
cooling using the double balloon and triple lumen catheter (Maastricht protocol)
273,274
, intra-
peritoneal lavage and cooling (Washington protocol),
104
 hypothermic and normothermic 
cardio-pulmonary bypass with extra-corporeal membrane oxygenation (ECMO) (Madrid and 
Barcelona protocol).
17
 Additionally machine preservation methods may help to “resuscitate” 
the already compromised warm ischemic organs and may improve the organ quality and early 
graft outcomes.
50,51
 Machine perfusion may also help to select transplantable kidneys and to 
discard nonviable ones (kidney viability testing). The development of a DCD program is no 
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longer acceptable if machine perfusion and viability testing are not available. 
164
 With regard 
to the logistic organization, two initiatives have been applied effectively in practice to reduce 
primary WITs: the “Maastricht box”275 (a kit containing all the necessary equipment and 
instructions for in situ perfusion at the accident and emergency department) and the Madrid‟s 
“rapid identification and response system”17 (highly qualified pre-hospital emergency services 
with response time within 7 min in urban areas and with the ability to perform advanced life 
support measures in mobile intensive care units).  
 
Figure 3.2.2. Procedure of organ donation in type 4 controlled DCD. DE: waiting period  
(no touch period).  
 
For controlled donors, a super rapid recovery technique including rapid laparotomy 
and direct cannulation of the aorta has been proposed by the American Society of Transplant 
Surgeons
15
 as the method of choice. However, if withdrawal of life-sustaining support is 
realized outside the operating room, the pre-mortem cannulation technique may be used to 
decrease the rush inherent with the super rapid recovery technique and WIT.
15
 
A second WIT exists during vascular anastomoses of the graft, which also has impact 




Absence of brain death 
Brain death due to a rapid increase in intracranial pressure provokes a cascade of 
changes in the hemodynamics, hormones and immune response, which have a negative 
impact on donor organ viability and transplant outcome.
277,278
 In brain death, renal vaso-
constriction due to excessive secretion of catecholamines and volume depletion leads to renal 
hypoperfusion and ischemic damage. Renal inflammatory and degenerative lesions appear on 
histological examination, including glomerulitis, periglomerulitis, vacuolization/atrophy and 
necrosis of proximal and distal tubules, proliferation of the arterial intima and glomerular 
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endothelium. Upregulation of circulating cytokines and chemokines, increased endothelial 
cell expression of adhesion molecules and major histocompatibility class I and II, as well as 
greater infiltration of T cells, macrophages and polymorphonuclear leukocytes into renal 
parenchyma, result in an increased renal immunogenicity and host allo-responsiveness. 
Consequently brain dead donor kidneys are at higher risk of rejection. The more rapid 
increase in intra-cranial pressure occurs, the degree of peripheral organ damage is more 
intense. In clinical transplantation, mechanisms involving donor brain death are quite varied 
and a relationship between donor cause of death and transplant outcomes (graft rejection, 
function and survival) has been confirmed in different types of solid organ allografts.
279
 
Uncontrolled DCD whose cause of death is usually other than neurologic, do not 
undergo the process of brain death, while most controlled DCD have sustained irreversible 
cerebral injury. As a result, organs from controlled DCD are likely to suffer more from the 
harmful immunological, inflammatory and coagulatory effects than organs from uncontrolled 
DCD.
198,262,280
 Events around the time of brain death may play a more important role in the 
genesis of renal damage than warm ischemia.
281
 In addition, the impact of donor cause of 




Allocation of DCD kidney grafts 
Allocation of DCD kidney grafts varies according to countries and regulations. In 
Japan and in five countries belonging to the Eurotransplant International Foundation (Austria, 
Belgium, Luxemburg, the Netherlands and Slovenia),  DCD kidneys are allocated in the same 
manner as DBD kidneys, through the  Japan Organ Transplant Network (JOTN) and the 
EuroTransplant Kidney Allocation System (ETKAS), respectively. The legislation in Croatia 
and Germany (two other Eurotransplant countries) does not permit the procurement and 
transplantation of DCD kidneys.  
In Spain and France, allocation of DCD kidneys is center oriented, i.e. to patients on 
the waiting list of the center that procured the DCD kidney. In a hospital in Madrid, 70% of 
transplanted kidneys were type 1 and 2 DCD grafts, and several DCD kidneys had to be sent 
to other transplant centers because of no available recipients. Patients began to be transplanted 
preemptively with DCD kidneys.
45
 In the United Kingdom, in order to minimize cold 
ischemia time (CIT) and encourage new DCD programs, the policy is to transplant both DCD 
kidneys locally.
282
 The United States reserves the allocation organization to Organ 
Procurement Organizations (OPOs).
131
 Some OPOs distribute these kidneys using the 
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extended criterion donor (ECD) list, while others offer DCD kidneys to every recipient on the 
deceased donor waiting list and discuss the DCD status with the transplant center and 
candidate at the time of allocation. Recipients may refuse the allocated kidney without 
jeopardizing their chance of being offered another one.
6
 However, the allocation policy 
should hasten the process of organ placement.
14
 If there is no local suitable patient, DCD 
kidneys can be allocated by regional and national distribution.  
As DCD organs have already been subjected to WIT injury, it is conceivable that 
additional CIT would have a greater adverse impact on the graft survival of DCD than DBD 
kidneys.
212
 Kidneys considered as marginal are often turned down by multiple transplant 
centers prior to placement, resulting in prolonged CIT and increased DGF. The proper and 
rapid allocation of marginal kidneys could result in decreased CIT and DGF rates.
283
 Among 
DCD kidneys, the incidence of DGF was reduced 15% if CIT was less than 12 hr, compared 
to CIT over 12 hr (25.2% versus 40.2%).
131
 One-year graft survival of DCD kidneys was 
similar to DBD kidneys when shared locally (89.3% versus 89%, p=0.682) and slightly 
inferior when shared regionally (81% versus 87%, p=0.437) or nationally (82.7% versus 
89.5%, p=0.0089).
212
 Hence, Doshi supported the policy to favor local use of DCD 
kidneys.
212
 Locke argued that DCD kidneys from donors younger than 50 years may function 
like standard criterion donor (SCD) kidneys and should be allocated using the standard 
deceased donor waiting list, whereas the ECD list should be used for DCD kidneys from 
donors older than 50 years.
131
 Moreover these kidneys tend to be offered to non-sensitized 
recipients, hence the necessity for a pre-transplant cross-match is obviated and this may help 
to further shorten CIT.
237,263
   
 
Clinical results of DCD kidney transplantation 
Although DCD was the main donor source of cadaveric kidney grafts in the pioneer 
years, markedly inferior transplant outcomes led to the abandon of this practice during the 
mid 1970s in favor of DBD. However, since the resurgence of interest in DCD in the early 
1990s due to the growing discrepancy between graft demand and supply, there has been 
significant medical progress in organ preservation, surgical techniques, immuno-suppressive 
drugs, treatment of post-transplant complications, histo-compatibility testing and allocation of 
donor organs. Thanks to these developments, long-term KT outcomes from DCD have been 
significantly improved over time, and now can be considered comparable to those from DBD.  
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The finding that  DCD- and DBD-KT outcomes are comparable in the long term has 
several important implications in clinical practice: firstly it supports the use of DCD-KT 
despite the worse short-term outcomes, and emphasizes the interest of the development of 
DCD programs; secondly, to a certain extent, DCD kidneys should not be considered 
suboptimal; thirdly DBD and DCD kidneys should be allocated through the standard kidney 
allocation system; and finally, the use of such donor organs could considerably increase the 
donor organ pool and therefore, could  have  an  important  impact  on  the  organ shortage.  
In general, early graft function and survival (within the first 3 months post transplant) 
is worse in DCD kidney recipients than in DBD kidney ones, manifested by significantly 
higher rates of PNF, DGF, and lower renal function. Afterwards, comparable long-term 
results continue up to 10 and 15 years post-transplant. Better transplant outcomes are obtained 
in controlled rather than uncontrolled DCD. 
 
Primary non-function 
Primary non-function is defined as inadequate renal function after transplantation that 
necessitates continuation of dialysis. It is the consequence of ischemic cortical necrosis 
secondary to ischemia and reperfusion injury. Studies using type 3 and 4 DCD kidneys 
showed no significant difference in the rate of PNF compared to DBD kidneys  (between 0% 
and 13%).
40,91,197,198,237,248,253,268,284-286
  This is due to the fact that kidney grafts from 
controlled DCD have relatively short WIT (rarely exceeding 30 minutes). Their post-
transplant results may be similar to DBD kidneys without requirement for machine 
preservation and viability testing.
77,237,287
 
By comparison, the PNF rate of kidneys from uncontrolled DCD is significantly 
higher than from controlled DCD,
198,268,284
 and may vary between 13% and 25%.
198,268,284,288
  
A lower PNF rate (less than 6%) has also been reported
45,285,288
 and was explained by 
adopting restrictive DCD acceptance criteria (donor age <45-55 years, exclusion of donors 
with co-morbidities), improving donor management (rapid in situ cooling), preserving and 
choosing viable organs on the basis of machine perfusion. Up to one-third and one-half of 
kidneys from uncontrolled DCD were discarded due to poor perfusion parameters during 
machine perfusion or other reasons,
237,289,290
 a policy which may help to keep the PNF rate of 
uncontrolled DCD kidneys at acceptable levels (less than 10%).
284
 Therefore, the 
development of a successful uncontrolled DCD program may be not feasible if machine 
perfusion and viability testing were not existing. Transplantation of nonviable kidneys results 
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in unnecessary risk of surgery and immune-suppression, and immunologically sensitizes the 
recipient for future transplants.
291
 Moreover in most cases, KT is not directly life-saving, but a 
procedure that improves quality of life and life expectancy.
284
 Thus, a cautious approach to 
uncontrolled DCD-KT is necessary. 
Mixed studies including both controlled and uncontrolled DCD demonstrated a PNF 
rate between 6% and 15%.
198,209,211,268,284
 Snoeijs presented a PNF rate of up to 21% because 
more older DCD (donor age up to 74 years) and a relative high percentage of uncontrolled 
DCD were recruited in the study.
291
 A recent outcome meta-analysis comparing (controlled 










 when analyzing deceased donor KT outcomes from 
the UNOS database during different time periods, confirmed that DCD kidneys had a higher 
PNF incidence compared to DBD kidneys. However, no statistically significant difference 
was found between DCD kidneys from donors younger and older than 50 years
131
 as well as 




Delayed graft function 
Delayed graft function is commonly defined as the need for dialysis in the first post-
transplant week, with subsequent recovery of renal function, except dialysis treatments to 
correct hyperkalaemia or volume overload.
242
 The etiology of DGF is multifactorial. In the 
clinical setting, DGF can mask the presentation of acute rejection
292
 and serial transplant 
biopsies may be recommended to rule out subclinical acute rejection as a cause of graft 
dysfunction until resolution of DGF.
292,293
 Early effects of DGF include prolonged hospital 
stays, additional diagnostic radiology, repeated renal biopsies, need for supportive 
hemodialysis during DGF, as well as treatment of complications related to biopsy or 
inappropriate immune-suppression. The final inevitable consequences are increases in costs 
and patient dissatisfaction.
93
   
All studies agree that DGF is more frequent after DCD-KT. The DGF rate of type 3 
and 4 DCD kidneys may vary from 40% up to more than 70%,
91,197,198,237,248,253,268
 and 
uncontrolled DCD kidneys develop even higher DGF rate (from 60% up to more than 
80%).
45,188,268,288
  In mixed studies, the incidence of DGF was prone to be higher when higher 
proportion of uncontrolled donors compared to controlled donors was included.
198,209,211,291
 
The UNOS database from 1998 to 2004 suggests a 2.5 fold adjusted relative risk for DGF 
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among DCD- compared to DBD-KT.
14











when analysing the UNOS database at 
different periods of time. A recent meta-analysis of KT outcomes for all DCD types and DBD 
showed the incidence of DGF may be 3.6 times higher after DCD-KT.
206
  
Another interesting aspect is that the negative effects of DGF on graft survival in the 
recipients of DBD kidneys may not be observed in DCD.
245,246
 In several studies, survival of 
kidney grafts with DGF was better in the DCD compared to DBD groups.
45,131,179,209,212,285
 
DCD kidneys may tolerate DGF better than DBD kidneys, with 23–52% decrease in graft loss 
risk.
131
 Several factors seem to make DCD kidneys less vulnerable to lasting injury, as the 





hypothesized that the long-term functional consequences of 




Acute rejection  
Many studies demonstrated that DCD kidneys, despite showing greater DGF rates, do 
not have a greater incidence of acute allograft rejection, compared to DBD kidneys. 
197,209,211,237,251,268,288
 The acute rejection rate during the first year was not significantly 
different in DCD versus DBD kidneys, both in single center reports
197,209,211,237,288
 and in large 
studies using national databases,
212,251
 as well as in a recent meta-analysis of all DCD types,
206
 
except in Cho‟s study179 which showed DCD kidneys had higher rate of acute rejection than 
DBD kidneys (19% vs 14%, p=0.04).  
Most acute rejection episodes occur in kidneys with DGF, and the incidence of acute 
rejection in transplants with DGF and the incidence of severity of rejection may be 
comparable for DCD and DBD groups.
197,211
 Sanchez-Fructuoso found DBD transplants with 
DGF had a higher incidence of acute vascular rejection than DCD transplants with DGF 
(57.9% vs 27.9%), and brain death emerged as a clear risk factor for vascular rejection.
280
 
Rudich‟s study suggested that transplants from DCD sources have less graft loss from acute 
and chronic rejection episodes compared with conventional DBD organ sources (22.2% graft 
losses at 6 months in the DBD group, versus only 16.9% of graft losses in the DCD group 







In clinical transplant practice, renal function is determined by serum creatinine levels 
or estimated glomerular filtration rate (eGFR) via Cockcroft-Gault formula or MDRD 
(modification of diet in renal disease) equation. DCD kidneys recover slower than DBD 
kidneys, and fail to optimize their function in the early post-operative period. Given higher 
incidence of DGF, DCD kidney function is often poorer at the time of hospital discharge and 
at 1-month post-transplant, but the difference diminishes with time and become statistically 
insignificant from 3 months to 1 year post-transplant.
188,268,295
 Kidneys from different 
Maastricht categories may recover at different rates although their function may be similar at 
3 months. Recovery may be more rapid for category 4 DCD kidneys, and slower for category 
2 DCD kidneys.
268
   
A recent meta-analysis of DCD- and DBD-KT outcomes showed that serum creatinine 
levels at 3 and 12 months may be similar in both groups.
206
 One year after transplantation, 





 examined outcomes of DCD-KT which functioned for at least 1 year post-
transplant, and had a mean follow-up of 2-5 years. DCD and DBD graft loss was 
approximately 3% at 5 years, and both groups showed a similar decline in GFR after 1 year (-
1.3 ml/min for DCD vs -1.4 ml/min for DBD). This means that DCD kidneys have a reduced 
functioning glomerular mass because of initial ischemic damage, but once transplanted there 
is no evidence of accelerate deterioration.
198
 Comparable renal function between 2 groups has 
been proved up to 15 years post-transplant in a single center report.
211
 However, interpretation 
of this study should be cautious as the number of patients in each group was small (112 DCD 
and 164 DBD kidneys), and as general analysis showed that serum creatinine levels were 
significantly higher in DCD kidneys recipients.  
 
Graft survival 
Short-term graft survival at 1 year post-transplant was similar between DBD and type-
3 and -4 DCD kidneys and varied between 80% and more than 90%,
40,91,197,198,237,248,253,268,296
 
despite greater graft loss during the first 30 days and 3 months post-transplant in DCD than 
DBD kidneys.
197,248,286
 Kidneys from uncontrolled donors had 1-year graft survival between 
70% and more than 80%
45,188,198,268,288




Most studies considered long-term outcomes as the outcome beyond the first year 
post-transplant, which can be calculated as graft survival (according to Kaplan-Meier method) 
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or graft haft-life with or without death censoring. Many factors have been shown to have 
impact on the long-term outcome after KT, both immunological and non-immunological 
injuries. Five- and ten-year graft survival of kidneys from controlled DCD was 60-80% and 
50-60% respectively. The same percentage was observed in kidneys from uncontrolled 
donors. There is no difference in graft survival between DCD and DBD kidneys up to a 
follow-up period of 5, 6 and 10 years. Two studies published recently had a follow-up of 15 
years and again showed no significant difference in the 5-, 10- and 15-year allograft survival 
between DCD and DBD.
211,286
 Nevertheless, there was a tendency of better graft survival in 
the DBD group.
211,286
 In unpublished data, Snoeijs reported the long-term outcome of viable 
DCD kidneys is equivalent to DBD kidneys up to 25 years of follow-up.
48
 
Studies using UNOS database found that survival of DCD kidneys at 1-, 2- and 3-
years were nearly comparable to SCD (p=ns) and superior to ECD (p <0.001). ECD kidneys 
and extended criteria DCD kidneys had no significant difference in graft survival.
14
 With 
regard to graft survival at 5 years, DCD kidneys from donors younger than 50 years 
performed as well as SCD kidneys, while DCD kidneys from donors older than 50 years 
functioned as well as ECD kidneys (Table 3.2.2).
131
 Gagandeep found the same long-term 
outcome up to 5 years post-transplant between uncontrolled DCD, controlled DCD and 
DBD.
285
 A recent meta-analysis of outcomes of all types of DCD and DBD renal transplants 
confirmed graft survival of DCD kidneys is somewhat inferior to DBD kidneys from 3 








The comparable DCD and DBD long-term graft survival is supported by histological 
data that show kidneys from DCD do not have higher rate of allograft fibrosis than those from 
DBD
297
 and the rate of development of chronic allograft nephropathy in DCD transplant does 





 Likewise no statistical difference in the rate of technical complications has been 
demonstrated between DBD and DCD kidney recipients.
253,286
 However, when the ureteral 
fistula and stenosis rates were combined, the difference was statistically greater in the DCD 
group (15% versus 7%) for urological complications.
253
 By analyzing the UNOS database 
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between 1993 and 2000 from 708 DCD- and 97,990 DBD-KT, Rudich showed that surgical 
and urological complications, thromboses, and infections are not a greater cause of graft loss 




Table 3.2.2. Clinical KT outcomes according to deceased donors categories (UNOS database)  
Donor category PNF DGF Graft survival References 
1 year 5 years 
SCD  
(standard criteria donors) 
0.7 21 90 79.9 14,131 
ECD  
(extended criteria donors) 
1.82 33 83 66.9 14,131 
DCD  
(donors after cardiac death) 
1.71 40 89 81.6 14,131 
exDCD  
(extended donors after cardiac death) 
1.33 55 81 65.9 14,131 
cDCD 
(controlled donors after cardiac death) 
< 2 41 89 66.9 285 
uDCD 
(uncontrolled donors after cardiac death) 
< 3 51 - - 212,285 
 
Conclusion 
The results of DCD and DBD kidney transplantation should be comparable if careful 
donor selection and management are respected. As a result, DCD program should be 
continued and expanded. DCD donors are potential donor source that may partially solve the 
imbalance between the growing number of end-stage kidney disease patients on the waiting 
list and the limited number of available kidney grafts. DCD kidneys do not always mean sub-
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ABSTRACT 
Objectives: The Belgian multicentric experience with donation after cardiac death (DCD) 
liver transplantation (LT) was retrospectively updated to evaluate patient and graft survivals, 
and biliary complications.  
Patients-Methods: From 2003 to 2009, 111 DCD-LTs have been performed in Belgium. 
Characteristics of donors, recipients and transplant procedure as well as transplant outcomes 
were retrospectively reviewed. Mean donor age was 47.6±15.5 years. Mean total WIT was 
24.4±13 min and mean CIT was 367.3±128.9 min. Rates of local and national sharing were 
72.1% and 19.8%, respectively. Mean recipient age was 55.9±11.2 years. The most frequent 
indications for LT were end-stage liver disease (49.5%) and HCC (39.6%). Mean MELD 
score at transplant time was 16.6±7.5 points. 
Results: Overall patient and graft survival was 88.3% and 80.1% at 1 year, 74.4% and 64.9% 
at 3 years, 70.0% and 60.4% at 5 years, respectively. PNF rate was 4.5% (5 patients). Thirty-
seven patients (33.3%) developed biliary complications with ITBL encountered in 14 patients 
(12.6%). Thirteen patients (11.7%) underwent re-transplantation, six urgently for PNF (4) and 
HAT (2), and seven for intractable biliary stenoses. Donor bilirubin levels and duration of 
donor hepatectomy were associated with an increased risk of graft loss while CIT, MELD 
score and donor bilirubin levels appeared as risk factors for biliary complications in a 
multivariate analysis.  
Conclusion: Although DCD organ donors are a valuable source of viable liver grafts, they are 
associated with increased incidence of PNF and cholangiopathy that could be reduced with 






 Organ donation after cardiac death (DCD) has been reconsidered for use since the 
early 1990s to alleviate the serious shortage of donation after brain death (DBD) source. 
Although the use of DCD donors could decrease the mortality rate on liver transplantation 
(LT) waiting lists and increase the availability of organs for transplantation, it is associated 
with a higher risk of early graft dysfunction,
58,60,212,298
 more frequent vascular and ischemia-
type biliary lesions (ITBL),
299
 higher rates of re-listing and re-transplantation
300,301
 and lower 
graft survival,
57,59,89,302
 which are the consequences of the combined effect of warm ischemia 
and cold ischemia-reperfusion injury. 
 A DCD-LT program using Maastricht category-III donors has been initiated in 
Belgium since 2003 after being approved by different institutional review boards and the 
Belgian National Council of Physicians.
173
 Preliminary results during the 2003-2007 period, 
which had been published in 2010, appeared promising with overall patient and graft survival 
rates of 91.3% and 84.4% at 1 month, 83.3% and 72.4% at 1 year, and 66.9% and 48.8% at 3 
years, respectively. The primary non-function (PNF) rate was 3.4% and ITBL developed in 
32.7 % of liver allografts. Re-transplantation was necessary in 13.8% of liver recipients.
303
 
The aim of this retrospective study was to update the results of the Belgian multicentric 
experience in DCD-LT with regard to patient and graft survival, and biliary complications and 
to define risk factors associated with decreased graft survival and biliary complications. 
 
Patients and methods 
This retrospective review assembled the experience of six Belgian transplant centers in 
DCD-LT from January 2003 to December 2009. Among 111 liver grafts, one hundred and 
three were procured from Maastricht category-III donors, two from Maastricht category-IV 
and six from euthanasia donors. No category-II DCD-LT was performed despite active 
category-II DCD procurement programs in some Belgian centers. The acceptance criteria for 
DCD liver grafts were center-dependant. Donor causes of death were stroke (36.0%), head 
trauma (31.5%), anoxia (26.1%), euthanasia (5.4%) and other (0.9%).  With the approval of 
EuroTransplant (ET) and of the Belgian Liver Intestine Organ Procurement Committee 
(BLIC), liver grafts were allocated in a center-oriented manner in order to shorten the cold 
ischemia time (CIT). The recipients were chosen according to the urgent need for 
transplantation and his (her) chances to receive a liver graft in a timely manner according to 
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the regular patient-oriented rules, including patients with extended criteria hepato-cellular 
cancer criteria. If no adequate candidate was available, the DCD liver graft was offered to 
other centers in Belgium and the Netherlands, two ET countries that allow DCD procurement 
and transplant activity. The rate of local, national and international sharing was 72.1%, 19.8% 
and 8.1%, respectively, in our series.  
 
Organ procurement 
 In Maastricht category-III donors, withdrawal of life support was performed by a non-
transplant physician in the operative room. Intravenous heparin was given in most cases 
(91%) before cessation of circulation. Phentolamin (Regitin®), epoprosterol (Flolan®) and 
streptokinase were utilized in 28.8% of liver donors. Organ recovery started 2–5 min after 
declaration of death, by cannulation of the femoral vessels or by rapid midline laparotomy and 
sternotomy with aortic and/or caval cannulation. Once the cold ﬂush with University of 
Wisconsin (UW) or histidine–tryptophan–ketoglutarate (HTK) solutions was initiated, the 
aorta was cross-clamped in the chest just above the diaphragm, whereas the abdominal and 
thoracic cavities were ﬁlled with ice-crashed ﬂuid for topical cooling. HTK was the most 
common used preservation solution (84.7%). After completion of the aortic ﬂush, organs were 
removed and cold-stored until transplantation. Mean warm ischemia time (WIT) was 24.4 ± 
13 min (range: 8 - 109). This time period comprised the withdrawal phase (from treatment 
discontinuation to cardiac arrest, mean: 13.5 ± 11.4 min, range: 1 - 98) and the acirculatory 
phase (from cardiac arrest to initiation of aortic cold perfusion, mean: 11 ± 5.6 min, range: 4 - 
38). Mean CIT was 367.3 ± 128.9 min (range: 105 - 719). CIT was defined as the time 
interval from aortic cold perfusion until removal of the liver graft out of the cold preservation 
solution for implantation. Mean suture time, which was the vascular anastomosis time 
calculated from the removal of a liver graft out of iced preservation ﬂuid to its reperfusion,  






 Mean recipient age was 55.9 ± 11.2 years (range: 10 - 73). Indications for LT were 
end-stage cirrhotic liver disease in 55 patients (B and C viral infection: 12, alcohol 
dependency: 32, primary biliary cirrhosis: 4, non-alcoholic steato-hepatitis (NASH): 1, 
hemochromatosis: 1 and cryptogenic cirrhosis: 5), hepato-cellular cancer in 44 patients 
89 
 
(cirrhotic livers: 39, non-cirrhotic livers: 5), and  miscellaneous causes in 7 cases (primary 
sclerosing cholangitis: 3, familial amyloid poly-neuropathy: 1, neuro-endocrine liver 
metastases: 1, and biliary atresia: 2). In ﬁve cases, DCD-LT was performed for high-urgent 
(HU) patients (ET status equivalent to UNOS status 1a, UNOS: United Network for Organ 
Sharing) due to fulminant hepatic failure (2), liver failure after resection for Klatskin tumor 
(1) and urgent re-transplantation (2). Mean laboratory MELD (model for end-stage liver 
disease) score at transplantation was 16.6 ± 7.5 (range: 6 - 40). 
 
Study Endpoints 
 Primary endpoints of the study were graft and patient survival rates, and symptomatic 
intra- and extra-hepatic biliary complications requiring invasive management (endoscopy, 
surgery or re-transplantation). Graft survival was deﬁned as the time from LT to graft loss 
and/or patient death. Patient survival was considered from ﬁrst transplantation to patient 
death. Early patient death was defined as any event within the first 3 months post-transplant. 
We also calculated graft and patient survival rates censored for recipient death unrelated to 
the quality of the graft (malignant tumor, accident…) in order to better estimate the risk of 
DCD-LT. Patients were followed up until September 30, 2010. Secondary endpoints were 
ﬁrst-week peaks of transaminases and total bilirubin, occurrence of PNF, hepatic artery 




Continuous variables were presented as mean ± standard deviation (SD) and 
categorical variables as percentage. Differences between groups were evaluated by Student t-
test or non-parametric Mann Whitney U/Wilcoxon Ranked Sum test for continuous variables 
and Fisher‟s exact test or Chi-square test for categorical variables. Survival rates were 
estimated by the Kaplan–Meier method and compared by the log rank test with graft failure 
and patient death as events. Univariate and multivariate logistic regression analyses were used 
to identify potential risk factors for graft loss and biliary complications. All tests were two-
tailed and p-values < 0.05 were considered as significant. All analyses were performed using 





Table 4.1.1. Evolution of donor, recipient and transplant characteristics over time 
Variables  2003-2009 2003-2007 2008-2009 p value 
Donor age (years) 47.6 ± 15.5 44.3±14.6 51.3±15.8 0.018 
Donor gender: M/F (%) 71/40 (64/36) 39/19(67/33) 32/21(60/40) - 
Donor BMI (kg/m2) 25 ± 4.2 24.7±3.4 25.3±4.9 0.472 
Donor ICU stay (days) 6.1 ± 6.3 4.7±3.8 7.5±8 0.023 
Natremia (mEq/L) 142.6 ± 6.2 142.4±6 142.9±6.4 0.609 
ALT (U/L) 44.3 ± 74.1 47.8±94.2 40.3±39.9 0.585 
GGT (U/L) 72.9 ± 114.5 60±91.3 87±135 0.229 
Total bilirubin (mg/L) 5.5 ± 3.6 5.9±3.9 5.1±3.4 0.229 
Withdrawal phase (min) 13.5 ± 11.4 14.9±14.5 12.2±7.1 0.232 
Acirculatory phase (min) 11 ± 5.6 10.2±5.6 11.9±5.2 0.129 
Total WIT (min) 24.4 ± 13 24.6±15.5 24.2±10.1 0.869 
CIT (min) 367.3 ± 128.9 395.6±139.7 341.9±116.4 0.031 
Suture time (min) 47.8 ± 15.1 50.6±17.4 44.9±11.7 0.045 
Total ischemia time (min) 439.1±132.6 466.1±138.3 409.7±120.7 0.027 
Recipient age (years) 55.9 ± 11.2 54.9±11.6 57±10.9 0.344 
Recipient gender: M/F (%) 85/26(77/23) 46/12(79/21) 39/14(74/26) - 
MELD score at  transplant 16.6 ± 7.5 16±8,2 17.2±6.9 0.413 
Recipient serum creatinine (mg/L) 10.2±4.1 10.1±4.1 10.2±4.1 0.833 
Peak AST (U/L) 2409± 2929 2797±3727 1998±1673 0.156 
Peak total bilirubin (mg/L) 58.8 ± 56.5 64±64.6 53.4±46.6 0.331 
ICU stay (days) 6.9 ± 10.5 6.6±7.9 7.4±12.7 0.710 
Hospital stay (days) 29.5 ± 29.1 31.8±34.3 26.9±22.1 0.379 
M/F: male/female. BMI: body mass index. ICU: intensive care unit. ALT: alanine amino-transferase. 
AST: aspartate amino-transferase. GGT: gamma glutamyl transpeptidase, WIT: warm ischemia time. 
CIT: cold ischemia time. MELD: model of end-stage liver disease.  
 
Results 
 During the 7-year period (from 2003 to 2009), there have been 111 and 1546 liver 
transplants from controlled DCD and DBD donors in Belgium, respectively. The number of 
DCD liver transplants increased steadily over the study period and contributed up to 6.7% of 
the deceased donor (DD) liver pool (Figure 4.1.1).   
 
Patient and graft survivals 
No patients were lost during the study period (mean of patient follow-up: 29.0 ± 21.5 
months, range: 1 day to 91 months). Overall patient and graft survival rates were 91.0% and 
85.6% at three months, 88.3% and 80.1% at one year, 74.4% and 64.9% at three years, and 
70.0% and 60.4% at five years, respectively. Death-censored patient and graft survival rates 
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were 92.8% and 87.4% at three months, 92.8% and 84.5% at one year, 88% and 78.3% at 
three years and 82.8% and 72.9% at five years, respectively (Figure 4.1.2). Causes of early 
death were per-operative cardiac failure (2), PNF (1), hepatic artery thrombosis (HAT) with 
following liver insufﬁciency (1), biliary sepsis (1), acute respiratory distress syndrome (1), 
multiple organ failure (3) and patient suicide (1). Seventeen other  patients died later, 
including one from intractable biliary sepsis while awaiting re-LT, four from de novo cancers 
(melanoma: 1, lymphoma: 1, pulmonary tumor: 1, donor-transmitted sarcoma: 1), and four 
from hepato-cellular carcinoma recurrence, three from cerebral vascular accidents, one from a 
car accident, one due to Alzheimer disease, and three from unknown reasons. Graft and 
patient survival was compared between the 2003-2007 and 2008-2009 periods and the latter 
era had better although not statistically significant outcomes (Figure 4.1.3). This may be 
explained by shorter cold and warm ischemia times, and total ischemia times despite higher 


























Figure 4.1.1. Evolution of donation after cardiac death (DCD) and donation after brain death 






Figure 4.1.2. Overall and death-censored graft and patient survivals. Death-censored graft 
survival was 87.4% at three months, 84.5% at one year, 78.3% at three years and 72.9% at 
five years. Death-censored patient survival at corresponding points of time was 92.8%, 
92.8%, 88% and 82.8%.  
 
Post-operative evolution  
Post-operative mean peak-AST was 2409.2 ± 2929.8 U/L (range: 43 - 21928) and  
mean peak-bilirubin was 58.8 ± 56.5 mg/L (range: 3.6 - 296). The rate of PNF was 4.5% (5 
patients) and HAT 2.7% (3 patients). Mean ICU and hospital stays were 6.9 ± 10.5 days 
(range: 1 - 82) and 29.5 ± 29.1 days (range: 1 - 213), respectively. Thirteen patients (11.7%) 
underwent re-LT, six urgently for PNF (4) and HAT (2), and seven for intractable ITBL. In 





Figure 4.1.3. Graft and patient survivals during the 2 periods (blue line: 2003-2007 and green 
line: 2008-2009).  
 
Biliary complications 
Thirty-seven (33.3%) patients developed biliary complications in which thirty-five 
required various types of invasive treatment, either alone or in combination (endoscopy, 
surgery and re-transplantation). Table 4.1.2 displays the diagnosis and treatment of these 
biliary complications. ITBL was encountered in 14 patients (12.6%) and re-transplantation 
was necessary in 7 (6.3%). Anastomotic stenosis occurred in 18 patients (16.2%) and biliary 





Table 4.1.2. Biliary complications (n=37) 
Biliary complications Data 
Diagnosis  
Biliary fistula 4 (10.8) 
Biliary stenosis Anastomosis  14 (37.8) 
Anastomosis + ITBL 4(10.8) 
ITBL 10 (27) 
Without anatomic location of stenosis  2 (5.4) 
Biliary tract compression by recurrent hepatic tumor 1 (2.7) 
No diagnostic information 2 (5.4) 
Treatment   
Endoscopy  19 (51.4) 
Surgery  2 (5.4) 
Endoscopy + Surgery  7 (18.9) 
Re-transplantation 7 (18.9) 
No intervention  2 (5.4) 
 ITBL: ischemia-type biliary lesions 
 
Potential risk factors for graft loss and biliary complications 
 Univariate analysis showed a higher risk of graft loss in case of increasing donor age 
(p=0.04), donor bilirubin (p=0.03), CIT (p=0.01), suture time over 50 min (p=0.01), no use of 
heparin prior to treatment discontinuation (p=0.03) and hyper-urgent indication for LT 
(p=0.02). However, only donor bilirubin (OR=0.06, 95%CI 0.01-0.38, p=0.00) and duration 
of donor hepatectomy (OR=0.15, 95%CI 0.02-0.94, p=0.04) became statistically significant in 
the model of multivariate analysis.  
 Similarly, increasing donor ICU stay (p=0.02), donor bilirubin (p=0.02), WIT 
(p=0.02), CIT (p=0.01) and non local sharing of graft livers (p=0.03) were associated with 
increased risk of biliary complications in a univariate analysis. Nonetheless multivariate 
model revealed only donor bilirubin (OR=5.1, 95%CI 1.74-14.84, p=0.00), CIT (OR=12.8, 
95%CI 2.16-75.74, p=0.00) and MELD score at transplant time (OR=5.28, 95%CI 1.21-23, 
p=0.02) as significant risk factors for biliary complications.  
 
Discussion 
 This Belgian multi-centric experience in DCD-LT shows that controlled DCD donors 
constitute an alternative source of liver grafts enabling to alleviate the shortage of the DBD 
liver graft pool. However, the overall transplant outcomes appear inferior to DBD liver grafts 
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and are in accordance with previously reported results. Our results seemed particularly 
comparable to those at the Mayo clinic
304
 regarding the number of graft losses and re-
transplantation as well as one-year graft and patient survival, given the fact that the two 
studies are similar to each other in terms of study design, number of patients, warm and cold 
ischemia time, recipient age and MELD score at the transplant time, except that our donors 
were older than in Mayo clinic‟s study. Furthermore, our multivariate analysis demonstrated 
that better outcomes might be obtained through careful donor and recipient selection with low 
bilirubin at procurement and low MELD score, and short CIT at transplantation.  
 Graft and patient survivals in this series are comparable to those in other studies, and 
better results were however achieved in the latter 2008-2009 period. Transplant outcomes 
similar to those obtained from DBD-LT have been sporadically reported in select centers 
through careful donor selection, optimization of CIT, use of invasive techniques to optimize 
organ recovery before declaration of death
144,304-306
 and appropriate graft and recipient 
matching.
59,212
  Several authors could demonstrate that even if graft or/and patient survival is 
lower with a DCD liver, this DCD option is still better than continuing to wait for a DBD 
liver, as the patient‟s choice is frequently not between „marginal‟ livers (including DCD) and 
standard livers but between marginal livers and no livers.
94
 The benefit of earlier access to LT 
provided by a DCD graft could outweigh the risks of prolonged waiting for a standard graft.
95
 
Better knowledge of the risks of DCD-LT failure, and particularly the limitation of warm and 
cold ischemia, may offer better results in the future.
303
 
 Since the introduction of LT, biliary complications have always been and still are 
regarded as the „Achilles heel‟ and as a major cause of morbidity and graft failure in liver 
recipients.
307
  This study once again confirms the higher incidence of overall biliary 
complications and particularly ITBL in DCD-LT in comparison to DBD-LT.  Fifty per cent of 
our ITBL patients needed to be re-transplanted. A recent meta-analysis revealed that DCD 
recipients had a 2.4 times increased odds of biliary complications (95% confidence interval - 
CI = 1.8–3.4) and a 10.8 times increased odds of ITBL (95% CI = 4.8–24.2) versus DBD 
recipients. On average, biliary complications were present in 29% of DCD compared with 
17% of DBD recipients and ITBL in 16 % of DCD versus 3% of DBD recipients.
299
  
 In controlled DCD donors, the PNF rates are usually reported between 0% and 12%. 
Matched analyses
60,298
 and registry data
58,212
 showed a higher rate of PNF in controlled DCD 
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 The increased risk of PNF in DCD-LT recipients was also confirmed in a 
recent meta-analysis (odds ratio - OR = 3.6, 95% CI = 2.1–6.4).299 Case-series reports of 
controlled DCD-LT also had a rate of PNF between 0% and 10%.
303,311-315
  
 Early HAT is usually defined as the occlusion of the hepatic artery within the first 30 
days post-transplant.
316
 The frequencies of early HAT after DCD-LT varied from 0% to 
16.6% and did not seem significantly higher than those after DBD-LT in most 
studies
10,60,94,144,298,301,304-306,309,317,318
 except Yamamoto‟s study (33.3% versus 0%).308 
 DCD recipients more often require re-transplantation, as 21.6-42% versus 8.8-16% of 
DCD and DBD recipients were listed for re-transplantation, respectively.
300,301
 The re-
transplantation rate ranged from 7.6 to 31% in DCD-LT compared to 2.5-12% in DBD-
LT.
10,58,60,144,212,298,300,301,304,309,310,318,319
 DCD livers exhibited a 2.1 times greater risk of graft 
failure, a 2.5 times greater risk of re-listing, and a 3.2 times greater risk of re-transplantation 
compared with DBD livers.
301
 The majority of re-listing and re-transplantation in the DCD 
group were a consequence of biliary complications, especially ischemic cholangiopathy, but 




DCD liver grafts carry an increased risk of graft failure and post-operative morbidity, 
especially biliary complications and ITBL are worrisome. Patients who are potential 
candidates for a DCD liver transplant should be fully informed of the benefits and risks so 
they can determine their options. For the time being, these grafts should be reserved only for 
patients in  whom  current  allocation  schemes do  not  provide  sufﬁcient  chances  to  be  
transplanted with a regular DBD graft in a timely manner. Further improvements and better 





4.2 DCD liver transplantation in the world 
 
Published as 
H Le Dinh, A de Roover, A Kaba, S Lauwick, J Joris, J Delwaide, P Honoré, M Meurisse, 
and O Detry 
 
Donation after Cardio-Circulatory Death Liver Transplantation 
World Journal of Gastroenterology 2012, 18(33): 4491-4506 
 
ABSTRACT 
Objectives: The critical organ shortage has forced many transplant centers to reconsider the 
use of donation after cardiac death (DCD) since 1990s as an alternative donor source to the 
insufficient donation after brain death (DBD). This review aimed to examine the clinical and 
experimental experience in DCD liver transplantation (LT) in the world in order to help LT 
programs to develop DCD-LT and to better allocate DCD liver grafts. 
Methods: We conducted a systemic review of all mono- and multi-centric DCD-LT studies 
over the past 20 years, and evaluated the short- and long-term results of DCD-LT in terms of 
initial graft function (primary non-function-PNF and initial poor graft function-IPF), graft and 
patient survival, rejection, and post-transplant surgical complications. 
Results: DCD livers are a valuable organ source that helps to decrease the mortality rate on 
the waiting list and to increase the availability of organs for transplantation despite a higher 
risk of early graft dysfunction, more frequent vascular and ischemia-type biliary lesions, 
higher rates of re-listing and re-transplantation, and lower graft survival. Experimental 
strategies intervening in both donors and recipients at different phases of the transplantation 
process have focused on the attenuation of ischemia-reperfusion injury and already gained 
encouraging results, and some of them have found their way into clinical reality.  
Conclusion: The future of DCD-LT is promising. Concerted efforts should concentrate on the 
identification of suitable donors (probably Maastricht category III DCD donors), better donor 
and recipient matching (high risk donors to low risk recipients), use of advanced organ 
preservation techniques (oxygenated hypothermic machine perfusion, normothermic machine 
perfusion, venous systemic oxygen persufflation), and pharmacological modulation (probably 
a multi-factorial biologic modulation strategy), so that DCD liver grafts could be safely 






The first human liver transplantations (LT) were performed from donation after 
cardio-circulatory death (DCD) in the 1960s.
320-323
 DCD-LT was nonetheless almost 
universally abandoned in the following two decades, given the well-recognized Harvard 
brain-dead concept in 1968 and given the better results of LT originating from donation after 
brain death (DBD).
324
 In 1983, LT was approved as a therapeutic modality for end-stage liver 
diseases after a long period considered as an experimental procedure. The renewed interest in 
DCD donors started in the 1990s following the limited success of the transplant community to 
expand the DBD organ supply and following the request of potential DCD families.  
If DCD kidneys are increasingly accepted around the world,
238
 the use of DCD livers 
remains limited in experienced transplant centers due to higher risks of primary graft 
dysfunction and biliary complications as well as a lack of a reliable viability testing prior to 
liver implantation. However the number of DCD-LT increased rapidly over the past decade. 
In the United States, 276 DCD liver transplants were performed in 2008 compared to only 23 
cases in 1999, making up 5% of the deceased donor (DD) liver transplants.
69,325-327
 The same 









 Netherlands had the highest rate of DCD- over DD-LT in the world (22.5% in 
2008).
331
 France has just initiated its DCD-LT program since 2010.
332
 In Japan, although 
DCD donors were the essential DD source, its use was reserved mainly for kidney, pancreas 
and islet transplantation.
333
 Using a mathematical model to analyze the potential impact of a 
DCD policy on LT programs, Chaib reported if 1%, 5% and 10% of deceased individuals 
became DCD donors, there would be 8%, 27%, and 37% relative reductions in the size of 
waiting  list, respectively.
85
 The use of DCD livers could increase the supply of transplants by 
53%.
304
 Centers with active DCD-LT programs usually reported 4-10% rates of LT from the 
DCD source.
203
 The potential impact of DCD use on the DBD availability is also a 
controversial issue. Controlled DCD programs might negatively influenced DBD activity in 
Belgium, Netherlands and United Kingdom while uncontrolled DCD donors seemed to be a 
clear additional source of organs for transplantation in France and Spain.
19
  
Most countries use Maastricht-category-3 DCD donors for LT, except France and 
Spain, where categories 1 and 2 are exclusively used due to legal interdiction of 
discontinuation of therapy in irreversibly brain-injured individuals.
4,332,334
 German law 
prohibits any DCD organ procurement and transplant activity. In Italy, death of a human 
being must be declared 20 min after cardiac arrest using continuous electrocardiography. The 
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procedure therefore will enable, at best, retrieval of only a few marginal kidneys and some 
tissues, and will not be helpful for patients on LT waiting lists.
335
 This article aimed at 
reviewing mono- and multi-centric DCD-LT outcomes, experimental strategies on animal 
models to optimize the utilization of this donor source and its future development.  
 
Differences between DCD and DBD donors pertinent to LT outcomes  
Generally results of DCD-LT are inferior to those from DBD-LT with regard to both 
short-and long-term graft and patient survival as well as post-transplant morbidity. Expected 
DCD-LT outcomes could be explained by inherent differences between DCD and DBD 
donors in circumstances of death, warm ischemia time (WIT) and donor cause of death. 
Consequently, a different strategy of DCD use in terms of logistics of organ retrieval and 
preservation, allocation and recipient selection appears necessary to guarantee acceptable 
results. These differences will be briefly discussed prior to considering results of DCD-LT in 
detail. 
 
Circumstances of death and consequent WIT 
In DCD, donor death is diagnosed on the basis of irreversible cessation of cardio-
pulmonary function instead of conventional neurologic criteria. As a result, organs from DCD 
donors are subjected to a period of hypotension, hypoxia and acirculation prior to organ 
procurement and this WIT adversely affects tissue viability and graft function after 
transplantation.
336
 An international classification of DCD donors into 4 categories was first 
proposed in 1995 and widely accepted up to now.
7







 The length of WIT varies greatly according to 
the type of DCD process. It is longest among uncontrolled category -1 and -2 (usually 90–120 
min) and shorter among controlled category -3 and -4 DCD donors (usually 20-30 min). In 
brain death, issues related to donor warm ischemia are eliminated because DBD donors have 
an effective natural organ perfusion and a potentially well-preserved organ function and WIT 
is thus nearly equal to zero. 
However, WIT is heterogeneously defined among authors.
57
 In the controlled DCD 
context, the commonest definition is the time interval between withdrawal of both ventilator 
and cardiac support to start of cold ﬂushing of the organ.14,60 This definition includes the no-
touch period and the time of death declaration and is proposed to have two phases 
(withdrawal and acirculatory phases). Other authors used a blood pressure (BP) or oxygen 
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saturation threshold below which would be defined as the beginning of true WIT (systolic or 
mean BP < 35 - 60 mmHg, oxygen saturation < 25 - 70% or unreadable).
15,27,301,314,338-341
 De 
Vera did not use a BP threshold to define the start of WIT because tissues are still hypoxic in 
a DCD donor who maintains a BP but has ceased to ventilate.
60
 It is unknown at what BP or 
oxygen saturation the liver parenchyma and biliary system undergo irrecoverable injury.
305
 
The ﬁrst international Non-Heart Beating Donor workshop in Maastricht in 1995 suggested 
WIT should be calculated from the moment of cardiac arrest until the start of hypothermic 
ﬂush-out.189 This deﬁnition may be useful for consistency but is inaccurate at the cellular 
level. Hypoxia starts when the blood ﬂow or oxygenation no longer meets cellular metabolic 
needs.
339
 The start of WIT may be chosen prior to asystole, and the end of WIT may be at or 
after aortic ﬂushing.342 Apparently a well-accepted deﬁnition of donor organ ischemic times is 





Figure 4.2.1. Different ways of WIT definition in the controlled DCD setting (see text for more 
details). WIT: warm ischemia time. BP: blood pressure, t: time. Total WIT is also called overall WIT. 
True WIT is also called complete or functional WIT. Agonal phase is also called withdrawal phase.   
 
In transplant practice, WIT should be minimized as much as possible. For controlled 
DCD donors, the possibility to predict whether a potential donor will or will not expire in a 
time frame consistent with donation is extremely important, because prolonged time to 
asystole, likely resulting in suboptimal organ perfusion, is a common reason for non 
procurement of  DCD grafts.
343,344
 Time between therapy withdrawal and cardiac arrest 
usually does not exceed 1 hour in most DCD donors. However, if a DCD donor has a period 
of relatively hemodynamic stability after life-support withdrawal, this period may be extended 
102 
 
beyond 1 hour without additional warm injury to the organs.
345
 Some authors emphasized 
during the withdrawal phase, time to a systolic BP < 50 mmHg should be < 30 min
304
 and the 
hypotensive period (mean BP < 50 mmHg) < 15 min.
144
 Manara proposed the so-called 
functional WIT, which is measured from the donor‟s systolic BP < 50 mmHg, the arterial 
oxygen saturation < 70%, or both, to the start of cold perfusion, should not exceed 30 min and  
may be limited to 20 min in suboptimal donors.
16
  
Several factors have been identified as predictors of rapid death following treatment 
withdrawal and include the DCD tool of University of Wisconsin
30
, donor Glasgow coma 
scale, inotropic use, BP at treatment discontinuation, high FiO2 and mode of ventilation.
31,34
 
Withdrawal of therapy is preferably occurred in the operating room with a donor surgical 
team immediately available. Prior to cessation of the ventilator and organ perfusion support, 
the donor may be already prepared and draped, and the surgical instruments, preservation 
solution and tubing are set up to facilitate rapid organ recovery. The super rapid recovery 
technique is preferable and organs may be removed en bloc.
15,345
 For uncontrolled donors, in-
vivo organ preservation techniques, like in-situ intravascular cooling using a double balloon 
and triple lumen catheter or hypo- and normo-thermic cardiopulmonary bypass with 
extracorporeal membrane oxygenation (ECMO), should be employed. With regard to the 
logistic organization, two frequently mentioned initiatives are the “Maastricht‟s box” and the 
“Madrid‟s rapid identiﬁcation and response system”.238 
 
Donor cause of death 
DCD donors do not experience the brain dead process. Brain death provokes a cascade 
of changes in hemodynamics, hormones, and immune response, which negatively affect donor 
organ viability and transplant outcomes.
346,347
 Hemodynamic instability may have deleterious 
effects on liver function, although the liver has a high tolerance to marked hypotension and a 
large physiological reserve. Only a few histological changes were observed in the liver both 
on light and electron microscopic examination during the brain dead process.
348,349
 The most 
important changes are the increased liver immunogenicity with subsequent increased host 
allo-responsiveness and the occurrence of apoptosis of hepatocytes.
350
 Clinical ﬁndings in 
livers from DBD donors revealed signiﬁcantly higher leukocyte inﬁltrates, up-regulation of 
adhesion molecules (intercellular adhesion molecule - ICAM, vascular cell adhesion molecule 
- VCAM) and pro-inflammatory cytokines (interleukin-6 (IL-6), IL-10, IL-1β, interferon γ 
and tumor necrosis factor-α), along with an increased expression of major histo-compatibility 
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complex-II (MHC-II) relative to livers from living donors.
277,351
 The peak time of cytokine 
expression and cell infiltration is during brain death and organ procurement but not after 
reperfusion.
277
 These changes may amplify ischemia-reperfusion injury (IRI) during the 
transplant procedure and accelerate graft rejection after transplant.
352
 In reality, donor brain-
death mechanisms are quite varied and large differences may exist in the degree of impaired 
organ quality and transplant outcomes. The impact of donor cause of death on transplant 
outcomes has been recently confirmed in a UNOS (United Network for Organ Sharing) 
registry analysis, in which the cerebro-vascular accident presented as a predictor of worse 
graft survival across all organs relative to other donor modes of death.
279
   
Uncontrolled DCD donors whose cause of death is usually other than neurologic do 
not undergo the process of brain death, while most controlled DCD donors have sustained 
irreversible cerebral injuries. As a result, organs from controlled DCD donors are likely to 
suffer more from the harmful immunologic and inﬂammatory effects of acute brain injury 





It is reported that organs that have already subjected to warm ischemic injury have an 
increased susceptibility to damage during cold storage.
353
 The incidence of PNF was 2.5 times 
less in patients with cold ischemia time (CIT) ≤ 8h versus those with CIT > 8h (5% versus 
13%).
60
 The incidence of graft failure within 60 days of transplantation was 10.8% if CIT < 
8h and substantially increased to 30.4% and 58.3% if CIT > 8h and > 12h, respectively.
58
 
Proper and rapid allocation of DCD livers thus appears pivotal to minimize CIT. One-year 
graft survival of DCD livers shared regionally was less good than those shared locally (67% 
versus 77%)
212
 and the relative risk of graft failure from nationally shared DCD livers was 
31% higher than locally or regionally shared ones
300
. Thus a policy to favor local use of DCD 
livers seems reasonable.
58,212
 However, parallel (backup) offers should also be made to 
expedite organ placement.
14
 The exchange of DCD livers between transplant centers has been 
successfully done but requires a more efﬁcient and rapid referral system due to a lower 
tolerance of these allografts to cold storage.
311
 
Regarding recipient selection criteria, DCD livers could be routinely discussed and 
offered to all recipients on the waiting list
304,311,318
 or selectively reserved to uncomplicated 
cases to ensure short CIT (by avoiding cases with extensive history of abdominal surgery or 
portal-vein thrombosis).
304,338
 An expected long surgical procedure exceeding 8 h of CIT, 
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logistical reasons for an extended CIT, combined organ transplantation, recipients with high 
MELD (Model for End-Stage Liver Disease) scores or a large age difference between donors 
and recipients could all result in the refusal of a DCD liver.
144
 Patients with stable cholestatic 
liver disease or re-transplantation were also excluded from DCD programs because of 
problems related to the quality of life in primary biliary cirrhosis and to the fear that pre-
existent warm ischemic biliary damage could trigger the recurrence of primary sclerosing 
cholangitis.
298
 Using DCD livers in re-transplanted patients might increase the CIT associated 
with a difﬁcult hepatectomy. Recently LaMattina has demonstrated the feasibility of 
simultaneous liver and kidney (SLK) transplantation using DCD donors and shown short-term 
results comparable to those of SLK transplantation using DBD donors, making it a valid 




It is still controversial whether it is better to transplant such grafts into healthy or 
sicker recipients (i.e. according to the recipient liver disease severity). UNOS database 
reviews advocated utilizing DCD livers in „low-risk‟ recipients.57-59 De Vera also observed 
better graft survival when DCD livers were utilized in patients with MELD scores ≤30, but 
simultaneously could demonstrate that „sicker‟, high-risk recipients (at MELD scores >30 or 
on organ-perfusion support, like mechanic ventilation or hemodialysis) had a greater patient 
and graft survival beneﬁt from the transplantation of DCD livers compared to patients who 
are not as critically ill.
60
 Risk classification for DCD donors and DCD-LT recipients is 
summarized in Table 4.2.1. Other groups of patients that may have a true survival beneﬁt 
from DCD-LT include MELD „disadvantaged‟ patients (hepato-cellular carcinoma patients 
beyond the Milan criteria or who are listed in areas with long waiting times, patients with low 




Studies about the effect of DCD liver grafts on hepatitis-C virus positive (HCV+) 
recipients‟ transplant outcomes were inconsistent. Nguyen and recently Hernandez-Alejandro 
found a negative eﬀect of HCV on DCD livers, but a formal contraindication for the use of 
DCD liver allografts in HCV+ recipients was not justified except for older donors.
342,355
 In 
fact, while single-center series reported no significant difference in graft and patient survival 
rates of HCV+ recipients and graft loss from HCV recurrence between DCD and DBD 
groups,
60,95,304,356
 as well as no deleterious effects of DCD liver grafts on the disease 
progression (fibrosis) in comparison with DBD liver grafts in HCV+ recipients,
95
 the most 
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recent UNOS registry data showed inferior graft survival but similar patient survival of 
HCV+ recipients with DCD donors compared to ones with DBD donors. Furthermore, DCD 
livers on HCV disease do not fare worse than DCD livers on non-HCV disease. DCD livers 
thus appeared to be important source of LT for HCV patients.
357
 Split livers from DCD 




Table 4.2.1. Risk classification for DCD donors and DCD-LT recipients  
Authors  Donors  Recipients 
Mateo59 Low risk Both WIT ≤30 min and CIT ≤10 h RCRR ≤1.5 
High risk  WIT >30 min and/or CIT >10 h RCRR >1.5 
Re-transplantation and/or  
On life-support and/or  
A combination of  ≥ 3 risk factors:   
       Hospitalization or in ICU  
       Serum creatinine >2 mg/dL 
       On dialysis  
       Age >60 years 
Lee57 Low risk Donors with no identified donor risk 
factors  
Recipients with no identified 
recipient risk factors 
High risk  Donors with at least one identified 
donor risk factor:  
       Donor age >45 years 
       WIT >15 min 
       CIT >10 h 
Recipients with at least one 
identified recipient risk factor:  
        Previous transplantation 
        Life support at transplantation 
De Vera60 Low risk - MELD scores ≤30 
High risk  - MELD scores >30 
On life support (mechanical 
ventilation, hemodialysis) 
RCRR: recipient cumulative relative risk. MELD: model for end-stage liver disease.  
 
Transplant outcomes  
Currently one-year patient survival after DBD-LT and to a certain extent after 
controlled DCD-LT is about 85-90% in comparison to 60% in the early eighties and around 
30% in the early days of LT and at 5 years post-transplant patient survival rate remains over 
70%. Medical progress over the past 40 years in the field of organ preservation, surgical 
techniques, immunosuppressive drugs, treatment of post-transplant complications and organ 
allocation has permitted DCD to become reality in the modern era. Although there are 
concerns about the quality of such organs, with evidence that a prolonged WIT causes a raised 
incidence of primary non-function (PNF) and biliary complications as well as suboptimal 
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graft and patient survival when compared to DBD livers, DCD livers may be life-saving for 
those who would die waiting for a DBD liver
212
 and do increase the  number  of  organs  
available for LT. With careful donor/recipient selection and matching, minimization of 
ischemia and good post-operative care, acceptable results can be achieved. Essential results of 
most important publications in the last decade in DCD-LT are presented in Tables 4.2.2a, 
4.2.2b, 4.2.3a, 4.2.3b and 4.2.4.  
 
Primary non-function 
PNF is usually defined as unrecoverable hepato-cellular dysfunction leading to patient 
death or re-transplantation within the first week post-transplant after excluding other causes of 
graft failure such as vascular thrombosis, biliary complications, rejection or recurrent 
disease.
360-363
 Initial studies using uncontrolled DCD donors reported a rate of PNF as high as 
50%.
364
 Currently only a few transplant centers in the world (like Spain, France) used this 
kind of donors because of aforementioned reasons. By using different in-vivo organ 
preservation methods to maintain DCD donors and by strictly applying donor selection 




 and La Coruña
317,365-367
 could obtain promising 
results from Maastricht category I and II donors with a PNF rate of 10-25%. The discard rate 
nevertheless was high up to 50-75%.
10,318
 In controlled DCD donors, the PNF rates are 0% to 
12%. Matched analyses
60,298
 and registry data
58,212
 showed a higher rate of PNF in controlled 





. The increased risk of PNF in DCD-LT recipients was also 
confirmed in a recent meta-analysis (odds ratio - OR = 3.6, 95% confidence interval - CI = 




PNF is the consequence of severe IRI with the initial period of warm ischemia playing 
a crucial role. Experimental evidence supported that donor WIT should be less than 30 min to 
minimize PNF.
368
 This warm ischemia (WI) period increases graft susceptibility to damage 
during cold preservation and CIT was a main contributing factor to PNF,
58,60
 therefore, both 
periods of ischemia must be kept to a minimum. Many laboratory tests have been developed 
both in animal models and in human to predict the probability of occurrence of PNF post-
transplant, but none is yet clinically efficient.
369
 Recently Dahaba proposed bispectral index 







Since the introduction of LT up to now, biliary complications are always regarded as 
the „Achilles heel‟ and a major cause of morbidity and graft failure in patients after LT.307 The 
most common biliary complications are bile leakage and bile duct stricture.
371,372
 Strictures 
involving the donor bile duct (>1 cm above the biliary anastomosis) and requiring endoscopic 
or radiological dilatation/stenting or surgery in the face of a patent, non-stenotic hepatic artery 
was referred to as ischemic-type biliary lesions (ITBL), based on the radiologic resemblance 
of those occurring after hepatic artery thrombosis (HAT).
144,309,372
  
Abt first mentioned the significantly higher incidences of overall biliary complications 
as well as ITBL in DCD-LT recipients,
306





 studies except Fujita‟s and Manzarbeitia‟s 
series.
94,319
 The rates of overall biliary complications and ITBL were 10.5 - 53% and 8.3 - 
38%, respectively in DCD-LT compared to 8.3 - 22% and 0 - 8%, respectively in DBD-LT. 
Especially Jimenez-Galanes reported only a 5% incidence of ITBL in their patients receiving 
livers from uncontrolled DCD donors under normothermic ECMO.
318
 A recent meta-analysis 
revealed that DCD recipients had a 2.4 times increased odds of biliary complications (95% CI 
= 1.8–3.4) and a 10.8 times increased odds of ITBL (95% CI = 4.8–24.2) versus DBD 
recipients. In average, biliary complications were present in 29% of DCD compared with 17% 
of DBD recipients and ITBL in 16% of DCD versus 3% of DBD recipients.
299
 Furthermore 
DCD recipients who developed ITBL experienced a fairly rapid clinical deterioration, 
characterized by a relatively short mean time from transplant to ﬁrst endoscopic retrograde 
percutaneous cholangio-pancreatography (ERCP), from ﬁrst ERCP to relisting and from 
relisting to re-transplantation (within 180 days).
300,301
 ITBL results in re-operation, multiple 
endoscopic and percutaneous biliary interventions, re-transplantation and even patient death 
with markedly increased medical care costs.
64
 The relative risk (RR) of developing graft loss 
with ITBL formation was 3.02 (95% CI = 1.9 –5.3) and graft survival was significantly 
decreased in patients with non-anastomotic strictures, compared to patients without it.
317
 Up 
to 50% of all occurrences of ITBL lead to death and/or re-transplantation.
373
 
ITBL is usually a reflection of severe IRI in relation to various factors. In animal 
models, irreversible biliary tract damage has been observed after 40 min of cardiac arrest 
although hepato-cellular function could be preserved.
374
 Clinical observations showed that 
total WIT >30 min and chaotic donor physiology before asytole may increase the risk of post-
transplant biliary stricture.
14,375
 The mechanism could come from the stasis of blood and clot 
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formation in the peri-biliary micro-circulation whose blood is solely supplied by the hepatic 
artery.
313
 Many multivariate analyses recognized DCD liver grafts as an independent risk 
factor for the appearance of ITBL (RR = 47.1).
144,317
  Biliary epithelium is also known to be 
sensitive to cold preservation-reperfusion injury and the correlation between the incidence of 
ITBL and the duration of cold ischemia has been well documented. Li demonstrated that the 
rate of ITBL is significantly increased in livers with increased preservation injury, as reflected 
by post-transplant peaks in serum transaminases.
376
 Other variables implicating in the 
mechanisms of ITBL may include injury of the peri-biliary vascular plexus, bile salt toxicity 
and potential immunological etiologies (ABO incompatibility, liver diseases with 
autoimmune component like autoimmune hepatitis and primary sclerosing cholangitis).
371
 
Chan found donor age >50 years, donor weight ≥100 kg and total ischemia time ≥9 h were 
predictive for the development of ITBL.
305
 Patients who underwent LT from DCD donors >60 
years had a markedly high rate of biliary complications (67%), with a RR of 5.6 (95% CI = 
0.98–32.2).60  
Due to serious consequences of ITBL on the patient‟s quality of life and healthcare 
cost, preventive measures seem to play a pivotal role in the safe expansion of DCD liver use. 
Attempts to minimize biliary duct damage may include the use of normothermic ECMO for 
donor maintenance
10,318,377
 and machine perfusion for liver grafts, choice of preservation 
solutions (HTK versus UW),
378-382
 use of anticoagulation and thrombolytic agents,
313
 
extensive irrigation of the donor bile duct and pressure perfusion of the hepatic artery during 
organ retrieval and/or at back table,
378,383,384
 early porto-caval shunt to reduce portal 
hypertension in the recipient, choice of reperfusion techniques (concomitant versus sequential 
reperfusion of portal vein and hepatic artery)
385
 and certainly the most important thing is 




Hepatic artery thrombosis and stenosis   
HAT is a thrombo-embolic occlusion of the hepatic artery that can occur early or late 
after LT. Most authors used the first 30 days post-transplant as a time point to distinguish 
between early and late HAT.
316
 Early HAT results in fulminant hepatic failure, bile duct 
necrosis and leaks, relapsing bacteremia and ultimately graft loss and recipient death. The 
frequencies of early HAT after DCD-LT varied from 0% to 16.6% and did not seem 





except Yamamoto‟s study (33.3% versus 0%).308 Risk factors for early HAT have been well 
analyzed in a recent systemic review.
387
 Few detailed studies discussed late HAT. 
The incidence of hepatic artery stenosis (HAS) was not consistently found higher in 
DCD than DBD grafts (12.8-16.6% versus 0-5.4%).
298,309
 It is possible that hepatic arteries are 
susceptible to WI during DCD organ retrieval, resulting in subsequent scar and stenosis. 
Moreover the increased susceptibility of DCD livers to post-operative arterial ischemia might 
be responsible for more biliary strictures in DCD than DBD recipients with HAS (83% versus 
37%) as well as shorter time to the development of biliary strictures after HAS in the DCD 
group.
309
 Inadequate surgical technique, vascular trauma by clamps, graft rejection, recurrent 
hepatic disease… might also play a role in the mechanisms for HAS.298,388  
 
Graft and patient survival 
Graft survival is defined as the time from transplantation to either re-transplantation or 
patient death, with „early‟ and „late‟ graft failure occurring within and beyond 1 year post-
transplant, respectively.
60
 Few studies reported experience with LT from uncontrolled DCD 
donors. Early results were poor with a PNF rate of 50% and one-year graft survival rate of 
only 17%
364
 leading to a scarce usage of this donor category in the US. Subsequent series in 
Spain using advanced in-vivo organ preservation methods showed promising outcomes with 
one- and five-year graft survival rates of 50-80% and 49%, and one- and five-year patient 
survival rates of 70-85.5% and 62%, respectively.
10,317,318
 LT from controlled DCD donors 





 and in some comparative studies.
301,309,310
 One-, three-, 
five- and ten-year graft survival rates were 54-79.5%, 53-74.5%, 37.5-71% and 37.5-44%, 
respectively. Patient survival rates at corresponding time points were 61.9-91.5%, 62.8-
89.5%, 42.9-89.5% and 42.9-57%, respectively. Transplant outcomes comparable to those 
obtained from DBD-LT have been sporadically reported in select centers through careful 
donor selection and optimization of CIT or through invasive techniques designed to optimize 
recovery before declaration of death.
144,304-306
 
Signiﬁcant risk factors for DCD liver graft loss have been identified by multivariate 
Cox regression technique in both single center studies and large data registry analyses.
57-
59,212,300,389,390
 Among donor risk factors, age >50 years, total WIT >30 - 35 min, CIT >6 h, 
body weight >100 kg and regional or national liver distribution had deleterious effects on 
graft survival.
57,59,390
 There is a stepwise increase in the relative risk of graft failure among 
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donor age, WIT and CIT.
57,390
 Strong recipient determinants of graft failure include age >55 
years, history of previous transplantation, medical status at transplantation (ICU or non-ICU 
hospitalization, life support, dialysis, renal insufficiency), high MELD score (>30) and 
positive HCV serology.
57,59,390
  In the DBD-LT model, it has been shown that a single risk 
factor lessened outcome marginally, however, the additive effect of multiple risk factors in a 
given donor-recipient pair were disastrous.
362
 Grafts with ≥3 donor risk factors had 
significantly lower 1-year post-transplant survival than no or only 1 or 2 risk factors (58.3% 
versus 72.6%, 69.2% and 73.9%, respectively). No grafts with 4 risk factors survived within 1 
year.
391
 The relative risk of allograft failure from LT utilizing DCD donors was 31-87% 
higher than LT utilizing DBD donors.
58,212,300,302,389
 Causes of early graft failure included 
PNF, biliary complications, HAT and deaths from sepsis/multi-organ failure. Late graft 
failure was often secondary to chronic rejection and recipient death with a functioning graft. 
Although DCD livers may not be as good as DBD ones with potential inferior 
transplant outcomes, there are subgroups of grafts and recipients that could give favorable 
results through appropriate graft and recipient matching. Low-risk DCD grafts which are 
transplanted in low-risk patients lead to comparable graft survival rates with DBD livers. 
Livers from DCD donors transplanted into high-risk recipients fared poorly independent of 
the allograft quality.
59
 Doshi showed DCD liver grafts were not inferior to DBD livers from 
older donors (≥60 years).212 Given the ever increasing demand for LT, DCD livers appear to 
be a reasonable alternative to increasing use of older or split livers and are a reasonable option 
when death is imminent.
212
 Even if graft or/and patient survival is lower with a DCD liver, it 
is still better than dying because of turning down a DCD offer and continuing to wait for a 
DBD liver on these days as the patient‟s choice is frequently not between marginal livers 
(including DCD) and standard livers but between marginal livers and no livers.
94
 The benefit 
of earlier access to LT provided by a DCD graft could outweigh the risks of prolonged 





DCD recipients more often require re-transplantation. 21.6-42% versus 8.8-16% of 
DCD and DBD recipients were listed for re-transplantation, respectively.
300,301
 The re-
transplantation rate ranged from 7.6 to 31% in DCD-LT compared to 2.5-12% in DBD-
LT.
10,58,60,144,212,298,300,301,304,309,310,318,319
 DCD livers exhibited a 2.1 times greater risk of graft 
failure, a 2.5 times greater risk of re-listing, and a 3.2 times greater risk of re-transplantation 
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compared with DBD livers.
301
 The majority of re-listing and re-transplantation in the DCD 
group were a consequence of biliary complications, especially ischemic cholangiography, but 
not due to an increased incidence of PNF, HAT or technical complications.
300,301
 Particularly 
DCD livers had a temporally different failure pattern within the first year post-transplant that 
limited access to re-transplantation:
300,301
 graft failure was more likely to occur within the ﬁrst 
180 days (18.1% versus 11.7%,
58
 10.2% versus 2.5%,
298
 and 20.5% versus 11.5%,
300
 of DCD 
and DBD grafts failed within 60, 90 and 180 days, respectively); at re-transplantation, DCD 
recipients waited longer and received higher risk allografts; and more DCD recipients 
remained waiting for re-transplantation with fewer removed for death, clinical deterioration, 
or improvement. Re-transplantation arouses controversy on medical, economic, and ethical 
grounds: patient and graft survival rates after a second LT are inferior to those after initial 
grafting, the procedure is more expensive and in the context of organ shortage, re-
transplantation inevitably denies organs to ﬁrst-time recipients.392 
Utilization of DCD allografts for re-transplantation was rare (2.5% of initial DCD 
versus 3.1% of initial DBD) and outcomes from each group were comparable.
300
 The general 
practice is to avoid re-transplantation with a DCD graft.
301
 The use of DCD donors in the 
setting of re-transplantation resulted in an increased risk of recipient death (hazard ratio - HR 




Acute rejection  
The acute rejection rate did not differ significantly between DCD- and DBD-LT in 
most studies (1.9-29% versus 0.6-34%).
298,304,306,317,366
 Foley reported a one-year rejection rate 
of 61% in the DCD group similar to that in the DBD group (56%). There were little data 
looking at the impact of DCD source on the risk of acute rejection.  
 
Experimental strategies to improve DCD-LT outcomes 
The progressively increased DCD liver procurement to solve the shortage of DBD 
organs and to alleviate the waiting-list mortality has raised many challenges to the transplant 
community and transplant policy makers.
375
 A lot of experimental researches have been 
performed over the past decade, intervening in both donors and recipients at different phases 
of the transplantation process, at the aim of tackling some of these challenges and providing a 
deep insight into IRI mechanisms 
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Table 4.2.2a. Results of DCD-LT in single-center studies 
Authors 
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Floria - US 
1998-2006 108 DCDc 
1328 DBD 
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334 DBD 
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2004-2008 26 DCDc 39 5.3 h 29 m 
 




















2005-2009 22 DCDc 21 422  27 m 4.5 27 9 0 0 
115 
 









Graft survival % Patient survival % 































































































































































Graft survival % Patient survival % 





1993-2001 144 DCD 
26856 DBD 



















1996-2003 367 DCD 
33111 DBD 
15.6 8.3 h 
8.4 h 











1996-2006 874 DCD 
43734 DBD 
15.4 7.9 h 
8.2 h 
















1998-2004 345 DCD 
20289 young-DBD 
3604 old-DBD 

























2000–2004 472 DCD 
23598 DBD 
- 7.9 h 
8.1 h 









2002-2007 855 DCD  
21089 DBD 











2001-2009 1567 DCD 16.1 7.5 h - 13.6 - - - 78 64.9 - 
min: minute. h: hour. d: day. m: month. y: year. DCDc: controlled donors after cardiac death. DCDu: uncontrolled donors after cardiac death. DCD1, DCD2 
and DCD4: Maastricht category-1, category-2 and category-4 DCD donors. DBD: donors after brain death. SCD: standard criteria donors. ECD: extended 
criteria donors. WIT: warm ischemia time. CIT: cold ischemia time. PNF: primary non-function. ITBL: ischemic-type biliary lesions. HAT: early hepatic artery 
thrombosis. HAS: early hepatic artery stenosis. Major symptomatic biliary complications include biliary leak, anastomotic and non-anastomotic stenosis. 




Various cyto-protective substances have been successfully administered into the donor 
prior to cardiac arrest for prevention of liver microcirculatory disturbance. Microcirculatory 
disturbance was the main obstacle to successful DCD-LT, which was due to four major 
mechanisms: deterioration of sinusoidal endothelial cells (SEC) caused by activated Kupffer 
cells, sinusoidal narrowing caused by some vasoconstrictors and swollen hepatocytes, 
leukocyte and platelet adhesion, and hyper-coagulability.
393
 Up to now, only Heparin and 
phentolamin (an anti-coagulative substance and alpha-adrenergic antagonist) are allowed in 
clinical DCD organ procurement,
394
 other substances remain in animal models. Tacrolimus, 
besides its powerful immunosuppression, enabled to prevent liver normothermic IRI by 
multiple mechanisms.
395
 Milrinone, a type 3 phosphodiesterase inhibitor, attenuated graft 
injury caused by warm and cold ischemia via an increase in intracellular cAMP levels, 
protection of SEC, relaxation of hepatic stellate cells, inhibition of platelet aggregation and 
anti-inflammatory effect.
396
 Lazaroids, an antioxidant designed to inhibit iron-dependent lipid 
peroxidation, ameliorated SEC viability via antioxidant effects and membrane stabilization.
397
 
N-acetylcystein has a direct effect on oxygen free radicals, but its usage had no effect in both 
graft viability and lipid peroxidation.
398
 
Animal studies clearly showed the concept of pharmacological modulation of organ 
donors before procurement is feasible to improve the viability of marginal grafts. 
Nevertheless there are no definitive recommendations for the use of these drugs. Application 






Preservation of DCD livers by hypothermic machine perfusion (HMP) was shown 
superior to static cold storage (SCS) in many experimental studies.
400,401
 Nonetheless a 
putative drawback of HMP for livers is to induce alterations at the vascular endothelial site, 
especially if HMP was performed for a long time or under suboptimal conditions.
402
 
Endoplasmic stress activation promoted cellular apoptosis via activation of caspase-12.
403,404
   
The efﬁciency of HMP was markedly increased by oxygenation of the perfusate.405 The 
concern that high oxygenation  might favor the generation of oxygen free radicals, which in 
turn could impair tissue  integrity, was not justified. Several investigators could demonstrate 
the beneficial effect of oxygenated HMP in reducing the liver expression of pro-inﬂammatory 
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cytokines (TNF-α, IL-8), adhesion molecules (ICAM-1) and major histocompatibility 
complex class II antigens.
406-408
 This beneﬁt will likely be more pronounced in marginal grafts 
such as elderly, steatotic and DCD livers.
407
 Cyto-protective agents can be added into the 
machine perfusion (MP) solution to ameliorate the efficiency of HMP organ preservation.
409
  
The positive effects of HMP on warm-ischemically pre-damaged livers were observed 
even after a brief period of MP, before (pre-conditioning) or after SCS (post-
conditioning)
406,410
 and therefore, it was not necessary to require MP over a full preservation 
period and helped avoid side-effects of HMP on vascular endothelium.
404
 The use of HMP as 
the initial method for organ preservation followed by secondary SCS during transportation 
combined the advantage of aerobic resuscitation (i.e.  restitution of cellular homeostasis) with 
an ease of SCS for later surveillance and transportation.
404
 Manekeller showed a post-
conditioning of 1 hour after SCS can ameliorate the viability of marginal livers. The extension 
or abbreviation of post-conditioning time seems to have no further beneficial effects.
411
 
Schon and St Peter reported advantages of normothermic machine perfusion (NMP) 
over SCS in pig DCD-LT models. Livers subjected to 1 hour of WI and then cold-stored for 
4-24 hours were rendered completely nonviable while such livers under 4-24 hours of 
oxygenated NMP recovered function to a viable level.
353,412
 Due to the complexity of the 
logistics of clinical multi-organ recovery and of the NMP device, a period of cold 
preservation prior to warm perfusion of the liver is unescapable. A brief period of cold 
preservation (1hour) prior to NMP could maintain the synthetic and metabolic function but 
resulted in significant hepatocellular damage, sinusoidal endothelial cell dysfunction and 
Kupffer cell injury.
413
 Once this duration was prolonged to 4 hours, NMP completely failed to 
resuscitate porcine livers.
414
 Normothermically perfusing DCD livers throughout the 
preservation period not only replenished cellular substrate, ameliorating the ischemic injury, 
but also provided a clear assessment of liver function and therefore could permit the use of 
severely injured organs with reassurance of function.
412,415
  
Despite the aforementioned benefits of MP over SCS in liver preservation, only SCS is 
clinically approved up to now, MP is still in the pre-clinical stage and early clinical studies.
157
 
Tojimbara showed the impact of viscosity and temperature of initial flushing solutions on 
graft function. A low viscosity flushing solution was associated with lower vascular 
resistance, whereas a warm flush solution prevented cold-induced vasospasm and therefore 
improved the washout effect of the microcirculation.
416
 HTK (histidine-tryptophan-
ketoglutarate) solution possessing a low viscosity and low potassium is more preferable in the 
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DCD setting. The role of aeration of the cold-stored liver was also clarified. Oxygen provided 
either by surface diffusion (surface oxygenation) or intravascular diffusion (oxygen 
persufflation) helps improve the energy status of organs thus leading to earlier recovery. 
Surface oxygenation was not in use any more due to complicated technique, limited efficiency 
and risk of oxygen intoxication.417 Venous systemic oxygen persufflation (VSOP) was shown 
to improve organ viability during hypothermic storage of the grafts and to be a feasible means 
for reconditioning of warm-ischemically pre-injured livers from DCD donors.
417-420
 
Experimentally even a short period of VSOP prior to long-term preservation of the liver by 
SCS may be sufficient for a relevant improvement of liver integrity upon reperfusion.
421
 
Gaseous persufﬂation with carbon monoxide was also tested in a DCD-LT rat model with 
enhanced liver graft viability.
422
 However no additive or synergistic effect was noted when 
livers were persufflated with a mixture of gaseous oxygen and carbon monoxide.
423
  
Pharmaceutical interventions during SCS aimed at conditioning marginal organs also 
increasingly gained attention. Different cyto-protective drugs have been added into the flush 
and/or preservation solution, like vasodilators (phentolamin, epoprosterol, dopamine),
424,425
 
anti-coagulants (heparin), fibrinolytic agents (streptokinase),
426
 antioxydants (superoxide 
dismutase, edaravone),
427,428
 antibiotics, hormones (glucagon, growth factors)
429… In the 
DCD setting, vasodilators, anti-coagulants, thrombolytic agents and antibiotics seem 
particularly necessary because the organs tend to develop vasospasm, thrombus formation in 
the microcirculation and the risk of colonic bacterial contamination secondary to translocation 





Due to serious consequences of transplanting a DCD liver with potentially severe IRI 
(PNF, re-transplantation or even recipient death), it would be ideal if the viability of such 
livers could be predicted prior to rather than after transplantation. WIT is not always exactly 
known and thus cannot be a reliable parameter. Light microscopic examination of biopsy 
specimens was unable to uniformly predict liver function after transplantation.
431
 Monbaliu 
showed the extent of parenchyma vacuolation predicted pig liver graft viability before LT.
432
 
Muiesan applied the mechanical digestion of liver biopsies with collagenase and assessed the 
viability of hepatocytes by trypan blue exclusion method.
311
 However, the test was not helpful 
and the decision as to whether to use the liver was generally made on gross appearance, ease 





Another approach is to evaluate the vascular resistance and enzyme release in the 
perfusate of HMP livers. Resistance index of the portal vein and hepatic artery showed no 
utility.
434
 Biomarkers of liver cell damage, like transaminases, lactate dehydrogenase (LDH) 
and liver fatty acid binding protein (L-FABP), correlated well with WI duration and 
concomitant hepatocyte damage in pig DCD-LT models.
435
 Possible other parameters are the 
ATP content and redox active iron status of the liver during HMP.
436
 During NMP, the 
assessment of liver viability may be easier because the liver is in a normal metabolic state. 
Bile production was a good viability indicator besides the measurement of other liver 
functions (detoxification, metabolism or synthesis).
437
 Recently Liu has tested the utility of 





Recipient treatment  
Pharmaceutical strategies aimed at modulating IRI mechanisms were also applied 
successfully in animal recipients and generally did not impose ethical problems as donor pre-
treatment. Such protocols without donor pretreatment will be favorable in clinical application. 
Most studies tested a single agent for a specific target of the IRI process. A multi-factorial 






The future of DCD-LT is promising. Concerted efforts should concentrate on the 
identification of suitable donors (probably Maastricht category III DCD donors), better donor 
and recipient matching (high risk donors to low risk recipients), use of advanced organ 
preservation techniques (oxygenated HMP and NMP, VSOP), and pharmacological 
modulation (probably a multi-factorial biologic modulation strategy) so that liver procurement 
and transplantation from DCD donors could be widely expanded and attain equivalent results 
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ABSTRACT 
Objectives: This article aimed to review the various DCD (donation after cardio-circulatory 
death) descriptions in the literature and proposed an adapted DCD classiﬁcation to better 
deﬁne the DCD processes, seeking to provide a better tool to compare the results of published 
reports. 
Methods: We conducted a systemic review of all studies that discussed the use and 
classification of DCD organs during the past two decades in the world.   
Results: The renewed interest in DCD in the early 1990s led to an increasing use of this 
donor source especially in the recent years. However, various DCD terminologies and 
classiﬁcations have been used, rendering it difﬁcult to compare reported experiences.  
Conclusion: The original DCD categories were efﬁcient to expand this type of procurement, 
but a more complete categorization is now needed to deﬁne the various situations and to 
compare the clinical results encountered among different clinical groups and countries with 
active DCD programs. Modiﬁcations of the Maastricht classiﬁcation presented here may be 
helpful in this matter and may be further modiﬁed in the future according to ongoing 







Deceased donor (DD) organ transplantation utilizes grafts procured from a deceased 
human being, the so-called “cadaveric organ donor.” In the pioneering days of organ 
transplantation, the ﬁrst DD organ procurements were performed after declaration of donor 
death based on cardio-circulatory arrest criteria.
320,439-441
 In 1963, Professor Alexandre, from 
Brussels, Belgium, performed the ﬁrst donation after brain death (DBD) in a patient whose 
death was declared based on neurological criteria.
172
 The concept of brain death was 
conﬁrmed in 1968 by the Ad Hoc Committee at the Harvard Medical School.1 The wide 
acceptance of brain death in the Western world, and the better of DBD results due to the 
absence of warm ischemia (WI), led to the near complete abandonment of donation after 
cardio-circulatory death (DCD).  
The interest in DCD was renewed in the early 1990s, as a means to partially overcome 
the shortage of DBD. In some European countries and in the United States, DCD has become 
an increasingly frequent procedure over this last decade,
19,240,326,442
 including more than 40% 
of the DD pool in the Netherlands in 2008.
239
 In Middle Eastern countries and in Asia, where 
DBD is rarely performed for legal, cultural, and/or religious reasons,
443,444
 DCD is nearly the 
only type of organ procurement.
445
 After several successful experiences with DCD kidney 
transplantation (KT),
45,91,173,238,239,288







 Despite a ﬁrst report of 
successful heart transplantation after procurement from DCD donors,
88
 DCD heart 
transplantation has not reached (yet?) a signiﬁcant clinical application. 
To improve the results of DCD transplantation, it is important to compare the 
practices, experiences, and results of various teams involved in this ﬁeld. It is therefore crucial 
to accurately deﬁne the different types of DCD. However, in the literature, different 
terminologies and classiﬁcations of DCD have been used, rendering comparisons difﬁcult 
among the reports. The authors have presented herein an overview of the various DCD 
descriptions in the literature and have proposed an adapted DCD classiﬁcation to better deﬁne 
the DCD processes, seeking to provide a better tool to compare the results of published 
reports. 
 
Definition and classification of DCD donors 
Cardio-circulatory death is deﬁned as the “irreversible cessation of circulatory and 
respiratory functions”.15 In DCD donation, donor death is diagnosed by the cessation of 
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heartbeat and/or blood circulation, as assessed by electro-cardiography, monitoring of arterial 
pulses, or invasive arterial pressure. DCD donation does not exclude donor brain death. The   
term “non–heart-beating donation (NHBD)” was often used in the past (and is still sometimes 
used), but DCD is now preferred, as it more clearly implies donor death and can be compared 
with DBD. Both DCD and DBD donations imply organ procurement from a deceased donor, 
in contrast to a living donation. The initials “DCD” sometimes refer to “donation after cardiac 
death”; however, as DCD may be used in the future for heart transplantation,88  a declaration 
of donor death based on irreversible cardio-circulatory failure may more accurately deﬁne the 
DCD process. Indeed it is difﬁcult to understand or ethically justify the declaration of donor‟s 
death by “irreversible cardiac failure” if within minutes after the so-called “cardiac death,” the 
donor‟s heart is procured for subsequent successful cardiac transplantation.452,453  
The ﬁrst DCD classiﬁcation, proposed by the Rochester group in 1994, was based 
upon the possibility of planning donor cardio-circulatory arrest and the DCD surgical 
procedure.
15
 Uncontrolled DCD involves organ procurement after unexpected cardio-
pulmonary arrest and/or unsuccessful resuscitation.
15
 In controlled DCD, the cardio-
circulatory arrest is the consequence of a planned medical act of withdrawal of ventilatory and 
organ-perfusion support that can be performed either in the intensive care unit (ICU) or in the 
operating room (OR). In controlled DCD, procurement WI is recorded and minimized, as the 
procurement team is notiﬁed of the process and may be ready to start the surgical organ 
procurement within a few minutes after the declaration of death. In addition, cold ischemia 
(CI) may also be minimized as the potential organ recipients may be called into the hospital 
before the planned withdrawal of donor life support. 
In addition, in 1995, after several years of extensive research and clinical experience in 
DCD KT, Pr Gauke Kootstra organized in Maastricht, Holland, an international meeting on 
NHBD. During this meeting, he proposed a DCD classiﬁcation of four categories, which has 
been largely used over the last 15 years as the NHBD Maastricht classiﬁcation (Table 5.1).7 
This classiﬁcation has the advantage of characterizing the DCD processes that may have their 
own particularities, including ethical or surgical aspects. This classiﬁcation also has the 





Table 5.1.  Kootstra’s 1995 Maastricht categories of donation after cardio-circulatory death7 
Category  Description 
1 Dead on arrival 
2 Unsuccessful resuscitation 
3 Awaiting cardiac arrest 
4 Cardiac arrest while brain dead 
 
Compared to DBD, DCD imposes an additional WI that induces a signiﬁcant ischemic 
insult, increasing the risk of early post-transplant graft dysfunction. As a consequence of this 
procurement WI, DCD transplantation may be complicated by increased rates of primary non-
function or chronic secondary ischemic lesions, leading to recipient death or re-
transplantation when difﬁcult and/or unstable conditions yield the organ. Indeed, the length of 
the WI during DCD may be variable according to the category of the DCD process, the 
longest being associated with the uncontrolled Maastricht category 1 DCD donation. 
While WI during DCD is easily understood, its precise deﬁnition is difﬁcult. At the 
cellular level, the WI insult to various organs is not identical, and does not start at the same 
time.
454
 Particularly, the presence of air in the lungs may avoid pulmonary tissue ischemia in 
the early period after cardiac arrest.
455,456
 The liver parenchyma, perfused in the majority by 
hypoxic portal ﬂow, is used to a low oxygen level to some degree.457 In uncontrolled DCD, 
the future donor undergoes resuscitation attempts that may provide some tissue oxygenation. 
However, these attempts are often not sufﬁciently efﬁcient to avoid organ ischemia. Up to 
now, there has been no objective pre- or post-harvesting parameter that helps to determine 
whether a given donor or abdominal organ has suffered an irreversible WI insult that would 
exclude the possibility of organ transplantation. In uncontrolled DCD, WI is usually deﬁned 
as the time between the ﬁrst cardiac arrest and the cold ﬂush of the organs. Controlled DCD 
processes may be deﬁned in two phases: the withdrawal phase, the period between support 
withdrawal and cardiac arrest, and the acirculatory phase, deﬁned as the period between 
cardiac arrest and aortic ﬂushing (Fig 5.1). The acirculatory phase is composed of a “no-touch 
period,” which is variable according to the ethical committee or legal requirements in various 
countries, (it is usually 2 to 10 minutes, but may be up to 20 minutes in Italy
11,15,19
) and the 
surgical period between declaration of death and cold organ perfusion. The exact measure of 
the duration of the two phases is easily adjusted in controlled DCD. However, if the time 
determining the end of WI and the  beginning of CI is clear, the  determination of the moment 
of the start of organ damage due to WI is difﬁcult (or even impossible) since it is variable 
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among organs. The withdrawal phase is often marked by a progressive drop of oxygen 
saturation that is usually difﬁcult to monitor as most pulse oxymeters are not calibrated to 
measure saturations below 90%. In addition, during the DCD process, the drop in arterial 
pressure is also not always progressive, with periods of relative hypotension followed by 
pressure normalization. In 1995, Kootstra deﬁned DCD WI as the period between cardiac 
arrest and organ ﬂush.189 This deﬁnition is still used by the Eurotransplant organization in 
2011.
458
 For DCD kidney grafts, WI is now usually deﬁned as the period between support 
withdrawal to aortic ﬂush, meaning the whole DCD process.238,284 In DCD liver 
transplantation (LT), most reports deﬁne WI as the period between support withdrawal and 
aortic cold perfusion,
58,60,95,303,305,459
 but some authors have proposed to evaluate more 
precisely the period of real hepatic tissue WI. The American Society of Transplant Surgeons 
deﬁned total WIT as the period between support withdrawal to aortic ﬂush, and true WIT as 
the time between the drop in the mean arterial pressure below 60 mmHg and the initiation of 
perfusion.
15
 But as shown in Table 5.2, many centers or procurement organizations use other 
criteria, often mixing (mean or systolic) arterial pressure and oxygen saturation criteria, to 
establish the beginning of “true” WI time in LT, without providing clear scientiﬁc  
evidence.
27,301,319,338,339,341
 The same issue has also been raised in DCD lung 
transplantation.
100,447,460,461
 There is clearly a need to standardize the nomenclature, but this 
problem is beyond the scope of this article.  
 
 
Figure 5.1. Process of controlled donation after cardio-circulatory death 
 
Problems of these classifications and the modifications proposed in the literature 
The Maastricht classiﬁcation and the “controlled/uncontrolled” characterization of 
DCD are clearly current, useful standards. However, within the different types of DCD, 
clinical differences may lead to various post-transplant results presented in the literature. In 
Maastricht DCD categories 1 and 2, donor cardio-vascular death is an unpredictable event   
occurring outside or within the hospital, respectively. In these categories, DCD is, per 
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deﬁnition, an uncontrolled procedure with a prolonged period of DCD WI, if deﬁned as the 
period between the ﬁrst cardiac arrest to the ﬂush of the potential grafts. Using one of the 
largest world experiences in category 1 and 2 DCD in Spain, Fondevila found it important to 
differentiate uncontrolled DCD with potential witnesses of the cardiac arrest and rapid 
attempt of resuscitation versus those that occur without any witness even in the hospital.
10
 
Experienced Spanish centers also have reported signiﬁcantly worse results in category 2 DCD 
donors hospitalized in the ICU compared  with  those  without  an  ICU  stay.
9
 The worst 
results of category-2 ICU DCD donors may be attributed to their long hospitalizations and to 
the cerebral damages that may be detrimental to donor organs due to signiﬁcant pro-
inﬂammatory and pro-coagulant responses.462,463 In this report, the authors proposed to call 
these donors “category 5,”  despite  the  fact  that  they  were  clearly  under  the Kootstra‟s  
category 2 deﬁnition.9 Category 5 has subsequently been used by other authors.98,464,465 
Recently an Italian group with  limited experience in the ﬁeld even proposed a category 6 for 
DCD patients on extra-corporeal membrane oxygenation.
11
 In addition, some English groups 
have proposed to separate the Maastricht category 3 into 3A for controlled DCD performed in 
hospital and 3B for controlled DCD performed in hospice, due to worse results among the 
latter group despite equivalent WI and CI.
284,466
 Moreover, in the literature there is also some 
misunderstanding in the characterization of Maastricht category 4 as controlled versus 




Table 5.2.  Deﬁnitions of procurement “true” warm ischemia in controlled DCD liver transplantation 





ASTS  2010 MAP <60 NA 15 
Philadelphia       2009 MAP <50 <70 319 
Seattle     2005   MAP <35 <25 339 
United Kingdom          2005 SBP  <50 NA 27,311,341 
Chicago      2009     SBP  <50  <70 301 
Miami   2003       SBP <35  <25 338 
MAP: mean arterial pressure, SBP: systolic blood pressure. 
 
  In addition, in the recent years, a new type of DCD has been performed in Belgium 
(i.e., DCD after euthanasia).
12,231,467
 There are now laws allowing physician-assisted suicide in 
the Netherlands, Belgium, and Luxembourg, under strict medical and legal conditions 
requiring the clear willingness of the patient with unbearable suffering to die in a humane 
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condition. Other countries have ongoing active political discussions on this subject. It is likely 
that in the future, other countries will establish laws on this practice. To our view, and to that 
of various Belgian university ethical committees that have been questioned on the subject, 
there is no ethical or legal objection to harvest organs after physician-assisted death following 
active, repeated requests of the patient who has been granted euthanasia. This is a clear 
voluntary donation by conscious people willing to help other human beings, despite the fact 
that their own medical condition may not be adequately palliated by modern medicine. These 
particular DCD donors may be a source of good organs, as these DCD donors have no recent 
brain damage at the time of the highly controlled cardio-circulatory arrest. The authors 
postulate that these DCD procurements after euthanasia may be more frequent in the future. 
Indeed, the Eurotransplant organization has ofﬁcially recognized these DCD donations in 
their computerized organ donor forms. Clearly, these DCD donations are not included in the 
original Maastricht classiﬁcation. Therefore, for all of these reasons, the authors consider the 
need to adapt the current classiﬁcations of DCD. 
 
Proposition for an adapted DCD Maastricht classification 
Table 5.3 shows the adapted DCD classiﬁcation proposed herein. The authors 
consider that Kootstra‟s Maastricht classiﬁcation should be conserved as the skeleton for 
further improvement, as it is simple and clear and classiﬁes easily the various DCD types for 
ethical issues and for non-medical, non-specialized readers interested in the ﬁeld. Up to now, 
other attempts to improve the Maastricht classiﬁcation have added new categories based on 
various ischemic insults, potentially altering transplant results, despite the fact that the DCD 
situation was already included in the Maastricht classiﬁcation. As an exemple, Sanchez-
Fructuoso et al proposed to create category 5 for uncontrolled DCD occurring in the ICU,
9
 
despite the fact that these DCD donors are included in Kootstra‟s category 2 (unsuccessful  
resuscitation). Compared with Kootstra‟s 1995 Maastricht classiﬁcation,7 we have proposed 
herein to conserve the categories 1 to 4 but to divide them into a series of clinical situations. 
In addition, category 5 namely, DCD after medically assisted death, is added, since this 
category has clearly separate ethical and legal issues from those in categories 1 to 4.  
As proposed by Fondevila,
10
 category 1 (dead on arrival) may be divided into 
subcategories; 1A if there was no witness to the cardio-vascular arrest versus 1B, if the 
cardio-vascular arrest was witnessed and the potential DCD underwent some kind of 
unsuccessful resuscitation.  
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Kootstra‟s category 2 (unsuccessful resuscitation) includes rapid but failed attempts of 
in-hospital resuscitation. As the Spanish experience has reported signiﬁcantly worse results in 
kidney transplantation from category-2 DCD occurring in patients hospitalized in the ICU,
9
 
we propose to divide the category into 2A (unexpected cardio-circulatory death in ICU) 
versus 2B (unexpected cardio-circulatory death in hospital including emergency room or 
ward).   
 




Proposed deﬁnition Controlled - 
Uncontrolled 
1A Cardio-circulatory death outside hospital without witnesses Totally 
uncontrolled 
1B Cardio-circulatory death outside hospital with witnesses and rapid 
resuscitation attempt 
Uncontrolled 
2A Unexpected cardio-circulatory death in ICU Uncontrolled 
2B Unexpected cardio-circulatory death in hospital (ER or ward), with 
witnesses and rapid resuscitation attempt 
Uncontrolled 
3A Expected cardio-circulatory death in ICU Controlled 
3B Expected cardio-circulatory death in OR (withdrawal phase >30 min) Controlled 
3C Expected cardio-circulatory death in OR (withdrawal phase ≤30 min) Highly 
controlled 
4A Unexpected cardio-circulatory arrest in a brain-dead donor (in ICU) Uncontrolled 
4B Expected cardio-circulatory arrest in a brain-dead donor (in OR or ICU) Highly 
controlled 
5A Medically assisted cardio-circulatory death in ICU or ward Controlled  
5B Medically assisted cardio-circulatory death in OR Highly 
controlled  
ICU: intensive care unit, ER: emergency department, OR: operating room. 
 
In Maastricht category 3 (awaiting cardiac arrest), DCD procurement is a medically 
planned, controlled procedure in an ICU patient with a dreadful neurological prognosis, in 
whom further medical treatment is deemed futile.
196
 WI and CI are precisely monitored and 
minimized. Category 3 represents a numerically signiﬁcant source of transplantable kidneys, 
livers, pancreata, and lungs. Even cardiac procurement may be considered in this category 3.
88 
But all categories 3 are not comparable in terms of ischemic insults to various organs. The WI 
may vary considerably according to the place and way in which one performs the withdrawal. 
If it is performed in the ICU, even with a double-lumen catheter,
47
 the WI may be prolonged, 
as there is no efﬁcient cooling of the body or topical application to the abdominal organs in 
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most cases; furthermore, the donor must be transported to the OR for the DCD procedure. We 
propose to name this category 3A (Table 5.3). When support withdrawal is performed in the 
OR among category-3 DCD, the procurement is performed within minutes after the 
declaration of death, using a rapid laparotomy technique. However, the period between 
support withdrawal and cardio-vascular arrest, the so-called “withdrawal phase” may vary 
considerably.
30
 Moreover, some category-3 DCD donors display rapid respiratory and cardiac 
arrest due to a lack of spontaneous breathing due to destruction of the brain stem respiratory 
center or to partial or total suppression of its function by withdrawal of support.
15,68
 The 
authors propose to separate these category-3 DCD OR donors into two groups: category 3B in 
whom the withdrawal phase is longer than 30 minutes versus category 3C in whom this phase 
in less than 30 minutes. It is possible that these categories 3C, highly controlled DCD donors 
may yield excellent liver, pancreas, or even heart grafts.  
The Maastricht category-4 DCD of cardiac arrest while awaiting brain death is 
different in Western and Eastern countries. In Western countries, most category-4 DCD 
donors are brain-dead organ donors with unexpected and uncontrolled cardiac arrest after 
unsuccessful resuscitation. They mostly occur in the ICU during the preparation for DBD 
organ donation. Indeed the death of these donors is declared because of brain death and not of 
cardio-circulatory failure. This category does not require a “stand-off period.” These donors 
may be urgently transported to the OR for organ procurement but their WI is usually long. We 
propose to classify these DCD donors as category 4A to differentiate them from the Eastern 
countries category-4B DCD donors. In Eastern countries, such as Japan,
468
 and many Muslim 
nations, the concept of brain death is not widely accepted for cultural and/or religious reasons. 
Brain-dead donors may be transported to the OR for organ procurement after controlled 
respiratory support withdrawal. These highly controlled DCD donors might be a potential 
source of all transplantable organs. The category 4B DCD donation may also be (rarely) 
performed in Western countries if the family does not rely on the brain-death diagnosis and 
requests a controlled DCD donation.
311
 
In addition to the four Maastricht categories deﬁned in 1995, we propose to add a ﬁfth 
DCD category, corresponding to organ donation after medically assisted death or euthanasia. 
As explained above, euthanasia was legally approved in a few countries. In Belgium, some 
individuals who had euthanasia expressed their willingness to have their organs procured after 
death. The authors propose to name these donations category 5 (Table 5.3), as they cannot be 
included in the Maastricht 1995 classiﬁcation. Most patients who require euthanasia in 
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Belgium and in the Netherlands are cancer patients who clearly are not candidates for DCD 
donation. But a small proportion of these cases are patients with severe, stable neurological 
deﬁcits, whose medical affectation cannot be transmitted through organ donation. These 
patients are potential DCD donors. Most euthanasias are performed at home by the regular 
family physician, but DCD donation after euthanasia requires one to perform the euthanasia in 
an OR (or in a preparation room close to the OR to allow the presence of the family at the 
time of death), in an ICU or in the ward, if requested by the patient and/or the family. In this 
condition, the authors propose to consider category 5A as medically assisted cardio-
circulatory death in the ICU or ward with the donor rapidly transported to the OR after the 
death diagnosis. If the euthanasia is performed in the OR, the authors propose to name this 
DCD category 5B (Table 5.3). 
 
Clinical interests of this adapted classification 
The original Kootstra 1995 Maastricht classiﬁcation separated DCD into four clear 
situations with common ethical and legal implications. This classiﬁcation is still useful; the 
authors have herein added a category 5, which also has clearly different ethical and legal 
issues. However, as it is of primary importance to more precisely analyze clinical DCD results 
in the literature, the authors propose that the adaptation described herein presents important 
clinical issues. 
Table 5.4 shows categories 2A, 3 (3A, 3B, 3C), and 4 in which the donor subjects 
may have experienced severe cerebral damage due to long ICU stays that may impair short- or 
long-term graft function.
238,239
 In particular, this was the reported cause of inferior results of 
DCD kidney transplantation from category 2A donors.
9
 Table 5.4 presents possible WI to be 
expected in various situations. Total WI is deﬁned as the period between the ﬁrst cardiac 
arrest and the organ ﬂush for uncontrolled DCD, and from withdrawal of support to organ 
ﬂushing for controlled DCD. In controlled DCD (categories 3, 4B, and 5), CI may be reduced 
by hospital admission and/or surgical preparation of the recipient. CI may also be reduced in 
uncontrolled DCD situations by allocation of the DCD graft to a hospitalized potential 
recipient. All of these DCD categories may lead to different clinical results of transplantation. 
Although this classiﬁcation is more complicated, it is more complete than the 1995 
Kootstra classiﬁcation, while maintaining the same basic categories 1 to 4 (adding a ﬁfth) that 
are now well-known and accepted criteria. Each category was divided into two or three 
subcategories: subcategory A is linked to longer WI (and worse results) than subcategory B; 
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and B versus C, respectively. In addition, subcategories A (2A, 3A, 4A, and 5A) are mostly 
linked to DCD  processes  occurring  in  the  ICU,  which  helps  to understand  and memorize 
this classiﬁcation (Table 5.3). Moreover, by keeping the original skeleton of the 1995 
classiﬁcation, space is left to add new subcategories in the future, if deemed clinically 
relevant. For example, category 1B (cardio-circulatory death outside hospital with witnesses 
and rapid resuscitation attempt) could one day be separated into 1B (resuscitation with human 
external massage and ventilation) versus 1C (resuscitation with mechanical reanimation as the 
cardio-compressor) versus 1D (resuscitation with ECMO), if clinically required by groups 
with the largest experience in this ﬁeld.147,469 
 
Table 5.4.  Clinical differences according to the modiﬁed DCD categories, and some literature 
references reporting clinical use of these DCD organs in clinical transplantation 




Total WI Kidney Liver 
1A CCD outside hospital  
without witnesses 
no no unknown - - 
1B CCD outside hospital  
with witnesses and rapid 
resuscitation attempt 
no no long  45 461 
2A Unexpected CCD in ICU variable yes  long 9 317 
2B Unexpected CCD in ER or ward,  
with witnesses and rapid 
resuscitation attempt 
no no long 9 317 
3A Expected CCD in ICU 
 
yes yes >60min 47 144 
3B Expected CCD in OR  
(withdrawal phase >30 min) 
yes yes >40 min - - 
3C Expected CCD in OR  
(withdrawal phase ≤30 min) 
yes yes ≤40 min 91 175,240 
4A Unexpected CCA in a brain-dead 
donor (in ICU) 
yes yes long - 303 
4B Expected CCA in a brain-dead 
donor (in OR or ICU) 
yes yes ≤40 min 91 311 
5A Medically assisted CCD  
in ICU or ward 
no no ≤40 min - - 
5B Medically assisted CCD  
in OR 
no no ≤20 min 12,231 12,231 




Despite higher complication rates due to procurement WI, DCD organ transplantation 
is increasing. It will expand even further in the future, as a partial means to overcome the 
donor shortage. The original DCD categories were efﬁcient to expand this type of 
procurement, but a more complete categorization is now needed to deﬁne the various 
situations and to compare the clinical results encountered among different clinical groups and 
countries with active DCD programs. We have presented modiﬁcations of the Maastricht 
classiﬁcation that may be helpful in this matter and may be further modiﬁed in the future 












6.1. Does the DCD source really contribute to the DD pool in Liège and Belgium? 
(chapters 2.1 and 2.2) 
Before incorporating the potential of a DCD pool, it is important to emphasize that the 
goal of DCD transplantation is to increase the organ pool and decrease the patient death on 
the waiting list (urgently for vital organs), but not to obtain better herein or increase graft and 
patient survival.
470
 During ten-year period (2002 - 2011), 71 cDCD procedures have been 
performed in Liège among 135 DCD referrals, supplying 176 organs for transplantation 
(including 62 livers, 104 kidneys, and 10 lungs) in addition to 1 liver and 1 pancreas for 
hepatocyte and islet preparation, and 43 hearts for homograft valve preparation and 
cryopreservation. On average, cDCD donors contributed 20.5% of the overall DD pool over 
10 years and up to one-third of the yearly DD pool since 2009. In the same time period, the 
absolute number of DBD procurements slightly increased, translating into an increased 
number of DD organ retrievals and kidney and liver transplants.  
In contrast, analyses on the DCD activity in Belgium during the same period (2000-
2009) demonstrated although the number of DCD procurements, DCD kidney and liver 
transplants increased steadily over time, particularly from the year 2005 onward, there is no 
major rise in the Belgian DD donation and transplantation activity. In other words, some kind 
of donor-type redistribution within the DD pool might occur. Consequences of this possibility 
might be extremely worrisome because (i) total DD transplant activity will not be increasing 
due to the fact that DCD donors do not yield as many other organs besides kidneys as seen 
with traditional DBD counterparts; (ii) furthermore, transplant outcomes from DCD and DBD 
are not generally equivalent with regard to initial graft function, long-term complications and 
graft survival. Brook warned that the concentration of effort and resources on DCD may have 
resulted in a decline in the transplant rate from other, possibly better quality, sources.
79
  
Therefore, only when the contribution of this category of donors leads to an increase in the 




The alarming phenomenon of donor-type shift was firstly mentioned at the center level 
in the early 2000s, and then confirmed at the national level in some countries with active 
cDCD programs like the Netherlands and the UK. Several hypotheses have been suggested to 
explain the changing pattern of donation to a greater proportion of DCD: (i) improved road 
safety with a marked reduction in traumatic deaths; (ii) changes in neuro-surgical practice (de-
compressive craniotomy and interventional radiology) that may delay or even prevent the 
140 
 
development of brain death after neurological disasters, and thus less patients fulﬁll brain-
dead criteria;
75
 (iii) donor family‟s choice between a cDCD and a DBD procedure with 
greater adoption of DCD to avoid unnecessary prolonged suffering for patients and families in 
case of unrecoverable neurological damage;
75
 (iv) high pressure on the ICU bed triggering an 
eagerness among intensive care professionals to initiate a DCD procedure as soon as possible, 
rather than to wait up a brain-dead and heart-beating donation;
239
 and (v) probably the limited 
intensive care resources making DCD the only or the main possibility of transplantation 
practices from DD and the way of progressing to self-sufficiency in transplantation.
19
 Indeed, 
any suggestion that treatments should be continued primarily to promote the potential for 
DBD are likely to be met with considerable professional caution and resistance.
81
  
In order to verify whether potential donors with irreversible catastrophic neurological 
injury are prematurely referred as DCD, before brain death has occurred, Saidi did examine 
the time intervals from hospital admission to organ recovery and from referral to organ 
recovery, and found no difference between cDCD and DBD groups, therefore eliciting the 
cDCD process is not moving more quickly and circumvents the brain death diagnosis.
75
 We 
have recently conducted a similar analysis and the results were in line with Saidi‟s study (D. 
Ledoux, personal communication). 
Obviously, cDCD might in fact jeopardize the practice of DBD. To effectively 
increase the DD pool without compromising the excellent results of transplantation, and 
without competing with DBD source, cDCD should be ideally reserved only to donors who 
have critical, irreversible brain injuries but who will never progress to brain death, and thus 
will never meet the neurological criteria for death diagnosis. cDCD should not be viewed as 
an option for clinical staff and families to support donation without the need for lengthy 
neurological evaluations and subsequent donor optimization.16 The attending physicians and 
ICU care teams, as well as donors‟ family should be clearly explained on the differences 
between DBD and cDCD in terms of the quantity and quality of organs that can be 
transplanted from each type of donor.
471
 When progression to brain death might occur if more 
time is allowed, it should be encouraged to maximize the opportunity of organ transplantation 
after brain death. 
 
6.2. Is the use of DCD in Liège and Belgium worth the effort in terms of kidney and liver 




Results of DCD-KT in Liège and Belgium (chapters 2.2, 3.1 and 3.2) 
cDCD-KT program was initiated in Liège since 2005. During seven-year period (2005 
- 2011), 80 DCD-KT have been undertaken, accounting for 24.2% of the DD kidney pool. 
The number of DCD kidney grafts increased steadily over time and comprised up to one-third 
of the yearly DD kidney pool since 2009. Overall and death-censored graft survival rates were 
89.5% and 93.7% at 1 year, 85% and 90.8% at 3 years, and 81.3% and 90.8% at 5 years, 
respectively. Patient survival rates at 1, 3 and 5 years were 93.3%, 91.4% and 87.6%, 
respectively. No PNF grafts were observed. The DGF rate was 35.5%. The occurrence of 
DGF did not adversely influence graft survival, but did prolong the length of hospital stay.  
 In Belgium, the DCD-KT program was introduced in 2000. During ten-year period 
(2000 - 2009), 287 DCD-KT were performed (93% from cDCD and 7% from uDCD), 
comprising 7.4% of the DD kidney pool. Between 2000 and 2005, only 1.5% (range: 0.75 - 
4.25%) of all transplanted DD kidneys originated from DCD, but from 2006 to 2009, this 
number increased to 16% (range: 12 - 16.5%). Death-censored graft survival rates at 1, 3 and 
5 years were 95%, 91% and 86%, respectively. Patient survival rates at the corresponding 
time points were 97%, 94%, 87%, respectively. PNF occurred in 1% and DGF in 31% of 
cases. Machine-perfused kidneys experienced a numerically 9% lower DGF rate compared 
with cold-stored kidneys (27% vs 36%, p = 0.07).  DGF rate in uDCD was higher compared 
with cDCD (65% vs 28.5%, p = 0.001); however, PNF rates were similar (0% vs 1%). Five-
year patient and death-censored graft survival of uDCD were similar to cDCD (85% vs 93%, 
and 94% vs 95%, respectively).  
 
Results of DCD-LT in Liège and Belgium (chapters 4.1 and 4.2) 
cDCD-LT program in Liège was commenced in 2003. During nine-year period (2003 - 
2011), there have been 56 DCD-LT, constituting 22.1% of the DD liver pool. DCD-LT 
activity increased rapidly over time and since 2009, made up more than one-third of the 
yearly DD liver pool. Global and death-censored graft survival was 92.6% and 92.6% at 1 
year, 73.8% and 87.7% at 3 years, and 60% and 87.7% at 5 years. Patient survival at the 
corresponding time points was 92.6% at 1 year, 73.8% at 3 years and 60% at 5 years. Biliary 
complications were encountered in 14.3% of patients. There was no intra-hepatic bile duct 
stricture, no re-transplantation and no PNF. 
 The ﬁrst Belgian DCD-LT were performed in 2003, following the successful 
development of DCD-KT in 2000. During seven-year period (2003 -2009), 111 DCD-LT 
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have been done, making up 6.7% of the DD liver pool. The number of DCD-LT also 
increased rapidly over time, and since 2009 contributed up to 20% of the yearly DD liver 
pool. Overall and death-censored graft survival rates were 80.1% and 84.5% at 1 year, 64.9% 
and 78.3% at 3 years, and 60.4% and 72.9% at 5 years, respectively. Patient survival rate was 
88.3% at 1 year, 74.4% at 3 years, and 70% at 5 years, respectively. PNF rate was 4.5% (5 
patients). 33.3% of patients developed biliary complications with ITBL encountered in 12.6%. 
11.7% patients underwent re-transplantation for PNF, hepatic artery thrombosis, and 
intractable biliary stenoses.  
 
Medical aspects of organ transplantation from DCD 
Liège‟s experience in using cDCD donor source for KT is comparable to the national 
level in Belgium and does not differ from the general results in the world. DCD-KT resulted 
in good early graft function and excellent medium-term outcomes. The relatively low rate of 
DGF in Liège was essentially attributed to the short warm and cold ischemia times, and rather 
favorable donor factors (young age and few co-morbidities). DCD kidneys were routinely 
cold-stored in Liège. 13.7% were machine-perfused in the context of a Eurotransplant 
randomized controlled trial about the efﬁcacy of HMP over SCS, and had less DGF than the 
cold-stored group (27.3% vs 36.9%), even the difference did not attain statistical significance.  
In this Eurotransplant trial, HMP was shown to reduce the risk and severity of DGF 
and to improve one-year graft survival in all DD kidney types, and its benefit was greater 
when kidneys are more vulnerable to DGF (i.e. marginal kidneys: ECD and DCD).
51
 
However, the graft-survival advantage after HMP disappeared in the DCD subgroup after 
three-year follow-up, although remained significant in DBD and especially ECD kidneys, 
advocating a different mechanism of DGF in DCD compared to DBD kidneys.
472
 To be 
beneficial from the machine effect, it has been suggested that kidneys should probably be 
pumped immediately following procurement until transplantation.
216,217
 Immediate or delayed 
HMP requires further investigation because of its important logistical consequences.  
 It is worth noting that organs that have already subjected to warm ischemic injury 
have an increased susceptibility to damage during cold storage. The use of these marginal 
organs further stresses the importance of avoiding prolonged CIT without any appropriate 
medical reasons. CIT is subject to manipulation by the organ-sharing system and is the most 
modiﬁable factor. Many factors contribute to the cold storage time and include the distance 
between the procurement and transplant centers, organ transport system, weather, 
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communication between the donor and recipient surgical teams, the availability of the 
recipient and the OR, and the potential reallocation of organs for alternative patients...
473,474
 




In every transplantation from DCD, we make efforts to keep CIT <18 hr for kidneys 
and <6 hr for livers. Liège data demonstrated that for kidneys, mean CIT was 722 ± 279 min, 
92% and 50% of the kidney grafts had the length of preservation time <18 hr and <12 hr, 
respectively; for livers, mean CIT was 265.6 ± 85.1 min, 87.5% and 44.6% of the liver grafts 
had the duration of cold storage <6 hr and <4 hr, respectively. Recipients are required to get 
to the hospital early before the scheduled time of organ arrival (or the planned withdrawal of 
donor life support) for the evaluation of medical status, dialysis requirement, anaesthesia 
examination, and possible surgical preparation. Transplantation usually starts upon the arrival 
of organs, even during the night. In DCD-LT, two teams of surgeons perform the donor and 
recipient operations virtually simultaneously. Upon declaration of death and after satisfactory 
hepatic visualization in the donor (weight, physical characteristics, perfusion quality, the 
presence of fatty change, and wedge biopsy), the second surgical team begins the recipient 
operation. We tend to reserve DCD liver grafts for uncomplicated cases by avoiding cases 
with extensive history of abdominal surgery or portal-vein thrombosis, re-transplantation, or 
combined organ transplantation, and livers are implanted in orthotopic position with standard 
or modified piggyback technique. The current Eurotransplant „center-driven allocation policy‟ 
for DCD liver grafts further reduce the ischemia time and facilitates the better donor-recipient 
matching.  
In some countries (the UK, France and Spain), DCD kidneys are locally attributed to 
patients on the waiting list of the center that has made the retrieval. This policy aims not only 
to minimize the CIT but also to encourage new DCD programs. Some transplant centers are 
prone to distribute these kidneys to low and non-sensitized recipients; hence, the necessity for 
a pre-transplant cross-match is obviated, which may shorten the CIT.
66,263
 Moreover, the 
increased immunologic reactivity of sensitized and/or re-grafted recipients may compound the 
ischemic endothelial injury that up-regulates immunogenicity, thereby leading to increased 
early rejection activity that frequently goes undetected.
112
  The Eurotransplant Senior Program 






 A welcome but unexpected finding in Liège‟s experience was the complete absence of 
PNF in DCD kidneys. PNF is a consequence of ischemic cortical necrosis and its absence 
may reflect the relatively short WIT (mean: 20.7 ± 7.5 min) incurred by kidneys from cDCD. 
In Liège policy, volatile anesthetics are administered for the purpose of confort therapy in an 
end-of-life patient given its pharmacological pre-conditioning effect and its analgesic and 
hypnotic properties. The ventilator switch-off in sedated DCD donors shortens the dying 
process. WLST takes place in the OR with the retrieval surgical team already in place to 
immediately perform laparotomy and directly cannulate the aorta after five-minute no-touch 
period and death declaration. Topical cooling by chilled physiological saline and crushed ice 
was promptly undertaken. The donor intervention is generally under experienced surgeons‟ 
responsibility. The experience of the attending recovery team play a crucial role because 
minimizing WIT demands rapid cold perfusion of the organs, and then swift but careful 
dissection to remove the transplantable organs in a cold bloodless field without injuring organ 
vasculature, especially  aberrant vessels. Our protocol follows closely the recommendations of 
the American Society of Transplant Surgeons in which acceptable total WIT, defined as the 
time interval between WLST and initiation of cold perfusion, should be <30-45 min for livers 
and <45-60 min for kidneys; and desirable true WIT, defined as the time interval between 
significant ischemic insult after WLST (mean arterial pressure <60 mmHg or systolic blood 
pressure <50 mmHg) and initiation of cold perfusion, should be <20-30 min for livers and 
<30-45 min for kidneys.
15
 Thus, no extra-renal organs will be used if the donors develop >15 
min of hypotension prior to death declaration. A few centers use pre-mortem cannulation in 
conjunction with immediate post-mortem perfusion during the interval between death 
pronouncement and organ procurement, further facilitating unhurried organ procurement and 
possibly improving graft function.
147
  
 Apart from the criteria of WIT, DCD donors must meet identical standards to those 
used for selecting organs from DBD donors. In Liège, the upper age limit for kidney donation 
is set at 65 years, which is the age limit under the Eurotransplant protocol, but no age 
restriction in case of liver donation provided that there are no other associated risk factors (i.e. 
prolonged CIT, abnormal liver function tests, abnormal histological examination like steatosis 
or fibrosis). Donor age is limited to 55 years in France and Spain,
78,477
 and 60 years in other 
countries because of the fear that the additional ischemic insult, when allied to an already 
marginal organ, will result in very poor transplant outcomes.
41
 Consequently, ECD donors are 
often not considered for DCD.  
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Contrary to the favorable results of KT using older donors in living and heart-beating 
settings, KT using non-heart beating donors older than 65 years was associated with 
unacceptable clinical outcomes that can be considered below the standards for KT at the time 
(5-year overall graft survival of more than 60%).
291,478
  Older kidneys suffer more IRI than 
younger kidneys, probably due to reduced functional nephron mass, atherosclerotic lesions 
and reduced regenerative capacity associated with greater age.
479
 Therefore, the use of elderly 
DCD donors in order to increase the donor pool cannot be justiﬁed without the guidance of 
histological assessment of pre-transplant biopsies.
480
 Limiting the cut-off donor age to 65 
might also improve the discard rate.
199
 
Preliminary results at our institute using older DCD liver donors (age ranging from 56 
to 79 years) did not show any difference in early graft function, biliary complications, and 
graft and patient survival after one-year follow-up  in comparison with the younger group.
481
 
A recent study comparing standard and extended criteria cDCD livers also found equivalent 
early transplant outcomes with a follow-up duration of 18.5 – 25 months. Advanced age (>60 
years), higher BMI (>30 kg/m
2
), longer true WIT (>30 min, time interval between MAP <50 
mmHg or oxygen saturation < 80% and initiation of cold perfusion) and CIT (>8 hr) alone 
should not be an absolute contra-indication to LT with cDCD grafts, provided the recipients 
are selected carefully to avoid accumulation of other risk factors.
28
   
 Liège experience in DCD-LT is also as good and promising as that in DCD-KT. We 
showed that cDCD is really an additional source of transplantable liver grafts and transplant 
outcomes were apparently as good as those from DBD-LT. The absence of PNF and intra-
hepatic biliary stricture at out center was the evidence of relatively short warm and cold 
ischemia times as aforementioned. Additionally, in accordance with the recipient selection 
criteria published by highly experienced transplant centers
60
 and register data,
57-59
 we 
preferentially offered DCD liver grafts to low risk patients (low MELD scores) and patients 
with hepato-cellular carcinoma beyond the Milan criteria.    
 An overview of the results of DCD-LT over the past two decades in the world 
revealed inferior graft and patient survival and higher risks of biliary complications and re-
transplantation than DBD-LT, although comparable or equivalent results have been 
sporadically reported in select centers through careful donor and recipient selection and 
optimization of CIT, or through invasive techniques designed to optimize recovery before 
declaration of death. Nonetheless, we believe that even if graft or/and patient survival is lower 
with a DCD liver, it is better than dying because of turning down a DCD offer and continuing 
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to wait for a DBD liver on these days, as the patient‟s choice is frequently not between 
marginal livers (including DCD) and standard livers but between marginal livers and no 
livers.
94 The benefit of earlier access to LT provided  by a DCD graft could outweigh the risks 




 Technical and logistical aspects of organ transplantation from DCD 
 Key considerations in establishing a cDCD program include the outcomes of DCD 
organs, the potential logistical difficulties relating to the process, and the difficulty in 
predicting death. The fear of high risks of DGF, PNF and other potential complications is not 
justified on the basis of good results of cDCD organ transplantation in Liège since the 
commencement of the program up to now. Therefore, these risks should not be considered as 
a medical barrier any more with careful donor and recipient selection and matching.  
 Kidneys from controlled Maastricht category-3 donors generally have a shorter and 
more predictable WIT than those from uncontrolled Maastricht category-1 and -2 donors, and 
thus more closely resemble those from the conventional DBD donors.
237
 Broad experience in 
using cDCD kidneys clearly demonstrates that machine perfusion and viability testing is not 
obligatory for kidneys recovered from cDCD donors, hence simplifying the logistics of organ 
procurement and cold storage.  
 It is the policy at our center that withdrawal of multi-organ support occurs during the 
normal working hours in the OR (with the possibility of disrupting elective or emergency OR 
activity) and under the supervision of senior anesthesiologists. There are no major problems 
in getting their support because they closely collaborate with our department and actively take 
part in the DCD program. Moreover, our surgeons are willing to allow scheduled operating 
lists to be cancelled in order to make DCD procurement and transplantation, and hospital 
management is also willing to accept the loss of this other operating room activity. 
 On average 30-40% of intended DCD do not progress to death in a timely manner 
after WLST and therefore do not proceed to organ retrieval.
16,75
 Reducing the number of 
„stood-down‟ donations would avoid family distress, reduce the burden on hard-pressed ICU 
staff, and also enable more efﬁcient resource utilization as the organ procurement process is 
costly and labor-intensive.
16
 However, time between therapy withdrawal and cardiac arrest 
(so-called the withdrawal phase or agonal phase) is beyond the control of the procurement 





but may be extended up to 4-5 hr for kidneys without compromising the transplant outcomes 
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and increased the number of retrieved cDCD kidneys by 30%.
41  Obviously, it is possible to 
prolong the agonal time beyond 2 hr provided the retrieved kidneys pass viability assessment 
using machine perfusion, but the discard rate was high (13% if <2 hr; 33% if >2 – 5 hr and 
45% if > 5 hr).
40
 DCD kidneys from elderly patients, which are susceptible to ischemic injury, 
should also be used with caution if agonal times are protracted.
42
 Furthermore, the importance 




 Prolonged agonal time is linked to prolonged donor instability and increased risk of 
severe organ ischemia. It is labor-intensive and has important logistical consequences, 
including indeﬁnite reservation of an OR, surgical staff on stand-by and unavailable for other 
duties, and transport delays.
34
 Several factors have been identified as predictors of rapid death 
following treatment withdrawal.
34
 Two predictive tools that have been validated and 
commonly used in the US are the University of Wisconsin
30
 and UNOS scoring systems.
31
 A 
novel predictive score, DCD-N score which incorporates the neurological status of the patient 
before WLST, has recently been introduced for specific use in neurological patients with 
catastrophic cerebral damage.
32
 Prediction of time to death after WLST on the basis of clinical 
impression has proven inaccurate.
33
 Therefore, improvement of the ability to identify good 
DCD candidates for donation remains the objective.  
 Our mean agonal time was 10.5 ± 6.8 min, ranging between 1 and 30 min. We accept 
this time period up to 60 min for organ donation. The use of volatile anesthetics as analgo-
sedation treatment modality helps reduce the length of dying process,
177
 ensuring the 
occurrence of patient death in the OR, and thus avoiding emotional stress, misunderstanding, 
or even confusion and intense workload due to stand-down for both OR medical staff and 
families. 
 
Particularities of the DCD program in Liège  
 As previously presented, DCD activity in Liège was started before an official DCD 
protocol was established and approved by all interested parties in 2009. Immediately after the 
issue of this important document, we observed a significant increase in the number of DCD 
procedures in the following years. So what are the problems for the development of DCD 
programs in Liège prior to 2009?  
 When the ﬁrst organ procurements from cDCD donors occurred in 2002, most of the 
medical and OR nursing staff was unaware of this procedure. The anesthesiologists on duty 
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were asked to terminate the patients‟end-of-life care with little information about the patients‟ 
medical history and the decision-making process on the futility of treatment. They 
acknowledged feeling uncomfortable with the DCD process as did the OR nursing staff. In 
2004, a meeting was held by the representatives of the Hospital Ethics Committee, ICU, and 
transplant team to inform the peri-operative staff about the procedure and reassure them. At 
the same time, another meeting between the Department of Anesthesiology and Intensive 
Care Medicine concluded that end-of-life care should be achieved in the OR by the intensive-
care physician in charge of the patient or a willing anesthesiologist. Unfortunately, the 
involvement of the attending intensive-care physicians did not create a climate of conﬁdence 
and serenity in the OR as expected. It was therefore decided to proceed to DCD procurements 
with the personnel knowledgeable about the procedure. Here are 1 of the 3 senior 
anesthesiologists in charge of the abdominal surgery and transplantation at our department. In 
the 2 main collaborating hospitals, end-of-life care is provided by one anesthesiologist 
intensivist invested in this program. However, problems persisted because of the 
inconsistency in the way of delivery of end-of-life care, death determination… between the 3 
anesthesiologists at our center, as well as between collaborating donor hospitals. This lack of 
consistency induced malaise, unease, questions, or even suspicions in the ancillary medical 
staff that might limit the acceptance of DCD programs.
177
 
  Our experience in the implementation of DCD programs emphasizes the need for a 
detailed protocol, the necessity of extensive discussions among all staff that are likely to be 
involved in DCD about the ethical, moral, professional, and legal issues surrounding DCD.  If 
a DCD program were to be successful, this would need to be addressed in a manner suitable 
to all parties involved.
482
   
 
6.3. Could the current Maastricht DCD classification be ameliorated? (chapter 5) 
 As experience increases in parallel with a rapid expansion of the number of DCD 
retrievals and transplants, subtle differences in the transplant outcome appear as a result of 
differences in the mode and location of the donor death within the same Maastricht DCD 
category and of resultant various ischemic insults.
9,10
 Furthermore, a new type of DCD with a 
substantial potential and good quality organs (i.e., DCD after euthanasia) emerged in Belgium 
and has not yet included in the original Maastricht classiﬁcation.232  For all of these reasons, 
we consider the need to adapt the current DCD classiﬁcations.  
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 We conserve the Maastricht categories 1 to 4 but divide them into a series of clinical 
situations (1A, 1B, 2A, 2B, 3A, 3B, 3C, 4A, and 4B), and add a category 5, namely DCD 
after medically-assisted death, as this category has separate ethical and legal issues from those 
in categories 1 to 4. All of these DCD categories may lead to different clinical results of 
transplantation.  
 Although  this  classiﬁcation  is  more  complicated,  it  is more complete than the 
1995 Maastricht classiﬁcation, while maintaining the same basic categories 1 to 4 (adding a 
ﬁfth) that are now well-known and accepted criteria. Each category was divided into two or 
three sub-categories: sub-category A is linked to longer WI (and worse results) than sub-
category B; and B versus C, respectively. In addition, sub-categories A (2A, 3A, 4A, and 5A) 
are mostly linked to DCD processes occurring in the ICU, which helps to understand and 
memorize this classiﬁcation. Moreover, by keeping the original skeleton of the 1995 
classiﬁcation, space is left to add new sub-categories in the future, if deemed clinically 
relevant.  
 In conclusion, DCD programs in Liège demonstrated that DCD donors are really an 
additional source of organs for transplantation. The medium-term transplant outcomes of 
DCD kidney and liver grafts are as good as those coming from DBD counterparts. These 
programs have no negative impact on the DBD activity and the public‟s perception. They 
partially meet the increasing demand of organs for transplantation and satisfy the request of 
the donors and/or their family. The use of this alternative donor source justifies the intense 
efforts and costly investments with regard to the growing number of patients on the waiting 
list of transplant.  
 
6.4 Future prospects 
DCD must progress in two directions: recovery and transplantation of more and 
different types of organs and improvement of outcomes. We have made evidence the 
expeditious rise in the number of organs retrieved and transplanted from cDCD in Liège over 
the past few years despite some impediments. With an active role of the procurement and 
transplantation coordinators, the full support and unanimity of all interested parties (ICU, 
Department of Anaesthesiology, operating room staff, Hospital Ethics Committee, Hospital 
Management Board), a favorable legal framework allowing maximal efforts to stimulate  
organ  donation  and  transplantation  (opting-out, legality of DBD, DCD, and living 
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donation), and a recent initiative of the GIFT-project about the „donor facilitators‟,221 this 
trend is likely to be consolidated in the future.  
Broad experience of Spanish centers in Maastricht category-2 kidney and liver 
transplants
17,145
 as well as promising results of the US and UK centers in Maastricht category-
3 pancreas transplants
66,86,89,483
 will certainly guide us for the establishment of similar 
programs in Liège when more patients are registered on the waiting list and the full potential 
of DBD is explored.  
We acknowledge the beneficial effects of HMP in reducing early graft dysfunction 
rates and revitalizing marginal kidneys that should have been discarded if HMP were not 
available. HMP will certainly play a greater role in DCD kidney programs in Liège when 
donor selection criteria are expanded and more sub-optimal kidneys are accepted. Economic 
evaluations of HMP versus SCS suggested that the implementation of HMP of all common 
types of DD kidneys is likely to be cost-effective with lower costs per life-year and reduced 
costs per QALY (quality-adjusted life-year) compared to SCS.
54,55
  
For DCD-LT, the identification of suitable donors (probably Maastricht category-3 
DCD donors), better donor and recipient matching (high risk donors to low risk recipients), 
use of advanced organ preservation techniques (oxygenated hypothermic or normothermic 
machine perfusion, venous systemic oxygen persufflation), and pharmacological modulation 
(probably a multi-factorial biologic modulation strategy) could assure equivalent results to 
DBD-LT and thus expand the DCD donor source.    
 
6.5 Applicability and feasibility of DCD programs in Viet Nam 
 
 The first related living donor KT was performed in Viet Nam in 1992. Until December 
2010, after nearly 20 years of organ transplantation, there have been 400 kidney and 16 liver 
transplants mostly from related living donors.  Just a few unrelated living donor grafts were 
accepted (between spouses and samaritan donors). In November 29
th
, 2006 the Law on 
Human Tissue and Organ Donation, Procurement and Transplantation was approved by the 
Vietnamese General Assembly, allowing the retrieval of tissues and organs from DBD donors 
for therapeutic purposes and scientific research. However, 3 years after the Law took effect on 
the first of July 2007, only 15 kidneys, 1 liver and 1 heart were retrieved from 8 DBD donors 
for transplantation and allocated locally for patients on the waiting list of transplant centers. 





 Estimates about end-stage organ disease patients showed Viet Nam had about 80000 
end-stage renal disease (ESRD) patients; the incidence of ESRD was 6400 patients/year (until 
April 1
st
 2009, there were 86 million habitants in Viet Nam).
485
 Approximately 10% of ESRD 
patients had access to hemo-dialysis or peritoneal dialysis (HD: 6000 patients, PD: >1000 
patients in all over the country).
486
 It is estimated that there have been 23000 cirrhosis and 
liver cancer patients. Alcoholism and virus B hepatitis were common causes of chronic liver 
disease, and followed by hepato-cellular carcinoma.
487
 National statistics on the advanced 
heart and lung diseases did not exist; however, published data from some large hospitals were 
considerable 
488
 National investigation in 2008 demonstrated 5.7% of the population was 




 Consequences of serious imbalance between the demand for and supply of organs 
available for transplantation led to a substantial number of patient deaths on the waiting list 
(no statistic data) and the development of transplant tourism abroad as well as illegal sales of 
organs. During the period of 1992 - 2005, 157 patients were transplanted in Viet Nam 
compared to 300 patients going abroad for transplantation.
490
 Some suspected sales of organs 
associated with lethal outcomes have been mentioned by the mass media.
491
 Therefore, the 
use of alternative donor sources other than living donors becomes necessary and urgent to 
solve the organ shortage in Viet Nam.  
Although there has not yet been an audit of the DBD potential in Viet Nam, estimates 
from large hospitals showed this potential is enormous. At Viet Duc hospital, 800-1000 
patients died each year because of traffic, labor or daily life-activity accidents, and about half 
of them were brain-dead patients.
492
 One study at Viet Duc, Bach Mai, and Military No 103 




Despite a huge number of potentially ideal DBD donors, few cases proceed to organ 
procurement. Traditional belief of the Vietnamese people, 'as a man lives, so shall he die', has 
become the most important barrier to organ donation. The family wants to keep the deceased-
donor body whole and intact so the dead person could be re-born perfectly in another world 
after death.
494
 Some people agree to donate their organs while alive, but once dying, their next 
of kin are unwilling to realize the wishes of their beloved. It is remembered that Vietnamese 
Law relies on the „opting-in‟ or „required consent‟ principle. More concerted efforts at 
supporting bereaved families in understanding the donation process and in balancing the 
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emotions of giving the „gift of life‟ with the perceived „sacrifice‟ of organ donation may 
increase the number of families assenting to donation.
199
 
Viet Nam has not yet Law on the DCD. Moreover, the current Law prohibits 
discontinuation of life-support therapy in patients with severe irrevocable neurologic injury 
and medically-assisted death. Until there are changes in the legislation, the most important 
and urgent mission now is to explore the huge pool of DBD that is largely underused. We 
acknowledge that although DCD is not yet feasible in the near future in Viet Nam, when 
compared to DBD, it helps us to better understand the deleterious impact of brain death on 
graft quality, the perplexing interaction between innate and adaptive immune system, the 
consequences of warm ischemia-reperfusion on early graft function, the necessity of better 
preservation solution and preservation techniques, the complex organization of the 
procurement and transplantation process, as well as the principles of organ sharing. The 
success of every deceased donor transplantation programs in Viet Nam could not be possible 
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Through a series of clinical studies, this thesis aims to clarify the contribution of 
donation after cardiac death (DCD) to the deceased donor (DD) pool and results of kidney and 
liver transplantation coming from this donor source in Liège and Belgium. Additionally, an 
adapted DCD Maastricht classification is also discussed.  
Chapters 2.1 and 2.2 summarize the DCD procurement and transplant activity in Liège 
and Belgium from 2000 to 2009 with an update on data up to 2011. In Liège, DCD really 
contributes to the DD pool and boosts the transplant activity of the center in both kidneys and 
livers by on average 30%. By contrast, the steady rise in DCD activity in Belgium does not 
lead to major increase in the DD donation and transplantation. In other words, some kind of 
donor-type redistribution within the DD pool might occur.  
Chapters 2.2, 3.1, and 3.2 discuss the results of kidney transplantation (KT) from 
DCD. We demonstrate that Liège‟s experience is comparable to the national level in Belgium 
and does not differ from the general results in the world with regard to early graft dysfunction, 
medium-term graft function, graft and patient survival. The excellent results of DCD-KT are 
attributed to the relatively short warm and cold ischemia, favorable donor factors, and the role 
of hypothermic machine perfusion (in Belgian series).  
  Chapters 4.1, and 4.2 discuss the results of liver transplantation (LT) from DCD. 
Liège‟s results are encouraging and apparently as good as those from donation-after-brain-
death LT because of short warm and cold ischemia times. Belgian results show an increased 
incidence of primary non-function and ischemic cholangiopathy which is in agreement with 
previously published data.  
 Chapter 5 proposes an adapted DCD Maastricht classification which maintains the 
original categories 1 to 4 that are now well-known and widely accepted, and adds a ﬁfth 
category, so-called „DCD after euthanasia‟. Each category is divided into two or three sub-
categories: sub-category A is linked to longer warm ischemia (and worse results) than sub-
category B; and B versus C, respectively. In addition, sub-categories A (2A, 3A, 4A, and 5A) 
are mostly linked to DCD processes occurring in the ICU, which helps to understand and 
memorize this classiﬁcation. By keeping the original skeleton of the 1995 Maastricht 







Au travers d‟une série d‟études cliniques, cette thèse a pour objectif d‟éclairer sur la 
contribution de donneurs à coeur arrêté (DCA) à l‟accroissement du pool de donneurs décédés 
(DD) et sur les résultats de la greffe rénale et hépatique àpd de ce type de donneurs à Liège et 
en Belgique. En outre, une classification adaptée de DCA de Maastricht a été aussi discutée. 
Les chapitres 2.1 et 2.2 résument l‟activité de prélèvement et transplantation àpd DCA 
à Liège et en Belgique de 2000 à 2009 avec une mise à jour des données jusqu‟à 2011. À 
Liège, la DCA a contribué au pool de DD et augmenté l‟activité de transplantation rénale et 
hépatique en moyenne de 30%. Au contraire, l‟augmentation progressive de l‟activité de DCA 
des autres centres Belges ne conduit pas à une augmentation significative du don et de la 
transplantation àpd DD. Comme ci, il existait une sorte de redistribution du type de donneur.  
Les chapitres 2.2, 3.1 et 3.2 discutent les résultats de la greffe rénale àpd DCA. On 
montre que l‟expérience Liégeoise est comparable au niveau national et international en 
termes de dysfonction primaire du greffon, de fonction du greffon, de survie du greffon et du 
patient à moyen-terme. Les excellents résultats de la greffe rénale àpd DCA sont attribués à 
l‟ischémie chaude et froide relativement courte, aux caractères favorables du donneur, et à 
l‟effet bénéfique de la machine de perfusion (en série Belge) 
Les chapitres 4.1 et 4.2 discutent les résultats de la greffe hépatique àpd DCA. Les 
résultats Liégeois sont encourageants et comparables à ceux de la greffe hépatique àpd 
donneurs en mort cérébrale grâce à l‟ischémie chaude et froide relativement courte. Les 
résultats au niveau des centres Belges montrent cependant une augmentation de l‟incidence de 
non-fonction primaire et de cholangiopathie ischémique, conforme aux données publiées 
antérieurement.  
Le chapitre 5 propose une classification adaptée de DCA de Maastricht qui maintient 
les catégories originales de 1 à 4 et y additionne une cinquième, sous le nom „DCA après 
euthanasie‟. Chaque catégorie est subdivisée en deux ou trois sous-catégories: sous-catégorie 
A est liée au temps de l‟ischémie chaude plus longue (et résultats moins bons) que sous-
catégorie B, et B versus C, respectivement. En plus, les sous-catégories A (2A, 3A, 4A, and 
5A) sont essentiellement liées aux procédures de DCA aux soins intensifs. Grâce au maintien 
de la structure initiale de la classification de Maastricht (en 1995), les potentialités sont 
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